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1 INTRODUCTION 
1.1 Female cancer burden 
Cancer was the second leading cause of death and disability after cardiovascular disease causing 
8.93 million deaths worldwide in 2016 (Naghavi et al., 2017). Cancers of breast, cervix, 
endometrium and ovary, predominantly known as female cancers add up to an approximate 44% 
of all cancer diagnosis and 12% of all cancer deaths among women globally (Ferlay et al., 2013). 
Among those cancers, breast cancer is the most commonly diagnosed cancer with estimated 2.1 
million new cases and an estimated 626,679 deaths worldwide in 2018 (Bray et al., 2018). 
Compared to the other three female cancers, ovarian cancer has lower incidence and mortality 
with 295,414 new cases and 184,799 deaths in 2018 (Bray et al., 2018), but it is a relatively fatal 
disease, for which no screening program is widely conducted and it is called “whispering 
disease” or “a silent killer” because of its vague abdominal symptoms and signs (Henderson et 
al., 2018). In US ovarian cancer contributes just 2.5% of all cancer diagnoses in women, but 5% 
of cancer deaths due to the disease’s low survival rate (Siegel et al., 2018). The cancer incidence 
varies in different countries and regions. The highest incidence rates of breast cancer are 
presented in North America, Australia, New Zealand, and Northern and Western Europe (Figure 
1).  Similarly, the high incidence rates of ovarian cancer are observed in Northern and Eastern 
Europe (Figure 2).  
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Figure 1 Regional differences of age-standardized incidence rates of breast cancer in women. Available 
from: http://globocan.iarc.fr, accessed on 18/09/2019. 
 
 
Figure 2 Regional differences of age-standardized incidence rates of ovarian cancer in women. Available 
from: http://globocan.iarc.fr, accessed on 18/09/2019. 
 
1.2 Classification of histology  
Cancer is a heterogeneous disease and it can be categorized into biologically and clinically 
meaningful subgroups according to histology grade and histological type. Grade is an assessment 
Breast and ovarian cancers in women…………………………………………………………………Introduction 
Guoqiao Zheng............................................................................................................................. 3 
of the degree of differentiation and proliferative activity of a tumor, and mirrors its 
aggressiveness. On the other hand, histological type refers to the growth pattern of the tumors. 
Specific types of cancer may present distinctive risk factors, genetic characteristics, clinical 
behavior and prognosis. 
Invasive breast cancers were classified as ductal and lobular based on the sites where the tumor 
originated (Lakhani, 2012).  However this sort of tumor growth is found not related to the site or 
the cell origin. Accounting for 80% of all types of breast cancer, ductal breast carcinoma is the 
most common type. According to cell type, amount, type and location of secretion, architectural 
features and immunohistochemical profile, it can be classified into diverse subtypes, among 
which invasive ductal carcinoma not otherwise specified (IDC-NST) constitutes about 75% of 
invasive ductal carcinoma (Lakhani, 2012). Other special types of IDC include tubular, 
mucinous, medullary, invasive papillary and so on. Tubular and mucinous usually occurs in 
elderly women (Makki, 2015). Medullary carcinoma has better outcome and favorable prognosis 
than common IDC (Makki, 2015). Invasive lobular carcinoma is the second major histology-
specific breast cancer, accounting for 5%-15%. Invasive lobular carcinoma has five distinctive 
histological variants. With efforts concentrating on molecular characteristics, the breast cancers 
are classified as follows according to their gene signature in order to better predict tumor 
behavior and improve therapeutic strategies: luminal A, luminal B, HER2 overexpression and 
basal like (Weigelt et al., 2010). 
Ovarian cancer is commonly classified into epithelial and non-epithelial types. Non-epithelial 
ovarian cancer contains a diversity of  tumor types such as granulosa cell and germinal 
malignancies, teratomas, and dysgerminomas, totally occupying for less than 10% of all ovarian 
cancer cases (Alifrangis and Seck, 2017). Histologically epithelial ovarian cancers is classified 
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into two subgroups (type I and II) according to their distinctive clinicopathologic and molecular 
genetic features (Kurman and Shih, 2010). Type I group consists of low-grade serous, low-grade 
endometrioid, clear cell and mucinous carcinomas, which are indolent and have a good 
prognosis. While tumors in type II group present more aggressive, including high-grade serous 
carcinoma, high- grade endometrioid carcinoma, carcinosarcomas and undifferentiated 
carcinomas.  In comparison with low-grade serous carcinoma, high-grade serous, endometrioid, 
clear cell, mucinous carcinomas may evolve from different pathways and originate outside of 
ovary: for instance,  high-grade serous carcinoma is considered from fallopian tube and on the 
other hand,  endometroid and clear cell carcinoma may originate from endometrium passing 
through the fallopian tube leading to endometriosis (Kurman and Shih, 2010). 
1.3 Protective and risk factors 
Cancer risk increases with aging. Besides, ovarian cancer is strongly influenced by reproductive 
and menstrual factors. Risk of ovarian cancer is reduced in the condition with any factors that 
can decrease the total number of ovulatory cycles including pregnancy, breastfeeding and use of 
oral contraceptives and is increased in the condition with any factors that prolong exposure to 
ovulation including low parity, early menarche and late menopause (Glance, 2009). As for oral 
contraceptive use, it is a commonly recognized protective factor for ovarian cancer and the 
widespread use in recent decades is considered as the main factor that contributed to the 
decreased incidence of ovarian cancer (Collaborative Group on Epidemiological Studies of 
Ovarian Cancer, 2008). An exception is that users of oral contraceptives were observed increased 
risk of mucinous ovarian cancer (Riman et al., 2002; Soegaard et al., 2007; Wentzensen et al., 
2016). High parity is a protective factor for ovarian cancer, which is well confirmed and is most 
strongly related to endometrioid and clear cell carcinomas (Wentzensen et al., 2016). Hormone 
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replacement therapy is considered to increase the risk of ovarian cancer (Reid et al., 2017). Some 
gynecologic conditions have been studied as risk factors for ovarian cancer, such as 
endometriosis and pelvic inflammatory disease (Chiang et al., 2018; Stewart et al., 2018). The 
strongest associations between ovarian cancer and endometriosis are observed with endometrioid 
and clear cell subtypes (Wentzensen et al., 2016).  Besides reproductive factors, other factors 
associated with ovarian cancer risk include smoking and body size (represented as height or body 
mass index) (CollaborativeGrouponEpidemiologicalStudiesofOvarianCancer, 2012; Gates et al., 
2010). The increased risk associated with obesity may be specific to non-serous and low-grade 
serous subtypes (CollaborativeGrouponEpidemiologicalStudiesofOvarianCancer, 2012; Olsen et 
al., 2013). Mucinous ovarian cancer was commonly found associated with smoking in a dose-
response manner (Kurian et al., 2005; Modugno et al., 2002; Wentzensen et al., 2016), 
Similar to ovarian cancer, breast cancer is also sensitive to female hormones. Any factor that can 
increase exposure to these hormones is a potential risk factor. Specifically, reproductive factors 
associated with elevated exposure to endogenous estrogens generated from the ovaries, for 
example earlier menarche, low parity, late age at first birth, and late menopause can increase the 
risk of breast cancer (Glance, 2009). Analogously, exposure to exogenous hormones (for 
instance, menopausal hormone therapy, oral contraceptives use) is often associated with an 
increased risk of breast cancer. Lobular carcinoma is reported to be more strongly related to 
hormonal levels than ductal carcinoma; for example, late age at birth and estrogen and progestin 
hormone replacement therapy use were found only associated with the increased risk of lobular 
breast cancer (Li et al., 2000; Nyante et al., 2013).  In addition, lifestyle related factors including 
alcohol consumption and postmenopausal obesity are related to development of breast cancer 
and those two factors can also be explained by hormonal factors as they are involved in higher 
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circulating estrogen levels. The protective effect of black tea was only found in premenopausal 
women with lobular histology (Baker et al., 2006). 
1.4 Familial clustering 
Evidence suggests that the cancer risk increases with having family member(s) diagnosed with 
the same cancer. Approximately 14% of women with breast cancer have a mother or a sister 
diagnosed with breast cancer and the familial risk is 1.80 (Frank et al., 2014; Frank et al., 2015). 
RR of ovarian cancer is estimated to be 2.0 to 4.0 with mother or sisters affected by ovarian 
cancer (Frank et al., 2017c; Hemminki and Granström, 2003; Hemminki et al., 2011b; Jervis et 
al., 2013; Teerlink et al., 2012). The risk increases when multiple first-degree relatives are 
affected. For women with one, two and three or more first-degree relatives diagnosed with breast 
cancer, RRs of breast cancer were respectively 1.80, 2.93 and 3.90 compared to the women who 
had no affected relatives (Cancer, 2001). The RR of ovarian cancer reached 24 when mother and 
sister were both diagnosed with ovarian cancer (Hemminki and Granström, 2003). The familial 
risk was higher for early-onset patients and the risk was also higher when the relatives were 
diagnosed at the younger age (Negri et al., 2003; Ziogas et al., 2000). The familial aggregation 
can be caused by the environmental factors commonly shared among family members, such as 
smoking, alcohol consumption, low physical activity and toxicant substance exposure, as well as 
by the genetic factors inherited from parents. One twin study carried out among more than 
200,000 same-sex twins sheds light on the important role of genetic factors in familial 
aggregation of breast and ovarian cancers, as cumulative risks of these two cancers were found 
significantly higher in monozygotic than in dizygotic twins (Mucci et al., 2016). Cancers that are 
diagnosed at younger ages tend to have more influential hereditary background than late onset 
cancers (Brandt et al., 2008; Goldgar et al., 1994; Kharazmi et al., 2012). 
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Up to 20% of familial breast cancers have been estimated as possible carriers of a germline 
variant associated with the increased risk of breast cancer (Cobain et al., 2016). Women with 
mutations in the most common high-risk genes BRCA1/2, which are known for hereditary breast 
and ovarian cancer (HBOC) syndrome, have a 40 to 85% lifetime risk of breast cancer and also a 
high risk (10 to 60%) of ovarian cancer (Yurgelun et al., 2015). In the population belonging to 
the central-European decent as well as that with African American ancestry, population 
frequency of deleterious BRCA1/2 mutations was reported to be around 1.4% of all breast 
cancers (Palomaki, 2015). Sporadic studies that seldom reports a much larger heritability is due 
to bias introduced by patient selections or founder populations. Additionally, some other high- or 
moderate-risk genes susceptible to breast cancer have also been found (Cobain et al., 2016), for 
example, germline mutation in TP53, PTEN, LKB1 and CDH1. A number of (around 100) low-
penetrant risk loci despite being discovered were found to contribute to less than 20% towards 
familial susceptibility (Skol et al., 2016). Medullary breast cancer is reported to be associated 
with BRCA1 mutations (Stratton, 1997). Germline mutation of CDH1 increases the risk of 
lobular breast cancer (Corso et al., 2018).  
Collectively, known cancer syndromes account for 36% of ovarian familial risk (Bahcall, 2013). 
Apart from BRCA1/2 genes, mutations in mismatch repair (MMR) genes that are common in 
hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, also known as Lynch syndrome, 
are the other major high-penetrance susceptibility genes for ovarian cancer. In women with 
MLH1, MSH2 and MSH6 mutations, the cumulative risk of ovarian cancer by age of 70 years old 
is 20%, 24% and 1% respectively (Barrow et al., 2013).  MMR gene mutations were reported 
associated with endometriod and clear cell carcinomas (Geary et al., 2008; Watson et al., 2001). 
In contrast, BRCA1/2 mutations predisposing to ovarian cancer are associated with high-grade 
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serous histology (Lakhani et al., 2004; Pal et al., 2005). Ovarian cancer risk can be also 
contributed by some other moderate and low penetrant genes mutations such as BRIP1, RAD51C 
and RAD51D with 12%, 5.8% and 5.2% life time risk (Norquist et al., 2016; Ramus et al., 2015; 
Song et al., 2015).  
Risks for other, i.e. discordant, cancers can also be elevated by those high- and moderate-risk 
genes that predispose to breast or ovarian cancers. Prostate, pancreatic and some other cancers 
were observed in the carriers with BRCA1/2 mutations (Rahman, 2014),  and endometrial, 
colorectal, liver, stomach cancers were observed in carriers with MMR gene mutations (Barrow 
et al., 2013). Furthermore, some environmental and lifestyle factors are shared among some 
cancers. Smoking is confirmed as the cause of several cancers. Reproductive factors that are 
related to hormonal levels are associated with most of the female cancers. In population study, 
familial clustering of breast and ovarian cancers has been reported with prostate and with few 
other cancers with lower statistical significance (Bermejo et al., 2004; Hemminki et al., 2012c).  
In addition, there are limited studies focusing on the familial association with specific 
histological types or with specific gender in relatives. The data on associated concordant and 
discordant cancers can be helpful for genetic counseling, and may provide evidence on the 
shared genetic or environmental factors for the related cancers. 
1.5 Multiple primary cancer 
Breast cancer patients are surviving longer due to improved early detection measures and breast 
cancer treatment as the 5-year survival has increased from 75% in 1976 to 91% in 2017 (Siegel 
et al., 2017). Similarly, survival of ovarian cancer also is increasing and the reported 5-year 
relative survival in USA is around 46% (Jemal et al., 2017). With continuous improvement in 
cancer survival, the occurrence of multiple primary cancers is increasing. Most of the multiple 
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primary cancers are second primary cancers (SPCs). The prevalence of multiple primary cancers 
in cancer patients is reported to range from 2% to 17% (Buiatti et al., 1997; Coyte et al., 2014; 
Karahalios et al., 2009; Rosso et al., 2009; Weir et al., 2013). It is reported that in Sweden 
23.1% of cancer patients developed additional cancers in 2016 
(NationalBoardofHealthandWelfare, 2017). In comparison with the risk of first primary cancer, 
around 1.5-fold increased risk for SPC was found,  and remarkably high risk was observed with 
connective tissue, small intestinal cancers and for leukemia (Hemminki et al., 2003a). The 
development of SPCs can be the results of various factors, such as the treatment of the first 
cancer, shared etiologic background that trigger the first primary cancers such as family history 
and environmental determinants (Schaapveld et al., 2015; Travis et al., 2013; Wood et al., 2012). 
Regarding family history, Hodgkin lymphoma patients who had first-degree relatives diagnosed 
with these cancers were reported to have excess risk of second lung, colorectal and breast 
cancers (Sud et al., 2017).  
About half of the cancer patients have a first-degree relative diagnosed with some other 
(discordant) cancers and for breast and ovarian cancers the respective proportions are 46% and 
56% (Frank et al., 2017c), which implies the importance of cancer family history on the risk of 
SPC. Cancer patients carrying high-risk genetic lesion have increased probability of developing 
multiple primary malignancy (of the same or different type). For breast cancer patients with 
BRCA1 and BRCA2 mutation, the 10-year risk of the subsequent ovarian cancer is estimated to 
be 12.7% and 6.8%, respectively (Metcalfe et al., 2005).  The concept that risk of SPCs may be 
increased by the genetic risk factors that drive the first primary cancer, can also be applied for 
individuals with unknown genetic background since high penetrant mutations are rare due to 
selection (Allan, 2008). It is suggested that genetic risk for multiple primary malignancies 
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depends on the cumulated effect from a number of low- and moderate-penetrance inherited risk 
alleles susceptible to malignancy, where all risk alleles are responsible for temporal aggregation 
of polygenetic risk resulting in substantial increase in susceptibility subject to co-inheritance 
(Peto, 2002; Pharoah et al., 2002).  
1.6 Cause of death 
Cancer is the second leading cause of death in the world (Naghavi et al., 2017). In cancer 
patients, the cause of death is diverse, and they can die from the diagnosed cancer, other cancer, 
non-cancer diseases such as cerebrovascular event, infection and from suicide. Previously, the 
cause of death in breast and prostate cancer patients was explored based on the Swedish Family-
Cancer Database and the results showed that approximately half of the patients died of breast and 
prostate cancer respectively and cardiovascular diseases were most common competing causes of 
death in these patients (Riihimaki et al., 2012; Riihimäki et al., 2011). The US Surveillance, 
Epidemiology, and End Results (SEER) data reported that prostate, breast and testicular cancer 
patients are least likely to die of their cancer and patients with lung, pancreas and brain tumors 
are most likely to die of their cancer (Zaorsky et al., 2016). The data on the cause of death in 
cancer patients with a second cancer diagnosis are limited. The SEER data also indicates that for 
the common cancers with an additional cancer, 55% of the patients died of their second primary 
malignancy (Donin et al., 2016). Assessing the difference in cause of death between cancer 
patients with and without a SPC is of interest, which can guide the management of cancer 
patients. 
1.7 Genetic counselling in clinical practice 
In genetic counseling, cancer patients can learn about genetic conditions such as gene mutations 
probably involving in breast or ovarian cancers, find out their chances of being affected by or 
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families with a genetic disorders, and make informed decisions about their treatment. The 
demand for clinical genetic counseling is increasing, and the quantity of DNA-based genetic 
counseling has increased three times between 1996 and 2002 in Germany (Schmidtke et al., 
2005).  With the ongoing technical improvement and the increasing capabilities of next 
generation sequencing, large-scale, high-throughput genetic testing has become more and more 
cost- and time- effective and thus, available for a variety of clinical and research applications 
(Durmaz et al., 2015).  
Genetic counseling might have good implications for mutational testing of known cancer 
predisposing genes, but for individuals without well-established familial cancer syndromes it is 
less competent. According to the guidelines from the American Cancer Society,  only for limited 
cancer sites such as breast, prostate, colorectal, endometrial and ovarian cancers, family history 
is regarded as a sign for genetic screening or surveillance and the emphasis is mainly on 
mutation testing (Smith et al., 2011). With the widespread use of next generation sequencing and 
the increasing focus on genetic testing (Samuel et al., 2014), it is wasteful and dangerous if the 
easily accessible information on family history is still not properly used. It is reported that no 
more than 50% of medical record in the US had information on family history; even if it’s 
documented, the information were not complete, for example only having or not having family 
history and lack of age at diagnosis (Murff et al., 2007). One of the reasons can be that the data 
on familial risk is limited and physicians have not been aware of the possible relevance of family 
history to the cancer risk. Therefore, family history has not been made full use in the current 
busy clinical oncology practice. However, family history is of importance for identification of 
individuals susceptible to both first and subsequent primary malignancies and for identification 
of those most likely to benefit from genetic counseling (Wood et al., 2014). 
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1.8 Aim of the study 
The aim of the study was to highlight the familial clustering of breast and ovarian cancers with 
themselves and other cancers as well as with SPCs. Additionally cause of death in these two 
cancers were to be assessed based on the diagnosis of SPCs. To this end the recent update of 
Swedish Family-Cancer Database was used to: 
1) Analyze RR of breast and ovarian cancers in offspring with first-degree relatives diagnosed 
with these cancers considering the familial risk stratified by proband type, age at diagnosis and 
histological type;  
2) Explore discordant familial associations of the two cancers with other cancers, with additional 
stratification on histological type;  
3) Assess the impact of family history in first-degree relatives on the risk of the same cancer as 
SPC in breast and ovarian cancer patients;  
4) Compare the cause of death in breast and ovarian cancer patients with a diagnosis of SPC to 
those without a diagnosis. 
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2 MATERIALS AND METHODS 
2.1 The Swedish Family-Cancer Database 
The Swedish Family-Cancer Database (FCD) was created by linking the Multigeneration 
Registry, the Swedish Cancer Registry, national censuses and the Cause of Death Registry 
(Hemminki, 2001). In the Multigeneration Registry, children (offspring) born since 1932 are 
registered with their biological parents (Figure 3). Except misinformation due to registration 
mistakes and inaccuracies which primarily affects the offspring population belonging to the first 
decade of the registry and in addition to some discrepancies for some groups of emigrants and 
immigrants, the registry is complete. The cancer notification in the Swedish Cancer Registry 
started from 1958 (Figure 3). The reliability of the Cancer Registry is considered very high. 
About 98% of the cases are morphologically verified, and in comparisons with the National 
Patient Register, under reporting is only 3.7% (Barlow et al., 2009). As cancer identification 
from Death Registry is not used in the Swedish Cancer Registry, data from these two registries 
can be used to estimate the underreporting of cancers. Among individuals identified from Death 
Registry who had cancer as underlying cause of death, the average agreement rate were about 
80% between the cancers recorded in Cancer registry and in Hospital Charge Registry (Ji et al., 
2012). The agreement rate varied across cancer site. In the same study breast cancer was reported 
with very low underreporting and pancreatic and lung cancers with high underreporting (Ji et al., 
2012). Additional linkage was conducted to obtain, individual’s socio-economic index, 
geographical region of residence and educational level in the FCD. The linkages were performed 
by using the national registration number. In the final matched records, individuals cannot be 
identified because those numbers were removed (Hemminki, 2001). 
Breast and ovarian cancers in women………………………………     ………………Materials and Methods 
Guoqiao Zheng............................................................................................................................. 14 
 
Figure 3 General information on the structure of the populations and cancer registration in FCD.  
 
In the FCD, cancers are coded using three digits of international classification of diseases (ICD). 
In the beginning, ICD-7 was used to record the cancer sites. Later ICD-9 was used in 1987, ICD-
O/2 in 1993 and ICD-O/3 in 2005. All the coding are translated to ICD-7 in order to facilitate 
identifying cancers over long time periods in the following version of FCD.  Table 1 shows the 
ICD-7 codes for all the cancer sites in the FCD. As for some cancers in ICD-7 encompass 
cancers in multiple sites; for example, endocrine gland cancer includes cancers in adrenal 
parathyroid, thymus, pituitary, insuloma of pancreas and some other sites related to endocrine 
gland. Four digits of ICD-7 were also used to identify the detailed cancer sites of liver, endocrine 
gland and leukemia. The four digits codes for some cancers in subsite are shown in 
Supplementary Table 1.  
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Table 1 ICD-7 code in FCD for the cancer sites  
Cancer sites ICD-7 code (first 3 digits) 
Upper aerodigestive tract (UAT) 140, 141, 143-148, 161 
Salivary glands  142 
Esophagus 150 
Stomach 151 
Small intestine 152 
Colorectum 153 and 154 (except 1541) 
Colon 153 
Rectum 154 (except 1541) 
Anus 1541 
Liver 155-156 
Pancreas 157 
Nose 160 
Lung 162-163 
Breast 170 
Cervix 171 
Endometrium 172 
Uterus 173 
Ovary 175 
Other female genital 176 
Prostate 177 
Testis 178 
Other male genital 179 
Kidney 180 
Bladder 181 
Melanoma 190 
Skin 191 
Eye 192 
Nervous system 193 
Thyroid gland 194 
Endocrine glands 195 
Bone 196 
Connective tissue 197 
Non-Hodgkin lymphoma (NHL) 200, 202 
Hodgkin disease 201 
Myeloma 203 
Leukaemia 204-209 
Cancer od unknown primary (CUP) 199 
 
Histological types are also reported in the FCD. Before 1993, WHO/HS/CANC/24.1 histological 
codes (“PAD”) were used. In 1993 and later, The Systematized Nomenclature of Medicine 
(SNOMED) was applied in order to give more detailed histological information. The 
confirmation of the SNOMED histology as PAD histologies was reported closed to 100% and 
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compared to PAD codes, the SNOMED codes provided more information for breast and thyroid 
cancers and for melanoma (Hemminki et al., 2010b). However, PAD codes can be used to 
distinguish malignant melanoma (PAD=”176”) from retinoblastoma medulloblastoma 
(PAD=”436”) for eye cancer (shown in Supplementary Table 1). The SNOMED code for the 
main histological types of breast and ovarian cancer is displayed in Table 2. Particularly, 
thecoma was used to represent non-epithelial type as it accounts the most of this type. 
Table 2 SNOMED code in FCD for the histological types of breast and ovarian cancers 
Breast cancer 
Histological type SNOMED code 
Ductal  85003 
Lobular  85203 
Mucinous  84803 
Tubular  82113 
Medullary  85103 
Ovarian cancer 
Histological type SNOMED code 
Undifferentiaed  83203 
Clear cell 83103 
Endometrioid  83803 
Serous  84413, 84603 
Mucinous  84703 
Thecoma 86203 
 
2.2 Study population and Follow-up time 
FCD has been updated regularly since its creation. In this thesis, two versions of the database 
were used: the 10
th
 version, which assembled in 2012 and the 11
th
 version, assembled in 2015. 
The first one is for the analyses of familial association in breast cancer patients, which includes 
15.7 million individuals and 1.8 million cancer patients diagnosed between 1958 and 2012 and 
aged 0-80 years old. The second one is for the analyses of second cancer risk and cause of death 
in breast cancer patients and all the analyses in ovarian cancer patients, which contains 16.1 
million individuals and more than 2.0 million cancer cases aged 0-83 years old until the end of 
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2015.  
There is a lack of information on the death cases before 1958 when the Cancer Registry started. 
Therefore, offspring generation was followed for the cancer diagnosis from 1958 (for 
histological analysis it was 1993), the birth year, or the immigration year, whichever occurred 
latest. The follow-up was terminated in the year when the person was diagnosed with cancer, 
emigrated or died, or at the end of 2012 (for breast cancer) or 2015 (for ovarian cancer), 
whichever came first.  In the follow-up for the second cancer risk, it started from the diagnosis of 
first cancer, and ended at the diagnosis of second cancer, emigration or death, or at the end of 
2015, which came earliest.  
Based on the follow-up period, the corresponding cases and person-years were assigned into 
different strata according to sex, age group (17 groups with 5-year gap), calendar year (10-year-
gap), residential area (big cities, South Sweden, North Sweden, or unspecified) and 
socioeconomic status (blue-collar worker, white-collar worker, farmer, private, professional, or 
other/unspecified). For the study purpose, cases and person-years were also allocated to different 
strata based on family history of cancer for familial clustering analysis or personal history of 
cancer for SPC risk estimation individually. Additionally when estimating breast or ovarian 
cancer risk, the adjustment for parity (0, 1, 2, 3 and ≥4 child births) was also performed. 
2.3 Familial clustering 
Familial history was defined as the concordant or discordant cancer diagnosis in first-degree 
relatives (including parents and/or siblings). RRs, estimated for the offspring generation, were 
used for the assessment of familial risk, which were obtained by comparing incidence rates of 
cancer for individuals with cancer family history to incidence rates for those who had no 
relatives affected by cancer (reference group). 
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2.3.1 Concordant familial associations 
For concordant familial risk analysis stratified by proband type, diagnosis of breast or ovarian 
cancer in first-degree relatives was regarded as having family history. For ovarian cancer, only 
family history in the relationship of mother-daughter, sister-sister and mother-two daughters was 
taken into account. On the contrary, the family history from father and brother were also 
included for breast cancer. Estimation of familial risk stratified by the age at diagnosis (over or 
below 50 years old) was performed. In order to see the role of histology in the familial 
association in breast and ovarian cancer, a two-way comparison was applied, the detail of which 
is shown in Figure 6. In this method, estimation for two sets of RRs were performed, i.e. RR for 
overall (histology-specific) breast or ovarian cancer with cancer diagnosis of histology-specific 
breast or ovarian cancer in first-degree relatives, and conversely, RRs for histology-specific 
breast or ovarian cancer with cancer diagnosis of overall (histology-specific) breast or ovarian 
cancer in first-degree relatives.  
2.3.2 Discordant familial associations 
The two-way comparison was performed to estimate the familial associations of breast and 
ovarian cancers with other cancers. Firstly, RR for breast or ovarian cancer was calculated when 
first-degree relatives were diagnosed with discordant cancer X, and then in the reverse order RR 
for cancer X was calculated when first-degree relatives were diagnosed with breast or ovarian 
cancer. In addition, gender-specific association and histology-specific association were 
considered for breast and ovarian cancer respectively. The two-way analysis is displayed in 
Figure 4. On the left side, RR was calculated for breast or ovarian cancer; person-years at risk 
were calculated for all offspring; probands were all first-degree relatives. The reverse analysis 
was shown on the right side: RR for cancer X was estimate.  
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Figure 4 The structure of the two-way analysis for RR estimates in the association of breast or ovarian 
cancer with cancer X. On the left, RR of breast or ovarian cancer was calculated when first-degree 
relatives were diagnosed with cancer X; on the right, RR of cancer X was calculated when female first-
degree relatives were diagnosed with breast or ovarian cancer. In addition, gender-specific association 
and histology-specific association were considered for breast and ovarian cancer respectively. BC, breast 
cancer, OC, ovarian cancer, X and Y are both other cancers. 
 
The two-way comparisons are independent for the family relationship between parents and 
offspring which was the main familial cases) while for the relationship between  siblings the 
pairs of cases are the same (Hemminki et al., 2010b). Although a bi-directional signal allude to 
true association, but absence of it in no way an evidence against it, as case numbers and age 
distributions may vary among two-way analyses. 
2.4 Impact of family history on development SPC 
Invasive cancer diagnosed after breast or ovarian cancers, including synchronous second 
malignancies (diagnosed within 1 year after breast or ovarian cancer diagnoses) were identified 
as SPC. The risk of second endometrial cancer after ovarian cancer was not considered as the 
primary treatment for ovarian cancer is surgery usually including uterus removal. However, for 
the overall calculation we kept second endometrial cancer. For the risk of particular SPC, the 
diagnosis of this cancer in first-degree relatives was considered as family history. In situ cancers 
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in breast, colorectum, melanoma and skin (squamous cell) in family members were also included 
in family history because familial risk in these in situ cancers are approximately equally as high 
as in invasive cancers (Hussain et al., 2008; Lorenzo Bermejo and Hemminki, 2005a). For risk 
estimation for any cancer as SPC, any invasive cancer diagnosis in first-degree relatives was 
regarded as family history.  
The impact of family history on the development of SPC was assessed by comparing the RRs of 
SPC in breast or ovarian cancer patients who had first-degree relative diagnosed with this cancer 
to the RRs without this family history. In risk estimation for SPC, the incidence of this cancer as 
first primary cancer in the population without family history of this cancer and breast cancer was 
used as reference. Cumulative incidence of SPC with or without a family history of concordant 
cancer stratified over age at SPC diagnosis were calculated considering death as a competing 
event. 
We performed sensitivity analyses for ovarian cancer by deleting families which might be 
carriers of the known high-risk genes in the risk estimation of SPC.  Families with increased 
likelihood of having BRCA1/2 carriers can be defined with any of the following situations: 1) 
with male first-degree relatives diagnosed with breast cancer; 2) with two or more first-degree 
relatives diagnosed with breast cancers before age 50 years; 3) with at least one first-degree 
relative diagnosed with bilateral breast cancers counted as two independent cases when 
diagnosed <50 years (Lorenzo Bermejo and Hemminki, 2005b). High risk families possibly 
associated with MMR mutations were defined as families with patients with colorectal or 
endometrial cancer diagnosed before 50 years (Bermejo et al., 2005). Based on the above 
criteria, 14,854 (0.35%) women among all the women followed in the database and 79 (0.70%) 
among 11,300 ovarian cancer patients were identified from possible high-risk family associated 
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with BRCA1/2 mutations. For possible high-risk families associated with MMR mutations, the 
respective numbers were 25,188 (0.60%) and (0.96%).   
2.5 Relative risk estimation 
Generalized liner model (GLM) fitted by Poisson regression was used to estimate the RR in this 
thesis, since this approach is possible to be used to perform hypothesis tests comparing familial 
risks for different family relationships. The model was formulated by Nelder et al. in 1972 (82), 
which is a flexible generalization of ordinary linear regression that allows error distribution 
models of response variables to have distribution not limited to a normal distribution. Briefly, 
GLMs model the relation between a response variable 𝑌 and a set of explanatory variables 𝑋 
(covariates) with the assumption that 𝑌 possesses a probability density function of exponential 
form and its distribution parameters depend on the linear predictor 𝑋 through a link function, 
where 𝛽 is called the regression coefficients. Poisson regression is a generalized model used to 
model count data and contingency tables, in which the count response 𝑌 is assumed to be a 
discrete random variable following a Poisson distribution with probability mass function 𝑓:  
𝑓 (𝑦𝑖; 𝜇𝑖) ∶=P(Y= 𝑦𝑖) =
𝑒−𝜇𝑖    𝜇𝑖
𝑦
𝑦𝑖 !
        𝑦𝑖=0, 1, 2,…; 𝜇𝑖>0 . 
In the regression model the observed count is represented by 𝑦𝑖, of which 𝑖 is used to emphasize 
the modeling of various observations 𝑦𝑖 (i=1,…,N) with a set of 𝐾 covariates 𝑥𝑖′=(1,𝑥𝑖1,…,𝑥𝑖K). 
In Poisson distribution, one of the unique features is that the variance equals the mean, which is 
called equidispersion. To conform to an equidispersed variance function, the link was adjusted 
with an offset variable. Based on the regression equation 
ln𝜇𝑖=𝑥𝑖′𝛽, 
𝜇𝑖 is linked to the linear predictor 𝑥𝑖′𝛽 through the natural logarithm which is the link function for 
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Poisson regression. The regression coefficients 𝛽 are estimated by maximizing the log-likelihood 
function.  
𝑙(𝛽|𝑋, 𝑌): = ∑[𝑦𝑖(𝑥𝑖
′𝛽) − 𝑒𝑥𝑖𝛽 − ln𝑦𝑖!]
𝑁
𝑖=1
 
As described previously, cases and person-years were stratified among different strata based on 
the follow-up data. Let 𝑛𝑗 be the number of person-years and 𝑑𝑗 denote the number of newly 
diagnosed cancers among individuals with a positive family history (for analysis of familial 
clustering) or with the prior breast or ovarian cancer diagnosis (for analysis of SPC risk) in the 
jth stratum, j=1,…, J different settings of 𝐾 covariates (the confounders used for stratification) 
that will be presented as 𝑥𝑗 below. Assuming 𝑑𝑗 to follow Poisson distribution with mean 𝜇𝑗, the 
mean incidence rate E (
𝑑𝑗
𝑛𝑗
) was derived as 
E (
𝑑𝑗
𝑛𝑗
) =
𝜇𝑗
𝑛𝑗
 
and the regression equation could be described as 
ln (
𝜇𝑗
𝑛𝑗
)= 𝑥𝑗 ′β 
or, in another way, as 
ln𝜇𝑗= 𝑥𝑗 ′β + ln𝑛𝑗, 
ln𝑛𝑗 is termed offset variable. 
Each combination of covariates 𝑥𝑗′= (1, 𝑥𝑗1, …, 𝑥𝑗𝑗) consisted of the binary information on family 
history (diagnosis of breast or ovarian cancer) 𝑥𝑗∗ which was coded 𝑥𝑗∗=0 for negative family 
history for familial association study and no diagnosis of breast or ovarian cancer for second 
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cancer risk study and correspondingly 𝑥𝑗∗=1 for positive family history and diagnosis of breast or 
ovarian cancer. The fitted incidence rate for any stratum 𝑗 was derived by 𝜇𝑗⁄𝑛𝑗. With the 
assumption that values of all other covariates from 𝑥𝑗 were constant except of 𝑥𝑗∗, then (𝜇𝑗⁄𝑛𝑗)
 +
 
represented the incidence rate given 𝑥𝑗∗=1 and (𝜇𝑗⁄𝑛𝑗)
 −
 was the corresponding rate for 𝑥𝑗∗=0. The 
ratio of both rates was only depended on 𝛽∗ other than 𝑗. Therefore, the RR was obtained by  
RR= 
(𝜇𝑗/𝑛𝑗)
+
(𝜇𝑗/𝑛𝑗)
−=𝑒
𝛽∗. 
Wald Chi-square estimates for 𝛽∗ were used to test for the significance of family history 
(diagnosis of breast or ovarian cancer) as a risk factor and provide CIs for RRs. Familial risk 
(risk of SPC) was regarded to be significantly increased or decreased with the lower bound of the 
RR’s 95% CI over 1.00 or with the upper bound below 1.00, respectively.  
For the analysis of familial clustering, if different family histories (for example, only one mother, 
only one sister or both mother and sister affected by cancer) were examined together in one 
regression model, 𝑥𝑗∗ was converted into a set of dummy variables using reference cell coding to 
calculate the corresponding RRs analogously to the binary case.  
In the analyses for familial clustering, to know whether there was dose-response relationship 
between familial risk and affected first-degree relatives i.e. the familial risk increases with the 
increasing number of the affected relatives, trend tests were carried out by adjusting the Poisson 
regression with the number of affected relatives treated as a continuous variable for the analyses 
of familial clustering. P value of the trend test (P-trend) calculated from non-parameter test 
(Median test) was used to assess the impact of family history on the risk of SPC. In the non-
parameter test, 100 000 bootstrapped samples of a particular second cancer risk in breast or 
ovarian cancer patients with family history of this cancer (RR positive family history) were 
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compared to those same number of samples in patients without family history among first-degree 
relatives (RR negative family history). 
To avoid chance finding and more importantly falsely discovered signals, a cautious sensitivity 
adjustment measure needs to be employed in studies where a large number of tests are to be 
performed (Brown, 1975). To this end adjustments for multiple testing were implicated with 
calculation of multiple confidence intervals (CIs). In this study, besides 95%, 99% and 99.9% 
confidence intervals (CIs) from Poisson regression models were also calculated in order to 
differentiate the likely true associations from likely chance findings, as a single 95%CI is not 
very informative in the context of multiple comparisons. All the statistical tests are based on two-
tailed hypothesis. SAS version 9.4 was used to perform the statistical analysis.  
2.6 Cause of death 
Underlying and contributing cause of death were obtained from the Swedish Cause of Death 
Register and its coding system was based on the ICD codes (ICD7 for 1961; ICD8 for 1969-
1986; ICD9 for 1987-1996; ICD10 for 1997-2015). For ovarian cancer, all cancer related deaths 
were grouped into ovarian cancer, SPC and ‘other cancer’.  For breast cancer, all cancer related 
deaths were stratified into breast cancer, SPC, higher order primary cancer and ‘other cancer’.  In 
breast cancer patients with second breast cancer diagnosis, the cause of death was assigned to 
breast cancer even though it was not known whether first or second breast cancer killed the 
patient. ‘Other cancer’ included cancers diagnosed at the issue of death certificates and they were 
not the first cancer, SPC or higher order primary cancer. As mentioned before, unlike other 
Nordic Cancer Registries, Swedish Cancer Registry death does not use cancer notifications from 
Death Registry (Brooke et al., 2017; Ji et al., 2012; Pukkala et al., 2017). Multiple cancers and 
cancer of unknown primary (CUP) were often included in the death certificate notifications, 
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which were considered as metastases in our previous study (Riihimaki et al., 2014a; Riihimaki et 
al., 2016). In the present analysis, cause of death was assigned into the reported primary cancer if 
this site was consistent with the death certificate notification. However, when cancer reported 
from Cancer Registry was different from death certificate notification, the classification for 
cause of death was to “other cancer”. In some analyses higher order primary cancers including 
third, fourth, fifth primary cancer, were reported separately. Other non-cancer cause of death 
such as suicide and heart attack were classified as ‘other cause’.  
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3 RESULTS 
3.1 Familial clustering of breast cancer 
3.1.1 Characteristics of breast cancer patients 
There are 235,316 breast cancer patients diagnosed between 1958 and 2012 in the database and 
among them, 76,060 were diagnosed in the offspring generation for which RRs were calculated 
(Table 3). Among breast cancer patients in offspring generation, 63,794 (83.9%) were from 
families without first-degree relatives affected by breast cancer, while 11,351 (14.9%) with one 
and 915 (1.2%) with at least two first-degree relatives affected by breast cancer. On the contrary, 
39.8% of women had one first-degree relative diagnosed with discordant cancer and 14.7% had 
at least two first-degree relatives diagnosed with discordant cancer. More than half of the breast 
cancer patients in the offspring generation were diagnosed in the recent 15 years. Most of the 
women (43.5%) had two children and 14.4% of the women had no children. Approximately half 
of the patients were living in big cities. Most of the patients were blue collar or worker upon the 
diagnosis of the breast cancer. In the patients with record of histological types, 69.2% of them 
were ductal, followed by lobular (12.9%). 
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Table 3 Characteristics of breast cancer patients in offspring generation (1958-2012) 
No. of females followed  4,139,937 
No. of breast cancer cases  76,060 
No. of breast cancer cases (1993-2012) 64,209 
Median age at diagnosis of breast cancer 55 years old 
No. of breast cancer cases with family history 
of breast cancer  
In one first-degree relative 11,351 (14.9%)  
In two first-degree relatives 889 (1.2%)  
In at least three first-degree relatives 26  
No. of breast cancer cases with family history 
of discordant cancers 
In one first-degree relative 30,239 (39.8%)  
In two first-degree relatives 9,317 (12.2%)  
In at least three first-degree relatives 1898 (2.5%) 
Diagnosed period (year) 
1958-1970 139 (0.2%) 
1971-1980 1413 (1.9%) 
1981-1990 7,285 (9.6%) 
1991-2010 21,277 (28.0%) 
2011-2012 45,946 (60.4%) 
Parity  
0 child 10,800 (14.2%) 
1 child 12,820 (16.9%) 
2 children 33,070 (43.5%) 
3 children 14,788 (19.4%) 
≥ 4 children 4,582 (6.0%) 
Residential area 
Big city 35,557 (46.7%) 
South 6,270 (8.2%) 
North 2,310 (3.0%) 
Other 3,1923 (42.0%) 
Socioeconomic status 
Agriculture 622 (0.8%) 
Private 2,253 (3.0%) 
Professional 6,965 (9.2%) 
Blue collar 30,888 (40.6%) 
Worker 23,004 (30.2%) 
Other 12,328 (16.2%) 
Histological type  
(1993-2012) 
Ductal  44,376 (69.2%) 
Lobular  8,240 (12.9%) 
Mucinous  856 (1.3%) 
Tubular  3,065 (4.8%) 
Medullary  6,84(1.1%) 
Others 6,988 (10.9%) 
Others include histological types of other breast cancers such as papillary, neuroendocrine breast cancers.  
 
3.1.2 Familial clustering of breast cancer with concordant cancer 
3.1.2.1 Familial risk by number of affected FDRs 
The RR for breast cancer was 1.76 (95%CI, 1.72-1.79, P<0.001) for women from families with 
one first-degree relative diagnosed with breast cancer and it went up to 2.76 (2.58-2.95, P<0.001) 
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with two first-degree relatives diagnosed but it increased no further (1.70, 1.16-2.50, P<0.001) 
with three or more first-degree relatives diagnosed (Figure 5). The proportion of invasive and in 
situ female breast cancer was calculated when there were zero, one, two and more than three 
first-degree relatives diagnosed with breast cancer (invasive) and the more affected first-degree 
relatives with breast cancer in family, the larger proportion of in situ breast cancer compared to 
invasive breast cancer (Supplementary Table 2).  
 
Figure 5 Relative risk of female breast cancer with family history of breast cancer in first-degree relatives 
(parents or siblings). FDR: first-degree relatives; *significant at 0.01 level, ** significant at 0.001 level. 
 
3.1.2.2 Familial risk by proband type and age at diagnosis 
Table 4 shows the familial risk of breast cancer stratified by proband type and age at diagnosis. 
Among all the breast cancer in offspring generation, 8,584 and 5,438 of them had only mother 
and only one sister diagnosed with breast cancer respectively, and the risk of breast cancer with 
one affected mother was similar to that with one affected sister (1.71, 95%CI:1.69-1.76, 1.75, 
1.71-1.80, respectively).  Accordingly, the risk when at least two sisters were affected by breast 
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cancer (2.52, 2.29-2.78) was found close to the risk when mother and at least one sister were 
affected (2.78, 2.59-2.98). However, in the families with mother and at least two sisters with 
breast cancer diagnoses, the risk of breast deceased (1.95, 1.35-2.82). When one brother was 
diagnosed with breast cancer, the breast cancer risk (2.64, 1.88-3.72) was higher than the risk 
with father affected by breast cancer (1.65, 1.26-2.16). In families with mother and father 
diagnosed with breast cancer, the risk of breast cancer increased up to 6.51 (3.78-11.21). When 
mother, sister and brother all were affected by breast cancer, the familial risk is extremely high, 
reaching 16.15 (4.04-64.6), but based on only two families of this kind. The familial risk of 
breast cancer was found higher in younger patients (<50 years old) no matter what proband type 
was affected.  
Table 4 Familial risk of female breast cancer according to proband type and age at diagnosis 
Affected first-degree relatives 
Overall <50 years >= 50 years 
N RR 95%CI N RR 95%CI N RR 95%CI 
Female relatives          
Only mother 8584 1.72 1.69-1.76 3236 1.95 1.88-2.02 5348 1.63 1.59-1.68 
Only one sister 5438 1.75 1.71-1.80 1406 2.02 1.92-2.14 4032 1.69 1.64-1.75 
At least two sisters 407 2.52 2.29-2.78 108 3.47 2.87-4.19 299 2.33 2.08-2.61 
Mother + one sister 798 2.78 2.59-2.98 262 3.70 3.28-4.18 536 2.53 2.32-2.76 
Mother + at least two sister 28 1.95 1.35-2.82 10 3.23 1.74-6.01 18 1.61 1.02-2.56 
Male relatives          
Only father 53 1.65 1.26-2.16 21 2.26 1.47-3.46 32 1.42 1.00-2.00 
Only brother 33 2.64 1.88-3.72 10 3.80 2.04-7.06 23 2.38 1.58-3.58 
Female and male relatives          
Father + at least one sister 6 2.81 1.26-6.26 2 3.89 0.97-15.56 4 2.53 0.95-6.75 
At least one sister + one brother 2 1.19 0.30-4.76 1 2.32 0.33-16.5 1 0.80 0.11-5.69 
Mother + at least one brother 3 3.30 1.06-10.22 1 4.76 0.67-33.79 2 2.93 0.73-11.72 
Both mother + father 13 6.51 3.78-11.21 8 9.55 4.78-19.10 5 4.59 1.91-11.02 
Mother + sister + brother 2 16.15 4.04-64.6 0   2 20.36 5.09-81.43 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively. 
 
3.1.2.3 Familial risk by histological types 
The familial associations of overall breast cancer and histology-specific breast cancer are shown 
in Table 5. The familial risks were similar between histological types and in the two way 
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comparisons the RRs ranged from 1.50 to 2.06. 
Table 5 Familial associations between overall breast cancer and histology-specific breast cancers 
Histological type 
Risk of overall breast cancer Risk of histology-specific  breast cancer 
N RR 95%CI N RR 95%CI 
Ductal 4893 1.72 1.67-1.77 9206 1.78 1.74-1.82 
Lobular 1028 1.73 1.63-1.84 1785 1.87 1.77-1.97 
Mucinous 157 1.50 1.28-1.75 170 1.63 1.38-1.92 
Tubular 380 1.97 1.78-2.18 619 1.97 1.8-2.15 
Medullary 74 2.06 1.64-2.59 119 1.71 1.4-2.07 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively. 
 
3.1.2.4 Familial risk among histological types 
Familial associations among different histology-specific breast cancers are shown in Table 6. 
Family history of all the histological types in first-degree relatives were found related to the risk 
of the concordant type of breast cancer and the risk with family history of concordant histology 
showed the highest compared to the risk with discordant subtypes apart from ductal carcinoma, 
among which medullary carcinoma presented the highest risk (7.88, 2.54-24.50). Furthermore, 
ductal carcinoma in first-degree relatives was observed with the increased risk of all the other 
subtypes of breast cancer, among which risk of tubular carcinoma was the highest (1.92, 1.67-
2.20). In addition, risk of ductal breast cancer elevated with family history of any other 
histology-specific breast cancers. Risks of tubular carcinoma increased when first-degree 
relatives were diagnosed with lobular breast cancer (1.75, 1.30-2.37). In the reverse analysis, 
family history of tubular carcinoma was associated with the risk of lobular type (1.91, 1.43-
2.55).   
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Table 6 Familial associations between histology-specific breast cancers 
Histological type Risk of overall breast cancer 
First-degree relative Offspring N RR 95%CI 
Ductal 
Ductal 3471 1.73 1.67-1.79 
Lobular 614 1.73 1.59-1.87 
Mucinous 53 1.38 1.04-1.82 
Tubular 221 1.92 1.67-2.20 
Medullary 42 1.46 1.07-1.99 
Lobular 
Ductal 731 1.76 1.64-1.89 
Lobular 154 2.06 1.75-2.41 
Mucinous 8 0.99 0.49-1.98 
Tubular 43 1.75 1.30-2.37 
Medullary 7 1.19 0.56-2.51 
Mucinous 
Ductal 113 1.55 1.29-1.86 
Lobular 15 1.13 0.68-1.87 
Mucinous 6 4.21 1.89-9.40 
Tubular 2 0.45 0.11-1.80 
Medullary 0 0.45 0.04-4.62 
Tubular 
Ductal 275 2.05 1.82-2.31 
Lobular 46 1.91 1.43-2.55 
Mucinous 5 1.90 0.79-4.57 
Tubular 22 2.68 1.76-4.08 
Medullary 4 2.08 0.78-5.57 
Medullary 
Ductal 52 2.06 1.57-2.71 
Lobular 7 1.58 0.75-3.32 
Mucinous 1 2.09 0.29-14.88 
Tubular 2 1.40 0.35-5.60 
Medullary 3 7.88 2.54-24.5 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively. 
 
3.1.3 Familial clustering of breast cancer with discordant cancer 
3.1.3.1 Risk of breast cancer with first-degree relatives affected by other cancer 
A group of 20 discordant cancers with significance in the two-way comparison or trend test were 
included in Table 7 and Table 8. Results on risk of breast cancer with first-degree relatives 
affected by discordant cancers are shown in Table 7. A total of 17 cancer sites showed at least 
one significant association. RRs of breast cancer displayed a ‘dose-response’ relationship with 
numbers of first-degree relatives affected by prostate cancer (trend test P<0.0001): RR was 1.08 
(1.06-1.10) when one first-degree relative was affected by prostate cancer, 1.15 (1.06-1.25) when 
two first-degree relatives affected and 1.38 (1.09-1.71) when at least three were affected. The 
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trend test was also observed highly significant in families with ovarian cancer patients (trend test 
P<0.0001, RR, 2.44, 1.66-3.59) in families with two women diagnosed with ovarian cancer). In 
addition, significance was shown in families with lung cancer patients (trend test P=0.0002) 
although the RRs were modest. Besides those three cancers, only a single significant RR was 
found for the rest of the 14 cancer sites. Curiously, RRs for breast cancer were not elevated when 
only one first-degree relative diagnosed with melanoma, non-Hodgkin lymphoma or leukemia 
patient but high RRs were shown when two first-degree relatives were diagnosed with those 
diseases (1.56, 1.23-1.98, 1.48, 1.05-2.09 and 1.50,1.07-2.11, respectively). When first-degree 
relatives had any cancers, RRs for breast cancer were highly significant and it was 1.63 (1.58-
1.69) in families with three or more first-degree relatives affected by any cancer. When breast 
cancer was excluded from any cancer diagnosis in first-degree relatives, the respective familial 
risk decreased to 1.22 (1.17-1.28).     
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Table 7 Relative risks for female breast cancer in families where parents or siblings were 
diagnosed with cancers 
Cancer site 
Cases with one FDR Cases with two FDRs Cases with ≥ three FDRs 
P- trend 
N RR 95%CI N RR 95%CI N RR 95%CI 
Stomach 2265 1.05 1.01-1.09 41 1.30 0.96-1.77 2 1.85 0.46 – 7.39 0.0080 
Colorectum 6474 1.06 1.03-1.08 300 1.09 0.97-1.22 11 0.83 0.46 - 1.50 <0.0001 
Liver 1579 1.05 1.00-1.10 11 0.81 0.45-1.46 - - - 
- 
0.0773 
Pancreas 1618 1.06 1.00-1.11 13 0.82 0.48-1.41 - - - 
- 
0.0571 
Lung 4242 1.06 1.02-1.09 161 1.18 1.01-1.38 6 1.05 0.47-2.35 0.0002 
Breast 11351 1.76 1.72-1.79 889 2.76 2.58-2.95 26 1.70 1.16-2.50 <0.0001 
Endometrium 1709 1.06 1.01-1.11 20 1.25 0.81-1.94 1 1.49 0.21-10.59 0.0122 
Ovary 1640 1.26 1.20-1.32 26 2.44 1.66-3.59 - - - 
- 
<0.0001 
Prostate 8808 1.08 1.06-1.10 564 1.15 1.06-1.25 71 1.38 1.09-1.71 <0.0001 
Testis 223 1.14 1.00-1.31 - - - 
- 
- - - 
- 
0.0490 
Bladder  2824 1.05 1.01-1.09 45 0.99 0.74-1.32 4 2.26 0.85-6.02 0.0089 
Melanoma 1922 1.02 0.98-1.07 67 1.56 1.23-1.98 2 1.63 0.41-6.52 0.0752 
Skin, squamous cell 2373 0.99 0.95-1.03 51 1.09 0.83-1.43 - - - 
- 
0.6013 
Eye 201 1.16 1.01-1.33 - - - 
- 
- - - 
- 
0.0408 
Nervous 1761 1.05 1.00-1.10 22 0.91 0.60-1.39 - - - 
- 
0.0739 
Thyroid gland 504 1.08 0.99-1.18 4 1.38 0.52-3.67 - - - 
- 
0.0645 
Endocrine glands 1071 1.08 1.02-1.15 9 0.99 0.52-1.91 - - - 
- 
0.0112 
Connective tissue 381 1.01 0.92-1.12 1 1.54 0.22-10.96 - - - 
- 
0.7469 
Non-Hodgkin lymphoma 1781 1.02 0.97-1.07 32 1.48 1.05-2.09 1 3.03 0.42-21.49 0.2690 
Leukemia 1664 1.03 0.98-1.08 33 1.50 1.07-2.11 1 1.78 0.25-12.61 0.0852 
Cancer of unknown primary 1971 1.05 1.01-1.10 16 0.91 0.56-1.48 - - - 
- 
0.0320 
All cancers
a
 31348 1.17 1.16-1.19 12929 1.36 1.33-1.39 3393 1.63 1.58-1.69 <0.0001 
All cancers
b
 30239 1.08 1.06-1.09 9317 1.11 1.09-1.14 1898 1.22 1.17-1.28 <0.0001 
FDR: first-degree relatives (parents or siblings);  
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include breast cancers and all other cancers; b: all cancers include all other cancers except breast 
cancer. 
 
To acknowledge the association of breast cancer risk with specific cancer sites. We did subtype 
analyses for eye, endocrine gland tumor and leukemia. The increase in risk of breast cancer in 
families with eye cancer patients was associated with uveal melanoma (N= 158, RR 1.16, 1.00-
1.35); only family history of the parathyroid tumors was related to increased breast cancer risk in 
families with endocrine gland tumor patients (708, 1.07, 1.00-1.16); chronic myeloid leukemia 
showed the only significance in the analyses for leukemia (181, 1.19, 1.03-1.38).  
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3.1.3.2 Risk of other cancer with first-degree relatives affected by breast cancer 
RRs for discordant cancers in families with breast cancer patients are displayed in Table 8. A 
total of 14 cancers showed significant results in the two-way analysis (Table 7 and Table 8) 
among the 20 discordant pairs of cancer. Risks of 16 cancers were associated with family history 
of breast cancer, among which connective tissue tumors only showed significance in the trend 
test. Elevated risks for ovarian and stomach cancers were observed in families with one and two 
family members diagnosed with breast cancer patients; risk for CUP was increased in families 
with one and three or more  family members affected by breast cancer (2.28, 1.02-5.07). The RR 
of nervous system tumors was 1.99 (1.00-3.98) when at least three first-degree relatives were 
diagnosed with breast cancer and it was 1.90 (1.38-2.63) for thyroid cancer (significant at 0.1% 
level) when two first-degree relatives were diagnosed with breast cancer.  
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Table 8 Relative risks for cancers in offspring in families where mother or sisters were 
diagnosed with breast cancer 
Cancer site 
Cases with 1 FDR Cases with 2 FDRs Cases with ≥3 FDRs 
P-trend 
N RR 95%CI N RR 95%CI N RR 95%CI 
Stomach  531 1.10 1.01-1.21 44 1.69 1.26-2.28 3 1.90 0.61-5.89 0.0005 
Colorectum  3256 1.03 0.99-1.07 183 1.09 0.94-1.26 5 0.53 0.22-1.28 0.3322 
Liver  520 1.00 0.92-1.10 26 0.93 0.63-1.36 3 1.78 0.57-5.52 0.9535 
Pancreas  664 1.13 1.04-1.22 35 1.08 0.78-1.51 3 1.51 0.49-4.68 0.0037 
Lung  2253 1.03 0.99-1.08 135 1.12 0.94-1.32 7 0.98 0.47-2.05 0.0866 
Breast  11342 1.76 1.72-1.79 876 2.72 2.55-2.91 26 1.71 1.16-2.51 <0.0001 
Endometrium  1072 1.07 1.01-1.14 65 1.20 0.94-1.54 2 0.74 0.18-2.95 0.0149 
Ovary  1045 1.23 1.15-1.31 61 1.45 1.13-1.86 3 1.44 0.46-4.45 <0.0001 
Prostate  6499 1.12 1.09-1.15 343 1.06 0.96-1.18 26 1.35 0.92-1.98 <0.0001 
Testis  621 1.14 1.05-1.23 19 0.99 0.63-1.56 - - - 
- 
0.0053 
Bladder  1304 1.03 0.97-1.09 79 1.15 0.92-1.43 6 1.48 0.66-3.29 0.1183 
Melanoma  2615 1.06 1.02-1.11 128 1.16 0.97-1.37 6 1.07 0.48-2.38 0.0007 
Skin, squamous cell 1141 1.10 1.04-1.17 55 1.01 0.78-1.32 3 1.03 0.33-3.20 0.0056 
Eye  170 1.25 1.07-1.47 7 1.12 0.53-2.35 - - - 
- 
0.0103 
Nervous system 1763 1.02 0.97-1.07 80 1.07 0.86-1.33 8 1.99 1.00-3.98 0.2047 
Thyroid gland 478 1.05 0.96-1.16 37 1.90 1.38-2.63 1 1.02 0.14-7.27 0.0157 
Endocrine glands 880 1.07 1.00-1.15 41 1.06 0.78-1.44 2 0.99 0.25-3.95 0.0678 
Connective tissue 323 1.10 0.98-1.23 20 1.48 0.95-2.30 - - - 
- 
0.0332 
Non-Hodgkin lymphoma 1289 1.06 1.00-1.12 58 0.96 0.74-1.24 4 1.18 0.44-3.14 0.1076 
Leukemia  1175 1.08 1.02-1.15 62 1.27 0.99-1.63 2 0.75 0.19-3.00 0.0026 
Cancer of unknown primary 894 1.11 1.04-1.19 49 1.13 0.85-1.49 6 2.28 1.02-5.07 0.0011 
All cancers
a
 44003 1.18 1.17-1.19 2620 1.38 1.33-1.43 132 1.27 1.07-1.50 <0.0001 
All cancers
b
 32661 1.06 1.05-1.07 1744 1.10 1.05-1.16 106 1.19 0.99-1.44 <0.0001 
FDR: first-degree relatives (mother or sisters); 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include breast cancers and all other cancers; b: all cancers include all other cancers except breast 
cancer. 
 
In the analysis for subtype cancer sites, uveal melanoma was found likely related to the increased 
risk for eye cancer (N= 97, RR 1.29, 95%CI 1.04-1.59); pituitary tumors was the only site among 
all the endocrine gland tumors associated with family history of breast cancer (257, 1.16, 1.02-
1.32); the association between risk of acute and chronic myeloid leukemia and breast cancer 
family history may contributed to the increased risk of leukemia: the increased risk of chronic 
myeloid leukemia was observed when two first-degree relatives were diagnosed with breast 
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cancer (10, 2.06, 1.11-3.85), and the RRs for acute and chronic myeloid leukemia were 
marginally significant in families with one first-degree relative affected by breast cancer (231, 
1.13, 0.98-1.29 and 125, 1.18, 0.98-1.42, respectively). 
3.1.3.3 Familial association of female breast cancer with other cancers limited by sex 
The two-way analysis with stratification on gender of first-degree relatives was performed for 
the association of breast cancer and other cancers. When considering other cancer risk in female 
relatives (Supplementary Table 3), risks for kidney (3.90, 1.26-12.08) and bladder (3.60, 1.16-
11.17) cancers and for myeloma (4.87, 1.22-19.49) were found high when three or more female 
family members were affected by breast cancer, however each association was only based on one 
or three familial cases. When considering the familial association with other cancer in male 
relatives (Supplementary Table 4), RR of breast cancer was remarkably high  in two families 
with three or more male relatives diagnosed with stomach cancer (24.03, 6.03-96.08) and it was 
1.88 (1.14-3.12) in 15 families with two patients affected by squamous cell skin cancer. 
Specifically, the results for colorectal cancer are summarized in Table 9. Breast cancer risk was 
not increased when female relatives were diagnosed with colorectal cancer. On the contrary, a 
‘dose-response’ trend was found between breast cancer risk and number of male relatives having 
colorectal cancers and the RR increased up to 2.67 (1.11-6.40) with three or more patients (p < 
0.0001).     
Table 9 Familial association of female breast cancer with female and male colorectal cancer 
Calculation item 
Cases with 1 FDR Cases with 2 FDRs Cases with ≥3 FDRs 
P-trend 
N RR 95%CI N RR 95%CI N RR 95%CI 
BC by female CRC 3242 1.02 0.98-1.06 46 1.03 0.77-1.38 1 0.77 0.11-5.38 0.2946 
Female CRC by BC 1433 1.02 0.96-1.08 92 1.25 1.02-1.54 3 0.80 0.26-2.48 0.1553 
BC by male CRC 3605 1.08 1.04-1.11 75 1.27 1.01-1.59 5 2.67 1.11-6.40 <0.0001 
Male CRC by BC 1823 1.04 0.99-1.09 91 0.96 0.78-1.19 2 0.35 0.09-1.40 0.2998 
FDR: first-degree relatives; BC: breast cancer; CRC: colorectal cancer 
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Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively. 
 
 
3.2 Familial clustering of ovarian cancer 
3.2.1 Characteristics of ovarian cancer patients 
A group of 46,227 ovarian cancer cases were identified in the database from 1958 to 2015. The 
median age was 63 years among 11,301 ovarian cancer cases in the offspring generation (Table 
10). Since 1993 a total of 8,850 ovarian cancer cases in the offspring generation were diagnosed 
with SNOMED codes, and non-epithelial ovarian cancers accounted for 11.9% of them. 
Regarding family history of discordant cancer, 4526 (40.0%) cases in the offspring generation 
were from families with one first-degree relative diagnosed with by any discordant cancer and 
2395 (21.2%) cases were from families with at least two first-degree relatives diagnosed with 
any discordant cancer. For family history of concordant cancer, 467 (4.3%) cases were from 
families with one first-degree relative diagnosed with ovarian cancer and 20 (0.2%) cases were 
from families with two first-degree relatives diagnosed with ovarian cancer. 
Most of the ovarian cancer patients were diagnosed in the latest decades (1991-2010). More than 
half of the patients (51.0%) had no children. A total of 40.8% patients were living in big cities 
upon ovarian cancer diagnosis. A large portion of patients were blue collars and workers, 
accounting for 35.6% and 33.4% respectively. Among the patients with histology types, serous 
carcinoma accounts for the most (46.9%). 
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Table 10 Characteristics of ovarian cancer patients in offspring generation (1958-2015) 
No. of females followed  4,216,676 
No. of ovarian cancer cases  11,301 
No. of ovarian cancer cases (1993-2015) 8850 
Median age at diagnosis of ovarian cancer 63 years old 
No. of ovarian cancer cases with family 
history of ovarian cancer  
In one first-degree relative 467 (4.3%)  
In at least two first-degree relatives 20 (0.2%)  
No. of ovarian cancer cases with family 
history of discordant cancers 
In one first-degree relative 4526 (40.0%)  
In at least two FDRs 2395 (21.2%)  
Diagnosed period (year) 
1958-1970 199 (1.7%) 
1971-1980 511 (4.5%) 
1981-1990 1233 (10.9%) 
1991-2010 3045 (26.9%) 
2011-2015 6313 (55.9%) 
Parity  
0 child 5760 (51.0%) 
1 child 1493 (13.2%) 
2 children 2391 (21.2%) 
3 children 1119 (9.9%) 
≥ 4 children 538 (4.8%) 
Residence area 
Big city 4614 (40.8%) 
South 1035 (9.2%) 
North 369 (3.3%) 
Other 5283 (46.7%) 
Socioeconomic status 
Agriculture 151 (1.3%) 
Private 331 (2.9%) 
Professional 780 (6.9%) 
Blue collar 4023 (35.6%) 
Worker 3775 (33.4%) 
Other 2241 (19.8%) 
Histological type  
(1993-2015) 
Undifferentiated  193 (2.2%) 
Clear cell  511 (5.8%) 
Endometrioid 999 (11.3%) 
Serous 4149 (46.9%) 
Mucinous 726 (8.2%) 
Non-epithelial  
1053 (11.9%), 300 of them 
were thecoma 
Others  1219 (13.8%) 
Others include histological types of other ovarian cancers such as papillary ovarian cancer, as well as 
unspecified ovarian cancers. 
 
3.2.2 Familial clustering of ovarian cancer with concordant cancer 
The total number of familial ovarian cancer cases was 807 among daughters and mothers; among 
them a total of 487 were daughters. Thus 4.31% (487/11,301) of invasive ovarian cancer cases 
were familial in Sweden. The overall familial risk of ovarian cancer was 2.51 (2.29-2.75, P 
<0.001) with any first-degree relative diagnosed with ovarian cancer. The RR was 2.42 (2.21-
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2.66) in families with one first-degree relative diagnosed with ovarian cancer and it increased up 
to 11.36 (7.33-17.62) with two affected first-degree relatives, both of which were significant at a 
0.001 level.  
3.2.2.1 Familial risk by proband type and age at diagnosis 
Table 11 displays familial RRs of ovarian cancer with stratification of proband type and age at 
diagnosis. In families with only mother, only sister and both mother and sisters affected by 
ovarian cancer, familial RRs were respectively 2.40 (2.14-2.68), 2.59 (2.21-3.03) and 10.40 
(6.16-17.57), and all of them were significant at the 0.001 level. The corresponding risks went up 
to 2.74 (2.29-3.26), 3.86 (3.01-4.96) and 16.05 (7.20-35.74) when only considering women 
diagnosed before the age of 50 years (P <0.001 for all). While the respective risks were relatively 
lower, 2.22 (1.93-2.56), 2.12 (1.73-2.60) and 8.33 (4.16-16.67) when considering the age at 
diagnosis over 50 years, but the results were still highly significant (P <0.001). Notably, in the 
older age group similarly high risks were observed for women having only mother and only 
sister with diagnosis of ovarian cancer, compared to the younger counterpart. For group with RR 
10.40, ten out of the 14 patients had recorded histological type and they were serous (N=5), non-
specified adenocarcinomas (2), clear cell (1), endometrioid (1) and undifferentiated (1).  
Table 11 Familial risk of ovarian cancer in daughters by proband type and age of diagnosis 
Age at diagnosis 
(years) 
Only mother Only sisters Mother and sister 
N RR 95%CI N RR 95%CI N RR 95%CI 
< 50 120 2.74 2.29-3.26 63 3.86 3.01-4.96 6 16.05 7.20-35.74 
≥50 195 2.22 1.93-2.56 95 2.12 1.73-2.60 8 8.33 4.16-16.67 
All 315 2.40 2.14-2.68 158 2.59 2.21-3.03 14 10.40 6.16-17.57 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively. 
3.2.2.2 Familial risk by histological types 
Table 12 displays familial associations between ovarian cancer and histology- specific ovarian 
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cancers. Overall ovarian cancer risk was increased no matter which type of ovarian cancers was 
diagnosed in first-degree relatives. The histological types with RRs in descending order were 
undifferentiated (4.79, 2.49-9.21, P <0.001), endometrioid (3.81, 2.65-5.49, P <0.001), non-
epithelial (2.72, 1.02-7.25), mucinous (2.21, 1.26-3.90, P <0.01), clear cell (2.16, 1.03-5.54) and 
serous (2.15, 1.70-2.73, P <0.001) type. In the reverse analysis, when mother or sisters had 
ovarian cancer, risks for all histology specific ovarian cancers increased apart from mucinous 
and non-epithelial types. The histological types was undifferentiated (5.45, 3.36-8.86, P <0.001), 
serous (2.96, 2.58-3.40, P <0.001), endometrioid (2.81, 2.10-3.75, P < 0.001) and clear cell 
(1.67, 1.00-2.80).  
Table 12 Familial associations of overall ovarian cancer with ovarian cancer of specific 
histological type 
Histological type 
Overall risk of ovarian cancer in 
daughters 
Risk of histology-specific ovarian cancer in 
daughters 
N1 N2 RR 95% CI N1 N2 RR 95% CI 
Undifferentiated 8841 9 4.79 2.49-9.21 175 18 5.45 3.36-8.86 
Clear cell 8843 7 2.16 1.03-4.54 496 15 1.67 1.00-2.80 
Endometrioid 8821 29 3.81 2.65-5.49 951 48 2.81 2.10-3.75 
Serous 8780 70 2.15 1.70-2.73 3934 215 2.96 2.58-3.40 
Mucinous 8838 12 2.21 1.26-3.90 708 18 1.51 0.94-2.41 
Non-epithelial 8846 4 2.72 1.02-7.25 295 5 1.10 0.46-2.66 
N1: Number of cases without family history in first-degree relatives; N2: Number of cases with family 
history in first-degree relatives;   
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
 
3.2.2.3 Familial associations among histological types 
Table 13 presents familial associations among different histological types of ovarian cancers in 
offspring and their relatives. Risk of undifferentiated ovarian cancer elevated when mother or 
sisters were affected by ovarian cancer with clear cell (15.44, 2.16-110.37, P <0.01), serous 
(6.01, 2.23-16.20, P <0.001) or mucinous (9.23, 1.29-65.89) types. Having first-degree relatives 
with endometrioid ovarian cancer was related to the increased risk of same histological type of 
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ovarian cancer (3.59, 1.15-11.14); in families with patients diagnosed with undifferentiated 
(9.27, 2.31-37.12, P <0.01) and serous (2.26, 1.13-4.53) ovarian cancer, risk of endometrioid 
ovarian cancer was also elevated. Diagnoses of all the other histological types except clear cell 
type in mother or sisters were related to risk of serous ovarian cancer. Familial risk of mucinous 
ovarian cancer risk was increased in families with family members diagnosed with mucinous 
(6.91, 2.22-21.49, P <0.001) or undifferentiated (7.08, 1.00-50.33) ovarian cancer. Non-
epithelial showed increased risk in families with ovarian cancer patients of clear cell type (9.70, 
1.36-69.12).  
 
Table 13 Familial associations among different histological types of ovarian cancers 
Histological type Cases without  
family history 
Cases with family history 
Offspring First-degree relative N RR 95%CI 
Undifferentiated 
Clear cell 175 1 15.44 2.16 110.37 
Serous 175 4 6.01 2.23 16.2 
Mucinous 175 1 9.23 1.29 65.89 
Endometrioid 
Undifferentiated 951 2 9.27 2.31 37.12 
Endometrioid 951 3 3.59 1.15 11.14 
Serous 951 8 2.26 1.13 4.53 
Serous 
Undifferentiated 3934 4 4.80 1.80 12.8 
Clear cell 3934 3 2.08 0.67 6.45 
Endometrioid 3934 12 3.50 1.99 6.17 
Serous 3934 36 2.47 1.78 3.43 
Mucinous 3934 6 2.44 1.09 5.43 
Non-epithelial 3934 3 4.62 1.49 14.33 
Mucinous 
Undifferentiated 708 1 7.08 1.00 50.33 
Endometrioid 708 2 3.26 0.81 13.05 
Serous 708 4 1.56 0.58 4.17 
Mucinous 708 3 6.91 2.22 21.49 
Non-epithelial 
Clear cell 295 1 9.70 1.36 69.12 
Serous 295 2 1.97 0.49 7.93 
Only items with at least two cases with family history, or with significant results are displayed in Table 
13. No such items were found for clear cell type of ovarian cancer. 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
 
We summarized the familial associations between different histological types of ovarian cancers 
in Supplementary Figure 1, based on the two-way association in Table 13.  
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3.2.3 Familial clustering of ovarian cancer with discordant cancer 
3.2.3.1 Risk of ovarian cancer with first-degree relatives affected by other cancer 
Risk of ovarian cancer when first-degree relatives were diagnosed with discordant cancers are 
displayed in Table 14, which only includes the cancer sites with more than 30 familial cases 
with family history of corresponding cancer or those with significant results. Eight discordant 
cancers displayed significant familial associations. Family history of breast cancer presented a 
dose-response on ovarian cancer risk (P trend test <0.0001), with a RR of 1.20 (1.14-1.28) when 
one first-degree relative was diagnosed with breast cancer (P<0.001) and a RR of 1.47 (1.20-
1.82) when two first-degree relatives were affected (P<0.01). We found increased ovarian cancer 
risk in families with one first-degree relative diagnosed with colorectal (1.06, 1.00-1.13), liver 
(1.20, 1.06-1.35, P <0.01), pancreatic (1.14, 1.01-1.28) and endometrial (RR 1.27, 1.14-1.42, P 
<0.001) cancers, melanoma (1.12, 1.00-1.25) and CUP (1.25, 1.13-1.38 P<0.001). For the 
subtypes of liver cancer (N=277), risk of ovarian cancer was increased in families that had 
members diagnosed with gallbladder cancer (N=95, 34.3% of all liver cancer; RR=1.27, 95%CI 
1.03-1.55; Supplementary Table 5). Risk of ovarian cancer was found to be elevated in families 
with one individual diagnosed with any cancer (1.13, 1.09-1.18), and RR was 1.29 (1.23-1.36) in 
families with two individuals affected by cancer. When only considering the family history of 
discordant cancers (excluding family history of ovarian cancer), we found the risk of ovarian 
cancer was still significantly increased. Cancer sites with significant results are shown in Figure 
6. 
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Table 14 Relative risk of ovarian cancer in families where parents or siblings were diagnosed 
with other cancers 
Cancer site 
Cases with 1 FDR Cases with ≥ 2 FDRs 
P-trend 
N RR 95%CI N RR 95%CI 
Upper aerodigestive tract  239 1.08 0.95-1.23 4 1.46 0.55-3.90 0.1887 
Esophagus  70 0.94 0.74-1.19 0 - - - 
Stomach  349 1.08 0.97-1.2 3 0.57 0.18-1.76 0.2887 
Small  intestine 41 1.02 0.75-1.38 1 4.07 0.57-28.93 0.7269 
Colorectum  1009 1.06 1.00-1.13 58 1.16 0.89-1.50 0.0377 
Colon  659 1.04 0.96-1.13 28 1.33 0.92-1.92 0.141 
Rectum  395 1.07 0.97-1.19 10 1.48 0.80-2.76 0.0974 
Liver  277 1.20 1.06-1.35 4 1.64 0.62-4.38 0.0024 
Pancreas  271 1.14 1.01-1.28 2 0.70 0.18-2.80 0.0595 
Lung  655 1.05 0.97-1.14 27 1.04 0.71-1.52 0.2382 
Breast  1243 1.20 1.14-1.28 88 1.47 1.20-1.82 <.0001 
Cervix  184 1.14 0.98-1.32 0 - - - 
Endometrium  317 1.27 1.14-1.42 4 1.40 0.53-3.73 <.0001 
Other female genitals 39 0.94 0.69-1.29 0 - - - 
Prostate  1320 1.02 0.96-1.08 121 1.14 0.95-1.36 0.2174 
Testis  35 1.20 0.86-1.68 1 4.37 0.62-31.03 0.1904 
Other male genitals 30 1.74 1.21-2.49 0 - - - 
Kidney  276 1.08 0.96-1.22 3 0.89 0.29-2.75 0.2458 
Bladder  403 0.96 0.87-1.06 14 1.57 0.93-2.66 0.8195 
Melanoma  339 1.12 1.00-1.25 8 1.02 0.51-2.04 0.0573 
Skin, squamous cell 387 0.98 0.88-1.08 12 1.20 0.68-2.11 0.8309 
Nervous system 279 1.08 0.96-1.22 2 0.49 0.12-1.97 0.2972 
Thyroid gland 75 1.04 0.83-1.31 0 - - - 
Endocrine glands 148 0.97 0.83-1.14 1 0.72 0.10-5.10 0.6948 
Connective tissue 61 1.06 0.83-1.37 0 - - - 
Non-Hodgkin lymphoma 296 1.08 0.96-1.21 5 1.27 0.53-3.05 0.1882 
Hodgkin lymphoma 52 1.28 0.97-1.68 0 - - - 
Myeloma  141 1.07 0.90-1.26 0 - - - 
Leukemia  250 0.99 0.87-1.12 2 0.50 0.13-2.01 0.6704 
Cancer of unknown primary 396 1.25 1.13-1.38 4 1.08 0.40-2.87 <.0001 
All cancers
a
 4553 1.13 1.09-1.18 2589 1.29 1.23-1.36 <.0001 
All cancers
b
 4340 1.10 1.06-1.15 2315 1.20 1.14-1.27 <.0001 
FDR, first-degree relative (parents or siblings);  
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include ovarian cancers and all other cancers; b: all cancers include all other cancers except 
ovarian cancer. 
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Figure 6 Relative risk of ovarian cancer according to the number of the first-degree relatives affected by 
other cancers. Only cancer sites with significance are displayed. CUP, cancer of unknown primary; a: all 
cancers include ovarian cancers and all other cancers; b: all cancers include all other cancers apart from 
ovarian cancer. 
3.2.3.2 Risk of other cancers with first-degree relatives affected by ovarian cancer 
Reversely the overall risk for any cancer in the offspring generation increased with first-degree 
relatives diagnosed with ovarian cancer (Table 15). When one first-degree relative had diagnosis 
of ovarian cancer, the overall risk for any cancer was 1.12 (, 1.10-1.14, P<0.001) and when two 
or more relatives were diagnosed the risk increased up to 1.49 (1.27-1.75, P<0.001). When only 
considering cancers other than ovarian cancer, the RRs were 1.09 (1.07-1.11, P<0.001) and 
1.31(1.10-1.56, P<0.01) with respectively one and at least two relatives affected. In combination 
with the results from Table 14, cancers in colorectum, liver, breast, endometrium and CUP 
presented significant familial associations with ovarian cancer in the two-way comparison. In 
addition, the effect of family history of ovarian cancer on the risk of liver and breast cancers and 
CUP had dose-response trend. Although based on two families, the RR of Hodgkin lymphoma 
was high (4.11, 1.03-16.46, P <0.01) for individuals having first-degree relatives with diagnosis 
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of ovarian cancer. Increased risks were also found for lung (1.10, 1.01-1.19) and prostate (1.05, 
1.00-1.10) cancers in families with one ovarian cancer patient. While declined risk of esophageal 
(0.76, 0.58-1.00) cancer was observed in families with one ovarian cancer patient. All the 
significant cancer sites are displayed in Figure 7. 
Table 15 Relative risk of other cancer in families where mother or sisters were diagnosed with 
ovarian cancer 
Cancer site 
Cases with 1 FDR Cases with ≥ 2 FDRs P-
trend N RR 95%CI N RR 95%CI 
Upper aerodigestive tract 220 1.02 0.89-1.17 3 1.32 0.43-4.09 0.7011 
Esophagus  52 0.76 0.58-1.00 1 1.29 0.18-9.16 0.0552 
Stomach  134 1.11 0.94-1.32 3 2.29 0.74-7.10 0.1435 
Small intestine 54 1.29 0.98-1.68 0 - - - 
Colorectum 884 1.07 1.00-1.15 6 0.70 0.31-1.56 0.0708 
Colon 552 1.06 0.98-1.16 2 0.38 0.09-1.50 0.2651 
Rectum 332 1.09 0.97-1.21 4 1.23 0.46-3.27 0.1264 
Liver 167 1.20 1.03-1.40 4 2.66 1.00-7.10 0.0083 
Pancreas 157 0.97 0.82-1.13 2 1.14 0.28-4.54 0.6918 
Lung 634 1.10 1.01-1.19 5 0.80 0.33-1.92 0.0320 
Breast 1981 1.24 1.19-1.30 30 2.13 1.49-3.05 <.0001 
Cervix 165 1.08 0.92-1.26 2 1.65 0.41-6.61 0.3036 
Endometrium 304 1.22 1.09-1.36 2 0.86 0.21-3.44 0.0014 
Uterus 6 2.63 1.16-5.95 0 - - - 
Other female genitals 27 0.89 0.61-1.30 0 - - - 
Prostate 1727 1.05 1.00-1.10 29 1.40 0.97-2.01 0.0149 
Testis 117 1.15 0.95-1.37 0 - - - 
Other male genitals 22 1.16 0.76-1.77 0 - - - 
Kidney 226 1.10 0.96-1.25 5 2.30 0.96-5.53 0.0905 
Bladder 333 0.99 0.89-1.10 4 1.07 0.40-2.85 0.8401 
Melanoma 628 1.07 0.99-1.16 7 1.29 0.62-2.71 0.0645 
Skin, squamous cell 333 1.06 0.95-1.18 2 0.62 0.16-2.49 0.3549 
Nervous  system 380 1.04 0.94-1.15 3 0.89 0.29-2.77 0.4900 
Thyroid gland 111 1.11 0.92-1.34 1 1.18 0.17-8.35 0.2767 
Endocrine glands 193 1.01 0.88-1.16 2 1.13 0.28-4.51 0.8776 
Connective tissue 70 1.01 0.79-1.28 0 - - - 
Non-Hodgkin lymphoma 327 1.11 0.99-1.24 3 0.99 0.32-3.08 0.0751 
Hodgkin lymphoma 71 1.20 0.95-1.51 2 4.11 1.03-16.46 0.0732 
Myeloma 107 1.09 0.90-1.32 0 - - - 
Leukemia 248 0.98 0.86-1.11 3 1.22 0.39-3.79 0.8095 
Cancer of unknown primary 227 1.14 1.00-1.30 6 2.81 1.26-6.26 0.0157 
All cancers
a
 10492 1.12 1.10-1.14 147 1.49 1.27-1.75 <.0001 
All cancers
b
 10025 1.09 1.07-1.11 127 1.31 1.10-1.56 <.0001 
FDR: first-degree relative (mother or sisters);  
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include ovarian cancers and all other cancers; b: all cancers include all other cancers except 
ovarian cancer. 
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Figure 7 Relative risk of other cancer according to the number of first-degree relatives affected by 
ovarian cancer. Only cancer sites with significance are displayed. CUP, cancer of unknown primary; a: all 
cancers include ovarian cancers and all other cancers; b: all cancers include all other cancers apart from 
ovarian cancer. 
 
3.2.3.3 Familial clustering of ovarian cancer with other cancer by histological type  
Familial associations of ovarian cancer of different histological types with other cancers in the 
two-way analysis were shown in Table 16. The pairs (histological type-cancer site) significant in 
the two-way comparison were clear cell-pancreas, endometrioid-nose, endometrioid-breast (P < 
0.05 and P <0.001), endometrioid- endometrium (both P <0.001), serous-breast (both P <0.001), 
serous-male genitals (P<0.05 and P<0.001), mucinous-gallbladder (P <0.01 and P < 0.001; see 
Supplementary Table 6). For familial association between endometrioid ovarian cancer and 
cancer of nose, the histological type for the latter included squamous cell carcinomas (N=2) and 
adenocarcinomas (N=1). Of note, only few cases were used for the familial clustering of non-
epithelial ovarian cancer.  
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Table 16 Familial associations of histology-specific ovarian cancer with other cancers  
Histological type Cancer site 
Risk of ovarian cancer Risk of invasive cancer 
N RR 95% CI N RR 95% CI 
Undifferentiated   
Stomach 11 1.95 1.06-3.60 2 1.65 0.41-6.61 
Liver 8 2.00 0.99-4.06 4 2.76 1.04-7.36 
Pancreas 5 1.16 0.48-2.81 7 4.07 1.94-8.55 
Lung 17 1.48 0.90-2.44 11 1.85 1.02-3.34 
Hodgkin lymphoma 3 4.35 1.39-13.61 1 2.35 0.33-16.71 
Clear cell 
Pancreas 18 1.69 1.05-2.70 7 2.23 1.06-4.68 
Testis 3 2.19 0.70-6.81 6 3.94 1.77-8.76 
Endometrioid 
Stomach 35 1.25 0.89-1.75 11 2.15 1.19-3.88 
Nose 4 3.08 1.15-8.21 2 4.02 1.00-16.10 
Lung 58 0.98 0.75-1.28 37 1.43 1.04-1.97 
Breast 121 1.24 1.02-1.49 94 1.35 1.10-1.65 
Endometrium 49 2.22 1.67-2.96 22 2.04 1.34-3.09 
Other female genitals 6 1.65 0.74-3.69 4 3.08 1.16-8.22 
Kidney 34 1.50 1.07-2.12 12 1.41 0.80-2.49 
Connective tissue 8 1.54 0.77-3.09 6 2.53 1.13-5.63 
Serous  
Breast 515 1.27 1.15-1.39 373 1.24 1.12-1.38 
Other male genitals 12 1.87 1.06-3.29 8 2.42 1.20-4.85 
Thyroid gland 38 1.42 1.03-1.96 14 0.89 0.53-1.51 
Cancer of unknown primary 134 1.23 1.04-1.47 39 1.06 0.77-1.45 
Mucinous 
Upper aerodigestive tract 23 1.73 1.14-2.63 11 1.70 0.94-3.08 
Nose 3 3.43 1.10-10.67 0 - - 
Breast 83 1.23 0.98-1.54 67 1.38 1.08-1.75 
Bladder 37 1.46 1.05-2.04 11 1.15 0.64-2.08 
Non-epithelial  
Thyroid gland 5 2.82 1.17-6.48 1 1.20 0.17-8.50 
Connective tissue 5 3.69 1.52-8.94 1 1.81 0.25-12.84 
Non-Hodgkin lymphoma 6 0.90 0.40-2.02 7 2.72 1.30-5.71 
Cancer of unknown primary 14 2.25 1.31-3.86 3 1.66 0.54-5.15 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include all other cancers as well as ovarian cancer; b: all cancers include all other cancers apart 
from ovarian cancer. 
 
Familial associations of different histological type of ovarian cancer with any cancer including or 
excluding ovarian cancer are shown in Table 17. When considering ovarian cancer into other 
cancers, all the histological types showed significance in the association with any cancer apart 
from clear cell and non-epithelial types. Additionally, familial associations for undifferentiated, 
endometrioid (both P <0.001) and serous (P<0.05 and P <0.001) types were significant in the 
two-way analysis. When removing ovarian cancer from other cancers, endometrioid, serous and 
mucinous types were still in the significant familial associations with any other cancers. 
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However, only the result of endometrioid carcinoma showed significance in the two-way 
analysis (P<0.01 and P <0.001).  
Table 17 Familial associations of histology-specific ovarian cancer with any cancer 
Histological type Cancer site 
Risk of ovarian cancer Risk of invasive cancer 
N RR 95% CI N RR 95% CI 
Undifferentiated  
All cancers
a
 134 1.45 1.07-1.97 119 1.23 1.03-1.48 
All cancers
b
 116 1.29 0.94-1.77 110 1.16 0.96-1.40 
Clear cell 
All cancers
a
 302 0.99 0.82-1.18 168 1.01 0.87-1.18 
All cancers
b
 287 0.96 0.80-1.15 161 0.99 0.85-1.16 
Endometrioid  
All cancers
a
 675 1.41 1.23-1.61 477 1.21 1.11-1.32 
All cancers
b
 627 1.34 1.17-1.54 448 1.16 1.06-1.27 
Serous  
All cancers
a
 2663 1.19 1.12-1.27 1781 1.04 1.00-1.09 
All cancers
b
 2448 1.13 1.04-1.23 1711 1.02 0.98-1.07 
Mucinous 
All cancers
a
 439 1.19 1.02-1.38 290 1.05 0.94-1.18 
All cancers
b
 421 1.17 1.00-1.37 278 1.03 0.91-1.16 
Non-epithelial 
All cancers
a
 159 1.00 0.79-1.27 80 1.03 0.83-1.28 
All cancers
b
 154 1.00 0.79-1.27 76 1.00 0.80-1.25 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a: all cancers include all other cancers as well as ovarian cancer; b: all cancers include all other cancers apart 
from ovarian cancer. 
 
3.3 Influence of family history on the risk of SPC in breast cancer patients 
3.3.1 Familial demography of breast cancer population 
Among 87,752 breast cancer patients diagnosed at the median age of 55 years (Table 18), 14,952 
patients (17.0%) developed SPC at the median age of 63 years, and among them 8653 (57.9%) 
was second breast cancer. In the 8626 patients who had second breast cancer diagnosis and had 
data on cancer side,  42.1% developed second breast cancer on the same side as previous one and 
57.9% developed contralateral tumors. The median follow-up time from diagnosis of first breast 
cancer to SPCs was five years. However, it was only one year to second breast cancer diagnosis 
while it was eight years to other SPC. In the patients with diagnosis of second cancer, 68.8% had 
a first-degree family history of any cancer. In patients with SPC as well as with a cancer family 
history, 2228 (21.6%) of the SPCs were the same (concordant) cancer that was diagnosed in the 
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first-degree relatives, and for 8052 (77.4%) patients it was a different (discordant) familial 
cancer. Third primary cancers occurred in 2543 (17.0%) patients who had SPCs. 
Table 18 Familial demography of breast cancer population followed during 1958-2015 
No. of females followed 4,216,676 
NUMBER OF CASES   
A. No. of BC diagnoses 87,752 
B. No. of SPC diagnoses in BC patients 14,952 (17.0% of all BC survivors, B/A) 
C.  Familial SPC 10,280 (68.8% of all BC survivors with SPC, C/B) 
D. Familial SPC (concordant) 2,228 (21.6% of all familial SPC, D/C) 
E. Familial SPC (discordant) 8,052 (77.4% of all familial SPC,D/C) 
F. No. of third primary cancer diagnoses 2,543 (17% of all BC survivors with SPC, F/B) 
NUMBER OF DEATHS   
G. Deaths among all BC patients 18,998 (21.6% of all BC patients, G/A) 
H. Deaths among BC patients with SPC 4,828 (32.3% of all diagnosed with SPC, H/B) 
I. Deaths among SPC patients with positive 
family history 
3,356 (32.6% of all familial SPC diagnoses, I/C) 
J. Deaths among SPC patients with negative 
family history 
1,472 (31.5% of all SPC patients with negative family history, J/(B-
C) ) 
K. Deaths among BC patients without SPC 14,170 (16.1% of all BC survivors without SPC, K/(A-B) ) 
BC, breast cancer; SPC, second primary cancer. 
 
3.3.2 Influence of family history on the SPC risk in breast cancer patients 
In the assessment of influence of family history on SPC risk (Table 19), breast cancer patients 
with family history of any cancer (RR, 3.54, 95%CI, 3.46-3.62) presented with higher risk for 
any cancer as SPC in comparison with patients without family history (3.00, 2.91-3.09). When 
taking SPCs other than breast cancer into consideration, the corresponding RRs were 1.51 (1.49-
1.58) and 1.25 (1.19-1.31), indicating an attributable risk proportion of 18.3% ((1.53-1.25) /1.53) 
for family history of cancer. The trend tests showed significance for 14 site-specific SPCs, 
including stomach, colorectal, liver, pancreatic, lung, breast, endometrial, ovarian, bladder, skin 
(squamous cell) and endocrine gland cancers, and melanoma, non-Hodgkin lymphoma and CUP. 
The maximum risk was observed with ovarian cancer (6.28, 4.50-8.75 with family history vs. 
1.49, 1.34-1.65 without family history of ovarian cancer). Patients either with or without family 
history of breast cancer were both presented with high RRs for second breast cancer (4.89, 4.67-
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5.12 and 3.90, 3.80-4.00, respectively). The major disease burden for familial SPCs was found 
for breast cancer (1909, of these 100 with only family history of in situ breast cancer), followed 
by colorectal (112, of these 12 with only family history of in situ colorectal cancer), lung (96) 
and skin (79, of these 41 with only family history of in situ skin cancer) cancers. 
Table 19 Relative risk of second primary cancers according to family history of the same cancer 
in breast cancer patients 
Site of second primary cancer 
Breast cancer patients 
P- Trend Negative family history Positive family history 
N RR 95%CI N RR 95%CI 
Upper aerodigestive tract 138 1.38 1.16-1.64 5 2.31 0.96-5.56 0.17 
Esophagus 44 1.56 1.15-2.11 0 - - - 
Stomach 93 1.37 1.11-1.69 8 3.14 1.57-6.28 0.003 
Small intestine 46 1.54 1.14-2.07 0 - - - 
Colorectum 683 1.17 1.08-1.26 112 1.50 1.25-1.81 <.001 
Colon 499 1.16 1.06-1.27 45 1.35 1.01-1.81 <.001 
Rectum 233 1.15 1.01-1.32 18 1.90 1.19-3.01 <.001 
Anus 37 1.38 0.99-1.92 0 - - - 
Liver 139 1.25 1.06-1.49 7 2.54 1.21-5.32 0.007 
Pancreas 176 1.20 1.03-1.39 9 2.35 1.22-4.52 0.02 
Nose 9 1.29 0.66-2.51 0 - - - 
Lung 744 1.54 1.43-1.66 96 2.93 2.40-3.58 <.001 
Breast 6744 3.90 3.80-4.00 1909 4.89 4.67-5.12 <.001 
Cervix 95 1.07 0.87-1.31 2 1.58 0.39-6.32 0.16 
Endometrium 627 1.42 1.31-1.54 37 3.32 2.40-4.58 <.001 
Uterus 1 2.38 0.32-17.49 0 - - - 
Ovary 364 1.49 1.34-1.65 35 6.28 4.50-8.75 <.001 
Other female genitals 53 1.09 0.83-1.44 0 - - - 
Kidney 180 1.44 1.24-1.68 7 2.12 1.01-4.44 0.24 
Bladder 189 1.30 1.12-1.51 14 2.21 1.31-3.74 0.005 
Melanoma 423 1.32 1.19-1.45 26 1.97 1.34-2.89 <.001 
Skin, squamous cell 339 1.35 1.21-1.51 79 3.47 2.78-4.33 <.001 
Eye 25 1.42 0.95-2.12 0    
Nervous system 204 1.01 0.88-1.17 6 1.16 0.52-2.57 0.10 
Thyroid gland 90 1.72 1.39-2.12 1 2.73 0.38-19.42 0.31 
Endocrine gland 172 1.17 1.01-1.37 8 3.50 1.75-6.99 0.004 
Bone 10 1.83 0.96-3.48 0 - - - 
Connective tissue 66 2.15 1.67-2.76 0 - - - 
Non-Hodgkin lymphoma 224 1.21 1.05-1.38 10 2.03 1.09-3.77 0.01 
Hodgkin lymphoma 15 1.29 0.77-2.17 0 - - - 
Myeloma 79 1.06 0.85-1.33 2 2.08 0.52-8.31 0.15 
Leukaemia 222 1.38 1.20-1.57 5 1.32 0.55-3.17 0.18 
Cancer of unknown primary 253 1.37 1.21-1.55 10 1.82 0.98-3.38 0.01 
All cancers 
a
 4672 3.00 2.91-3.09 10280 3.54 3.46-3.62 <.001 
All cancers 
b
 1905 1.25 1.19-1.31 4394 1.53 1.49-1.58 <.001 
a: Breast cancer is included into all cancers; b: Breast cancer is excluded from all cancers 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
Breast and ovarian cancers in women……………………………………………………..     ………………Results 
Guoqiao Zheng............................................................................................................................. 51 
overlapped with 1.00 respectively; 
 
Cumulative incidence rates for second primary endometrial, lung, ovarian, colorectal and skin cancers 
and melanoma are shown in Figure 8 (A-F) based on age at diagnosis of SPCs. The cumulative 
incidence of SPC in breast cancer patients having a family history of concordant cancer was high at 
individual age compared to those patients without family history. Ovarian cancer was found with a 
large difference; for patients with ovarian cancer diagnosis in first-degree relatives, the cumulative 
incidence of second ovarian cancer increased up to 6% at the age of 75 years, compared to 1% for 
those without a family history. 
  
Figure 8 Cumulative incidence of second primary cancers (SPCs) at each age of breast cancer patients 
according to family history. SPC, second primary cancer. FH positive (negative), breast cancer patients 
had (had no) first-degree family history of specific cancer (for example, endometrial cancer in Fig.1-A). 
 
3.3.3 Cause of death in breast cancer with and without SPC diagnosis 
A number of 18,998 (21.6%) deaths were identified during the follow-up time in breast cancer 
patients (Table 18, lower part). A total of 4,828 (32.3%) deaths occurred among the 14,952 
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patients diagnosed with SPCs. The death rate was identical for patients who developed SPCs, 
either with or without a family history (32.6% and 31.5%, respectively). However, the death rate 
in the patients who only had breast cancer (16.1%) was half of the rate in those who had SPC. 
The cause of death for BC patients in different follow-up time from diagnosis of breast cancer is 
displayed in Table 20 according to the occurrence of SPC. In patients with diagnosis of SPCs, 
most of the deaths throughout the follow-up time were due to breast cancer and SPC and the 
former included largely patient with second breast cancer. Deaths resulted from SPCs other than 
breast cancer were responsible for 34.3% of deaths, but when considering second breast cancer 
also as SPC (30.6%), the joint SPC contributed to 64.9 % of all deaths. In the beginning after 
diagnosis of breast cancer, second breast cancer accounted for large proportion of deaths (first 
year, 42.6%) while after 10 years of diagnosis the proportion dropped to 23.2%. The proportion 
of death due to SPCs other than breast was constant throughout the follow-up ranging from 30% 
to 35%. For the death caused by higher order primary cancer, the proportion increased from 
2.1% in the first year to 7.6% after 10 years of breast cancer diagnosis. Breast cancer was the 
leading cause of death for women who only had breast cancer during the follow-up period and 
other causes were responsible for approximately 15% of all deaths but went up to 32.1% after 10 
years of breast cancer diagnosis.  
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Table 20 Cause of death according to follow-up time since first cancer diagnosis in breast cancer 
patients with or without second primary cancer 
Breast 
cancer 
Cause of death 
<1 year 
(% in 
column) 
1-4 years 
(% in 
column) 
5-10 years 
(% in 
column) 
>10 years 
(% in 
column) 
All 
(% in 
column) 
With SPC 
Breast cancer a 11 (7.7) 86 (10.1) 138 (9.2) 211 (9.1) 466 (9.6) 
Breast cancer b 61 (42.6) 344 (40.4) 533 (35.4) 540 (23.2) 1478 (30.6) 
SPC 40 (30.0) 258 (30.3) 543 (36.0) 815 (35.0) 1656 (34.3) 
Higher  order primary cancer 3 (2.1) 26 (3.0) 56 (3.7) 177 (7.6) 262 (5.4) 
Other cancers 11 (7.7) 54 (6.3) 100 (6.6) 252 (10.8) 417 (8.6) 
Other causes 17 (11.9) 83 (9.8) 136 (9.0) 333 (14.3) 569 (11.8) 
All 
(% in row) 
143 (3.0) 851 (17.6) 1506 (31.2) 2328 (48.2) 4828 (100.0) 
Without 
SPC 
Breast cancer 817 (77.0) 4032 (86.2) 4006 (81.1) 2190 (62.7) 11045 (77.9) 
Other cancers 48 (4.5) 104 (2.2) 152 (3.1) 184 (5.3) 488 (3.4) 
Other causes 196 (18.5) 541 (11.6) 779 (15.8) 1121 (32.1) 2637 (18.6) 
All 
(% in row) 
1061 (7.5) 4677 (33.0) 4937 (34.8) 3495 (24.7) 14170 (100.0) 
a, breast cancer patients diagnosed with non-breast second primary cancer and dying of breast cancer;  b, 
breast cancer patients diagnosed with second breast cancer and dying of breast;  
SPC, second primary cancer; 
Higher order primary cancer, third, fourth or fifth primary cancer. 
 
Supplementary Table 7 displays the same data as Table 20 but covers only the follow-up time 
from 2001 to 2015. For patients with second breast cancer diagnoses, the overall proportions of 
deaths due to breast cancer decreased from 30.6% in Table 20 to 28.1% in Supplementary 
Table 7. A concomitant increase was found in deaths due to non-breast SPC (from 34.3 to 
38.5%).    
The distribution of the cause of death in patients with SPCs when SPC conferred at least 50 
deaths is shown in Figure 9. Second pancreatic, lung, liver, breast, stomach and ovarian cancers 
individually accounted for more than 70% of the deaths in breast cancer patients with the 
corresponding SPC, while skin and endometrial cancers and CUP appeared least fatal, 
accounting for less than 30% of deaths. The proportions of death caused by breast cancer and 
other causes were reversed in these two groups of cancers; for example, large proportions of 
death in the least fatal SPCs (skin and endometrial cancers) were caused by breast cancer and 
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other cause instead of SPC. Other cancers were a minor cause of death, but not for CUP, for 
which half of the deaths were caused by other cancers.  Details of the distribution of the cause of 
deaths for all SPCs are presented in Supplementary Table 8. 
 
Figure 9 Distribution of cause of death (second primary cancer, breast cancer, higher order primary 
cancer, other cancers and other causes) in breast cancer patients with diagnosis of second primary cancer. 
Only cancer sites with more than 50 death cases are displayed.  
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3.4 Influence of family history on the risk of SPC in ovarian cancer patients 
3.4.1 Familial demography of ovarian cancer population 
One patient was excluded from the 11,301 ovarian cancer patients in the offspring generation, as 
the second cancer diagnosis of this patient was later than the time of death. A total of 1,111 
patients (9.8%) among the 11,300 patients developed SPC during the follow-up (Table 21). 
Among patients with SPC, 67.6% (751) were from families with at least one first-degree relative 
having cancer diagnosis. For 622 patients, the site of the SPC was different (discordant) from site 
of the cancer diagnosed in their first-degree relatives and for the rest 129, the site of SPC was the 
same (concordant) as the cancer site in family members. The median age at diagnosis of first 
primary cancer was 50 years in ovarian cancer patients who were diagnosed with SPC later and it 
was 62 years for the diagnosis of SPC. In the ovarian cancer patients with SPC diagnosis, the 
median follow-up time from diagnosis of first primary to that of SPC was eight years. 
Additionally11.0% (122) of those patients developed a third primary at the end of the follow-up. 
Table 21 Familial demography of population followed during 1958-2015 
OC, ovarian cancer; SPC, second primary cancer; 
 
 
No. of females followed 4,216,676 
NUMBER OF CASES   
A. No. of OC diagnoses 11,300 
B. No. of SPC diagnoses 1,111 (9.8% of all OC survivors, B/A) 
C. Familial SPC 751(67.6% of all OC survivors with SPC, C/B) 
D. Familial SPC (concordant) 129 (16.2% of all familial SPC, D/C) 
E. Familial SPC (discordant) 622 (83.8% of all familial SPC,D/C) 
NUMBER OF DEATHS   
F. Deaths among all OC patients 5,559 (49.2% of all OC patients, F/A) 
G. Deaths among OC patients with SPC 544 (49.0% of all diagnosed with SPC, G/B) 
H. Total deaths among SPC patients with positive family history 362 (48.2% of all familial SPC diagnoses, H/C) 
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3.4.2 Influence of family history on the SPC risk in ovarian cancer patients 
Table 22 shows the influence of cancer diagnosis in first-degree relatives on the development of 
this cancer as SPC in ovarian cancer patients without removal of possible high risk families, and 
for the risk estimation, the reference group is the general population without neither ovarian 
cancer nor a family history of SPC of any cancer. With a cancer family history, the risk for any 
cancer as SPC was higher (RR, 1.74 95%CI, 1.64-1.87) than that without family history (1.49, 
1.34-1.65). Small intestinal (3.23, 1.73-6.03), connective tissue (3.13, 1.73-5.67) and bladder 
(2.72, 2.01-3.69) cancers and CUP (2.69, 2.06-3.52) were noted with high risks as SPC in 
ovarian cancer. The trend test was found significant for risks of SPC with concordant family 
history of four cancers, including colon, colorectal, lung and breast cancers. Furthermore, the 
trend test was found marginally significant for skin (squamous cell) cancer as SPC with a family 
history (3.25, 1.05-10.02) compared to that without a family history (0.74, 0.48-1.15). The RRs 
for pancreatic and bladder cancer and CUP as SPC with a concordant family history were high 
although based on few cases. Breast (52 patients) and colorectal cancers (29 patients) were found 
as the most common familial SPCs. Of note, cancer sites with less than 10 total cases are not 
shown in this and the subsequent tables, but they contributed to the estimation for ‘All cancer’. 
In the 122 patients identified with third primary cancers, 58% of third primary were breast (32), 
colorectal (27) and lung (12) cancer. The influence of cancer diagnosis in first-degree relatives 
on the probability of developing this cancer as SPC was still of significance even though 
individuals from possible high risk families were removed in the analysis (Supplementary 
Table 9). 
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Table 22 Relative risk of second primary cancers according to family history of concordant 
cancer in ovarian cancer patients  
Site of second primary cancer 
Patients with ovarian cancer 
P-trend Negative family history  Positive family history  
N RR 95%CI N RR 95%CI 
Upper aerodigestive tract 12 1.10 0.62-1.94 0 - - - 
Stomach 16 2.21 1.35-3.62 1 3.43 0.48-24.4 0.31 
Small intestine 10 3.23 1.73-6.03 0 - - - 
Colorectum 114 1.84 1.53-2.22 29 4.17 2.09-6.00 <0.001 
Colon 89 2.00 1.63-2.47 16 4.95 3.03-8.09 <0.001 
Rectum 37 1.72 1.24-2.37 1 1.30 0.18-9.21 0.32 
Liver 22 1.89 1.24-2.88 1 3.17 0.45-22.52 0.34 
Pancreas 36 2.35 1.69-3.27 3 8.38 2.70-25.98 0.52 
Lung 74 1.45 1.16-1.83 12 3.32 1.88-5.84 <0.001 
Breast 209 1.01 0.88-1.15 52 2.08 1.58-2.73 <0.001 
Other female genitals 11 2.07 1.14-3.75 0 - - - 
Kidney 21 1.61 1.05-2.48 1 2.56 0.36-18.17 0.32 
Bladder 42 2.72 2.01-3.69 3 5.32 1.72-16.52 0.15 
Melanoma 38 1.06 0.77-1.46 2 1.81 0.45-7.24 0.15 
Skin, squamous cell 20 0.74 0.48-1.15 3 3.25 1.05-10.02 0.06 
Nervous system 16 0.68 0.42-1.12 2 3.04 0.76-12.15 >0.99 
Thyroid gland 10 1.57 0.84-2.92 0 - - - 
Endocrine glands 22 1.35 0.89-2.06 0 - - - 
Connective tissue 11 3.13 1.73-5.67 0 - - - 
Non-Hodgkin lymphoma 17 0.87 0.54-1.40 1 1.45 0.20-10.29 0.32 
Leukemia 29 1.67 1.16-2.40 0 - - - 
Cancer of unknown primary 54 2.69 2.06-3.52 3 3.98 1.28-12.36 0.58 
All cancers 
a
 360 1.49 1.34-1.65 751 1.74 1.62-1.87 <0.001 
All cancers 
b
  334 1.38 1.24-1.54 714 1.66 1.54-1.74 <0.001 
Values with bold, italic or underlined format indicate their 95% CI, 99% CI and 99.9% CI were not 
overlapped with 1.00 respectively; 
a, all cancers including second ovarian cancer; b, all cancers excluding second ovarian cancer. 
 
Cumulative incidence for second primary breast and colorectal cancers after diagnosis of ovarian 
cancer is shown in Figure 10 stratified over age at SPC diagnosis. For SPCs with a concordant 
family history of breast or colorectal cancer, cumulative incidence increased steeply from about 
age 45 to 60, and less steeply at older ages. Having first-degree relatives diagnosed with breast 
cancer, the cumulative incidence for second primary breast cancer was 5.0% at age over 80 
years, approximately two-fold larger compared to that without a family history (2.5%).  
Similarly, the respective cumulative incidence for second primary colorectal cancer was 5.0% 
and 1.5%. 
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Figure 10 Cumulative incidence of second primary cancers (SPCs) at each age of ovarian cancer patients 
according to family history. SPC, second primary cancer. 
 
3.4.3 Cause of death in ovarian cancer with and without SPCs diagnosis 
As a whole, 49.19% (5,559) of all the ovarian cancer patients died during the follow-up time. 
Similarly, the death rate was 48.96% for patients with SPC and 48.20% for those with SPC and a 
family history (Table 21, bottom part).   
Causes of deaths were classified into ovarian cancer, SPC (if present), other cancer and other 
(non-neoplastic) cause for the analysis of distribution of causes of deaths in ovarian cancer 
patients with and without diagnosis of SPC in the different time period after first primary cancer 
diagnosis (Table 23). Among the patients with SPC, in the first 5 years since follow-up, ovarian 
cancer was observed as the main cause of death. However, SPC accounted around half of the 
death cases in the last two periods (43.1%, 5-10 years and 50.9%, >10 years) and overall follow-
up time (42.1%), which presented as the leading death cause in those times. Others causes was 
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only responsible for a small portion of the death cases, reaching 15.1% after 10 year diagnosis of 
ovarian cancer. On the contrary, ovarian cancer was the main cause of death throughout the 
follow-up time for patients free of SPC and larger proportion of those patients died of other 
causes in the last follow-up period (32.5%). Among 102 death cases due to other cancers, many 
multiple and poorly localized cancers or tumors with undefined behavior were observed and 
CUP was responsible for 19 death cases. 
Table 23 Cause of death according to follow-up time since first cancer diagnosis in ovarian 
cancer patients with or without second primary cancer  
Ovarian 
cancer 
Cause of death 
<1 year 
(% in 
column) 
1-4 years 
(% in 
column) 
5-10 years 
(% in 
column) 
>10 years 
(% in 
column) 
All 
(% in 
column) 
With SPC 
Ovarian cancer 10 (45.4) 71 (58.7) 47 (40.5) 31 (10.9) 159 (29.2) 
SPC 8 (36.4) 26 (21.5) 50 (43.1) 145 (50.9) 229 (42.1) 
Other cancers 4 (18.2) 19 (15.7) 13 (11.2) 66 (23.2) 102 (18.8) 
Other causes 0 5 (4.1) 6 (5.2) 43 (15.1) 54 (9.9) 
All  
(% in row) 
22 (4.0) 121 (22.2) 116(21.3) 285 (52.4) 544 (100.0) 
Without 
SPC 
Ovarian cancer 849 (86.5) 2238 (90.5) 950 (86.9) 269 (57.6) 4306 (85.9) 
Other cancers 88 (9.0) 177 (7.2) 75 (6.9) 46 (9.8) 386(7.7) 
Other causes 44 (4.5) 59 (2.4) 68 (6.2) 152 (32.5) 323 (6.4) 
All 
(% in row) 
981(19.6) 2474 (49.3) 1093 (21.8) 467 (9.3) 5015 (100.0) 
SPC, second primary cancer 
 
The distribution of cause of death in the 544 patients with SPC diagnoses is shown in 
Supplementary Table 10. As a whole, 29.2% (159) of the deaths was due to ovarian cancer, 
42.1% (229) was SPC, 18.8% (102) was other cancer and 9.9% (54) was other causes. In the 102 
deaths due to other cancers, higher order primaries (third, fourth and fifth primaries) were 
responsible for 28 deaths and the rest were cancers identified as the cause of death by the death 
registry. The death codes indicated eight patients had identical second and third primary cancers 
and cause of death (three were breast cancer and the rest were other individual cancers) among 
the 28 deaths due to higher order primaries. For all the patients with SPC, the leading cause was 
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breast (88), colorectal (75) and lung (66) cancers and CUP (47). The distribution of causes of 
death is displayed in Figure 11 for the patients with SPC and for the site of SPC with at least 10 
death cases. Pancreatic cancer, leukemia (seven acute myeloid leukemia, three acute monocytic 
leukemia and one megakaryocytic), liver and lung cancers were most fatal as SPCs since 70% of 
deaths were due to them individually. While in patients with second melanoma and CUP, SPC 
only accounted a small portion of the deaths.     
 
Figure 11 Distribution of cause of death (second primary cancer, ovarian cancer, other cancers and other 
causes) in ovarian cancer patients with diagnosis of second primary cancer. Only cancer sites with more 
than 10 death cases are displayed.  
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4 DISCUSSION 
4.1 Familial clustering  
4.1.1 Familial clustering of breast cancer with concordant cancer 
The risk of breast cancer was decreased in families with three or more first-degree relatives 
diagnosed with breast cancer compared to the families that had two breast cancer patients. This 
may result from the intensified screening activity in families with multiple affected patients, as 
the proportion of in situ breast cancer was observed the largest in families with multiple breast 
cancer patients. 
In the search of familial risk stratified by different proband type, family history from mother and 
sister individually had similar effect on breast cancer risk (mother vs. sister; mother and one 
sister vs. two sisters). Contextually, male breast cancer is a very rare disease, which is reported 
associated with BRCA2 mutation (Liede et al., 2004). Breast cancer risk was lower in family 
with father diagnosed with breast cancer compared to that with one brother diagnosed; for the 
latter, risk was identical to that with two sisters affected. Individuals with a father diagnosed with 
breast cancer showed similar risk to those with an affected mother. When both mother and father 
were diagnosed with breast cancer, the risk was extremely high, which suggests strong 
interactions between female and male risk genotype with much weaker effects when they are 
functioning individually. Women with mother and brother affected, also had high risk of breast 
cancer, but the results were based on only three families. 
Familial association between breast cancer and histology-specific breast cancer were found 
significant in the two-way comparison. Interestingly, the RRs were homogeneous, around 2.00, 
indicating that for different histological types, they share similar familial risk. In the analysis of 
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familial association among histology-specific breast cancers, highest risk with family history of 
concordant histological type was observed for medullary tumor despite three familial cases. 
Medullary breast cancer is reported particularly common in carriers of BRCA1 mutations 
(Stratton, 1997). There are limited data on the familial risk of histology-specific breast cancer. In 
Utah population, excess familial risk was found for lobular breast cancer and the familial risk 
was slightly higher than the present study with lobular breast cancer risk to be 2.38 in families 
with any type of breast cancer and 4.61 in families with lobular breast cancer.  To be noted, 
germline mutation of CDH1 gene increases the risk of lobular breast cancer (Corso et al., 2018). 
4.1.2 Familial clustering of breast cancer with discordant cancer 
Breast cancer was previously reported in familial associations with discordant cancers such as 
ovarian, endometrial, prostate, colon and thyroid cancers, melanoma and non-Hodgkin 
lymphoma but among which only ovarian and prostate cancers were frequently reported 
(Amundadottir et al., 2004; Jervis et al., 2013; Teerlink et al., 2012). The familial associations 
between breast cancer and other cancers were previously reported based on the earlier version of 
the Swedish Family-Cancer Database. In that study the familial risk was analyzed separately in 
siblings and parents-offspring pairs in order to avoid chance finding and ovarian and prostate 
cancers showed significance in both analyses (Hemminki et al., 2012c). In the present study, 
additional significant associations were found for small intestinal, colorectal and lung cancers as 
well as for non-Hodgkin lymphoma. Compared to other studies, the advantage of the present one 
is in the large sample size and the extensively stratified statistical analyses. Significant 
discordant associations in the two-way comparison together with a ‘dose-response’ trend in the 
increasing RRs with the increasing number of affected first-degree relatives increased credibility 
for the findings. Additionally, considering ‘dose-response’ model is helpful in the identification 
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of the underlying genetic risk (penetrance) and high penetrance may be noted in families with 
many members diagnosed with the same cancers.   
Genetic and hormonal factors contribute the most for the significant familial associations of 
breast cancer with discordant cancers, as only few common environmental factors can explain 
the association between breast cancer and other cancers apart from the association with female 
sex hormone/reproductive factor related cancers. The environmental factor was estimated to 
contribute only 29% of the familial risk of female breast cancer and breast cancer risk was 
observed to remain uninfluenced by the age difference of sisters diagnosed with breast cancer 
which indicates an important role of genetic factors instead of the influence from environmental 
sharing (Couto and Hemminki, 2007; Hemminki and Li, 2004). 
It is known that BRCA1 carriers have an increased risk of ovarian cancers and BRCA2 carriers 
are at excess risks of ovarian, prostate and pancreatic cancers (Rahman, 2014). Esophageal, 
stomach and colorectal cancers were also reported in BRCA1 mutation carriers (Levy-Lahad and 
Friedman, 2007; Moran et al., 2012; Sopik et al., 2015). In some studies uveal melanoma as well 
as cutaneous melanoma was found related to BRCA2 mutations. Result from a breast cancer 
clinic reported that BRCA1/2 mutations in breast cancer families were entirely responsible for 
ovarian cancer risk (Ingham et al., 2013). BRCA1/2 mutation frequencies are not well known in 
Sweden but in one study BRCA1 mutations were estimated responsible for less than 1% of 
unselected breast cancers and another study found mutation frequency of BRCA2 is one third of 
that of the BRCA1 in early onset patients (Loman et al., 2001; Margolin et al., 2004). Although 
many cancers have been reported in BRCA1/2 carriers, the question if those really present excess 
risks has remained unresolved. In this study, familial breast cancer accounted for 16.1% of all 
and if 1% of it is related to BRCA1/2, it can be concluded that the associations found here were 
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dominated by other factors. As mutations in other high risk genes are much less frequent than 
those in BRCA1/2, their contribution to breast cancer is most likely small (Tung et al., 2016). 
CHEK2*1100delC is a moderate-penetrance gene related to breast cancer which can also 
predispose to other cancers (Meijers-Heijboer et al., 2002). Results from Copenhagen Gerneral 
Population Study based on 80,000 individuals showed that in addition to breast cancer 
(RR=2.08), CHEK2*1100delC heterozygosity is related to 15% to 82% increased risk for at least 
some cancers, including stomach (5.76), kidney (3.61) and prostate (1.60) cancers and sarcoma 
(3.45) (Naslund-Koch et al., 2016).    
In the present study breast cancer displayed one of the strongest two-way association with 
ovarian cancer (four significant RRs, three of which were significant at 0.001 level), suggesting 
the likely contribution of hormonal effects and/or BRCA1/2 mutations. The association with 
prostate cancer was probably at least in part due to hormonal factors (Hemminki et al., 2010a; 
Risbridger et al., 2010). The associations with eye cancer were linked by uveal melanoma which 
may be related to the BRCA2 mutation (Levy-Lahad and Friedman, 2007; Moran et al., 2012). 
The significant association with leukemia may be due to chronic myeloid leukemia. In the two-
way analyses with endocrine tumors, parathyroid and pituitary tumors were observed with 
solitary associations.  
CUP is a rare disease in which the origin of the malignant (cancer) cell cannot be found. 
Compared to cancer with known primary, CUP is fatal as it is usually at a metastatic stage upon 
diagnosis (Pavlidis and Pentheroudakis, 2012).  Familial association of CUP with many primary 
cancers, including breast cancer, was reported previously based on the earlier version of the 
database (Hemminki et al., 2011a) . In that study the primary cancers in relatives were 
hypothesized to indicate the place where the primary cancer began in CUP patients. In the 
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current study familial association of breast cancer with CUP suggested the probable primary site 
for CUP may be the breast (Hemminki et al., 2012b; Hemminki et al., 2013; Hemminki et al., 
2016).  Significance in one-way analysis cannot provide strong evidence for the association in 
the present kind of studies. However, some rare yet unknown high penetrant genes may 
contribute to the associations with female kidney and bladder cancers and with myeloma in 
families of three or more breast cancer patients, or the associations may be found simply by 
chance or unknown environmental burden. The association of breast cancer with ‘All cancers’ 
was notable because of the high RRs. When at least three cancers including breast cancer were 
identified in the family, the RR for breast cancer was 1.63 (Table 7), which is as high as the risk 
for concordant breast cancer (Figure 5, 1.70). However, a total of 3393 breast cancer patients 
were found in such families with diverse cancer diagnoses whereas only 26 breast cancer patients 
had family history of breast cancer in family. This also allude to a shared familial risk among 
multiple cancers (Frank et al., 2017a; Frank et al., 2017b; Frank et al., 2017c; Yu et al., 2017).             
Even though these findings can provide evidence for germline genetics of cancer, the problem is 
in application of the information in clinical practice. Firstly, genetic counseling for suspected 
genetic risk factors should be encouraged based on the result showing significant breast cancer 
burden in families with prior history of diverse cancers. Secondly, according to Table 7, breast 
cancer risk was especially high for women with two family members affected by non-Hodgkin 
lymphoma, leukemia or melanoma. Thirdly, even by leveraging high-throughput sequencing 
merely a moderate number of genes are identified in multiple independent families that 
predispose to cancers. Hence a desirable technique to address such polygenic predisposition 
paradigm should include dynamic assessment of multiple cancer phenotypes compared to that of 
a single phenotype based process. These may increase the awareness of counselors about the 
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cancer patterns clustering in families although they are not related to clinical routine. 
4.1.3 Familial clustering of ovarian cancer with concordant cancer 
In the estimation of familial risks of ovarian cancer according to proband type, familial risk was 
higher in families with one sister diagnosed with ovarian cancer, compared to that in families 
that only had affected mother. This may implicate recessive inheritance or shared environmental 
factors among sisters. Familial risks for the mother or sister history were identical when only 
including cases diagnosed after 50 years of age, indicating that the excess risk for sisters may 
only influence women with early diagnosis with likely involvement of sex-related hormone 
levels. Notably high familial risk was found in families where both mother and sisters were 
affected by ovarian cancer suggesting possible involvement of high penetrant risk genes. 
Unfortunately, histology information are only available for 8 cases among the 14 cases with high 
familial risk and histological type of 5 cases was serous suggesting possible involvement of 
BRCA1/2 (Lakhani et al., 2004; Pal et al., 2005). One study from UK reported that germline 
mutations in BRCA1/2 contributed to around 24% of the familial risk of epithelial ovarian 
cancer, and for the relatives of cases without BRCA1/2 mutations the familial RR was reported at 
2.24 (Jervis et al., 2013). Serous ovarian cancer was found with higher familial risk compared to 
the non-serous type in that study, which may support the association with BRCA mutations; 
however, no obvious differences were observed in the current study. Without information on 
mutation status, information lacking data on ovariectomies is one of the caveats in population-
observational investigations on ovarian cancer. Contextually, familial risk of serous cancers may 
be affected by oophorectomy in mutation carriers.  
The present study on 46,227 ovarian cancer cases is by far one of the largest family studies for 
ovarian cancer stratified by particular histological type in cases and their first-degree relatives. In 
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a combined cohort study performed by the international Ovarian Cancer Cohort Consortium 
covering 5,584 invasive ovarian cancers, the overall familial risk was 1.48 and only serous 
carcinoma was found related to the family history of concordant type with relative risk (RR) of 
1.61(Wentzensen et al., 2016). This is in contrast to the current data in which the overall familial 
risk was 2.51 and all histological types here showed significance in the two-way comparison, 
although mucinous and non-epithelial types were significant only in one-way analyses. In the 
present study, the risks for serous ovarian cancer in the two-way analyses were 2.15 and 2.96. 
The familial risks for ovarian cancer in this study (2.51) are far larger than those reported by the 
Ovarian Cancer Cohort Consortium (1.48). However, it can be speculated that family risk was 
underestimated in that study as the estimated risks were not compared with values from other 
studies (Frank et al., 2017c; Hemminki and Granström, 2003; Hemminki et al., 2011b; Jervis et 
al., 2013; Teerlink et al., 2012). Information on family history is subjected to ambiguity when it 
is self-reported instead of being procured from registered resources and it was reported that the 
positive predictive value of correct reporting for ovarian cancer in first-degree relatives was just 
69% (Murff et al., 2004).     
The histology-specific analyses in cases and probands, although novel, were based on small 
number of familial cases. Significant risks for concordant histological type were observed for 
serous, endometrioid and mucinous ovarian cancers. However, an interesting finding was that 
among all the familial associations between concordant or discordant histological types, all the 
association between discordant histological types were observed with highest RRs except 
mucinous ovarian cancer. For instance, the endometrioid-endometrioid RR was 3.59 and 
undifferentiated-undifferentiated RR was not significant while the endometrioid-undifferentiated 
RR was 9.27. This may suggest that for familial ovarian cancer histological type is not specific. 
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Histological type of ovarian cancer may not be decided by the genes or polygenes responsible for 
familial aggregation or may be decided by those genetic factors together with the effects of 
hormone and environmental factors in variable levels.  
Clear cell and endometrioid ovarian cancers were reported to arise in the context of 
endometriosis (Campbell et al., 2004; Catasús et al., 2004; Obata et al., 1998; Sato et al., 2000). 
Unsupervised clustering of risk factors found that endometrioid and clear cell carcinomas share 
many common risk factors, including oral contraceptive use, history of tubal ligation, 
endometriosis and parity (Wentzensen et al., 2016). In contrast, the present results found no 
shared familial risks between these two histological types, which is consistent with genetic 
factors playing more important roles than environmental factors on familial clustering.  
4.1.4 Familial clustering of ovarian cancer with discordant cancer  
Ovarian cancer showed the strongest association with breast cancer (four significant RRs, of 
which three were significant at 0.001 level) and additionally familial association of serous 
carcinoma with breast cancer was significant in the two-way comparison. The possible 
explanation can be the involvement of BRCA1/2 mutations (Lakhani et al., 2004; Pal et al., 
2005). Only one weak association was found with prostate cancer here despite that BRCA2 is 
reported to have association with prostate cancer (BreastCancerLinkageConsortium, 1999; 
Moran et al., 2012). BAP1 mutations are considered as risk factors for cutaneous and eye 
melanomas and ovarian cancers, which may be responsible for the weakly increased risk with 
cutaneous melanoma and the associations with eye cancer (one of two was melanoma) in Table 
7 (BreastCancerLinkageConsortium, 1999; Carbone et al., 2013). The present study may not 
support the aggregation of HNPCC syndrome that clusters colorectal and ovarian cancers with 
presentation of only a weak association between these two cancers and insignificant associations 
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of endometrioid or clear cell ovarian cancers with colorectal cancer. However, the indication of 
the HNPCC link can be indicated in the strong association between endometrioid ovarian cancer 
and endometrial cancer in the two-way analyses. MSH6 mutations are related to ovarian cancer 
of endometrioid and clear cell types (Pal et al., 2012). A tendency of high risk for endometrial 
cancer was reported in carriers with MSH6 germline mutations compared to low risk for 
colorectal cancer (Castellsagué et al., 2015).  
Ovarian cancer is a group of diseases with diverse histological types that present unique risk 
factors, genetic features and clinical manifestation. Similarly, analyses stratified by histology 
suggest that the familial clustering of ovarian cancer with other cancer may be histology- 
specific. Endometrial cancer was only in familial association with endometrioid cancer among 
all the histological types, accompanied by the strongest significance (both RR>2.00, both P < 
0.001). Additionally, epithelial ovarian cancers of different histological types including 
endometrioid, serous and mucinous were associated with breast cancer individually with 
homogenous RRs between 1.20-1.40, which indicate that there is similarity of familial risk 
between epithelial ovarian cancers of different types and breast cancer. Mucinous ovarian cancer 
was found here associated with smoking related cancers including cancers in upper aerodigestive 
tract, nose, breast, bladder and gallbladder. This is consistent with the knowledge that smoking 
can increase the risk of mucinous ovarian cancer (Wentzensen et al., 2016). However, lung 
cancer was not observed in association with mucinous ovarian cancer instead of undifferentiated 
and endometrioid types.   
Liver cancer in the ICD-7 contains a group of cancers and the significant association of liver 
cancer with ovarian cancer in the two-way comparison indicated the need for analyses in subtype 
cancers. Only gallbladder cancer showed significant results and remarkably, with mucinous 
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carcinoma in the two-way analysis, which may be due to some risk factors like smoking and 
obesity that are commonly shared in family members (Campbell et al., 2017; Pandey and Shukla, 
2003; Wentzensen et al., 2016).   
Among notable associations were, cancer of nose significant in the two-way analysis with 
ovarian cancer of endometrioid histology as well as with mucinous ovarian cancer in one-way 
analysis. Known risk factors such as smoking and wood dust exposure, cannot adequately 
explain such finding (Greiser et al., 2012). However, cancer of the nose has been associated with 
Epstein-Barr virus infection, particularly in transiently immunocompromised individuals, which 
can probably explain the present associations (Dong and Hemminki, 2001; 
WorldHealthOrganization, 2012) . Male and female genital cancers were the other rare cancers 
found in familial associations with ovarian cancer; most of the cases presented with squamous 
cell carcinoma and infection related human papilloma virus (de Martel et al.; 
WorldHealthOrganization, 2012; Zur Hausen, 2002). Hodgkin lymphoma is also related Epstein-
Barr virus and the elevated risk was found based on two families where at least two patients were 
affected by ovarian cancer (WorldHealthOrganization, 2012). It should be noted that the 
association with virus related cancers may be found by chance due to the small number of 
familial cases. Nevertheless, this is an interesting finding, which can provide evidence for further 
researches. Socioeconomic factors and pro-inflammatory effects of obesity could be involved 
(Craig et al., 2016). Familial associations of CUP, as here with ovarian cancer, may indicate in 
CUP patients the cancer may began in the ovary. 
The proportion of the non-epithelial malignancies among all the ovarian malignancies is 
approximately 10% in our database and data on risk factor for this type of ovarian cancer is 
limited (Alifrangis and Seck, 2017). In this study although based on one single significant RR 
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familial association with thyroid gland and connective tissue cancers, non-Hodgkin lymphoma 
and CUP were found, which can help understand the etiology of non-epithelial malignancies.  
4.2 Influence of family history on the risk of SPC  
4.2.1 Influence of family history on the risk of SPC in breast cancer 
Risk of subsequent cancer in breast cancer patients has been the topic of many studies with the 
improvement in breast cancer survival, and second endometrial, ovarian, stomach and colon 
cancers, and melanoma were reported to occur most frequently (Molina-Montes et al., 2015). 
Besides these cancers, more second cancers were identified with elevated risks here. 
Additionally, cancer diagnosis in first-degree relatives of breast cancer patients was associated 
with the excess risk for the SPCs. No matter considering the presence of family history or not, 
risk of second breast cancer was very high, which is reasonable as first primary breast cancer 
should share more risk factors with second breast cancer compared to other SPC.  
A fourfold excess risk for ovarian cancer as SPC was observed in breast cancer patients who had 
first-degree relatives diagnosed with ovarian cancer. Additionally, a threefold risk for liver and 
endocrine gland cancers,  a two and half fold risk for skin (SCC) cancer, more than a twofold 
risk for endometrial cancer, close to a twofold risk for pancreatic and lung cancers and a one and 
half fold risk for rectal, kidney, bladder cancers, melanoma and non-Hodgkin lymphoma were 
observed. Some genetic and environmental factors, for the latter including reproductive and other 
behavioral factors, may contribute to the elevated risks for familial SPCs. High familial risk of 
second breast and ovarian cancers may be a consequence of BRCA1/2 mutations (Metcalfe et al., 
2005; Rhiem et al., 2012), which may be also responsible for the significant risk of second 
pancreatic cancer and melanoma (Moran et al., 2012). On the other hand, the elevated familial 
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risk for second breast, ovarian and endometrial cancers may be attributable to hormone exposure. 
Smoking may be associated with the elevated familial risk of second lung, bladder and kidney 
cancers, and alcohol consumption with second liver cancer. 
In patients who only had breast cancer diagnosis, death rate was half of that in those who had 
diagnosis of SPC (16.1% and 32.3% respectively). The possible reason can be the unfavorable 
survival in most of the cancers other than breast cancer which was demonstrated by high death 
rate in second stomach, pancreatic and liver cancers and CUP (Figure 9).  On the contrary, for 
cancers that have relatively good survival, for example, melanoma, endometrial and skin cancers 
when diagnosed as SPC, the main cause of death was breast cancer. It was reported that death 
rate of breast cancer is not affected by family history (Chang et al., 2009; Melvin et al., 2016), 
which is in line with our study showing that death rate in patients with SPCs was independent on 
the family history of cancer.  
4.2.2 Influence of family history on the risk of SPC in ovarian cancer 
SPC occurred to 9.8% of all the ovarian cancer patients after a median follow-up time of 8 years 
since the initial diagnosis. First-degree relatives of 67.6% ovarian cancer patients with SPC had 
cancer diagnoses, which may contribute to the elevated risk of concordant SPC in ovarian cancer 
patients. A colon cancer diagnosis in first-degree relative was related to a nearly two and half 
fold risk of this cancer as SPC, and diagnosis of lung and breast cancers more than two fold risk. 
The primary clinical implication that is observed in the investigation is the allusion to emergence 
of multiple primary cancers based on an inherited susceptibility (Travis et al., 2013; Vogt et al., 
2017). Hence, mutation carriers are largely expected to carry the disease burden, for instance 
BRCA1/2 mutation carriers predispose to cancers in pancreas and breast (Moran et al., 2012); 
MMR mutations associated with HNPCC give rise to colorectal cancer (Bonadona et al., 2011).  
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Although frequency of deleterious alleles of BRCA1/2 or MMR mutation carriers in Swedish 
population is in Sweden, the estimate frequency of MMR mutation carriers is 1/1200 (0.08%) 
(Lagerstedt-Robinson et al., 2016). In European ancestry, with cumulative incidence of 10%, 
1.4% of breast cancers are presumably due to BRCA1/2 mutations. Therefore, the population 
frequency of such mutation would be 0.14% (Palomaki, 2015);   the mutation prevalence among 
breast cancer in Sweden is 1.8%, which would extend to a population frequency of 0.18% (Li et 
al., 2018). At the same time 11% of ovarian cancers were reported to be caused by germline 
mutations in the BRCA1/2  and 2% of that in the MMR genes based on another Swedish study 
(Malander et al., 2006). The possible influence of such high penetrant genes on the familial 
aggregation of discordant cancers was explored by removing individuals from high-risk families 
based on the criteria defined earlier due to lack of the information on mutation status (Bermejo et 
al., 2005; Lorenzo Bermejo and Hemminki, 2005b).  The significant impact on the risk of SPC 
with a positive family history remained even after eliminating those kinds of individuals. There 
may be additional genetic or environmental factors involving the development of SPC in ovarian 
cancer patients.  
This study shows SPC, accounting for 42.1% of all deaths, is the main cause of death among 
ovarian cancer patients with SPC diagnosis. In contrast, ovarian cancer is responsible for the 
large amount of deaths (85.9%) in patients with only diagnosis of first primary cancer. The 
overall death rate in ovarian cancer patients was similar to that in patient whose first-degree 
relatives had cancer diagnosis despite that excess number of patients with diagnosis of SPCs was 
due to family history of cancer. Additional cancer diagnosis is supposed to worsen the prognosis 
especially for the cancer with good survival but SPC did not affect the survival in ovarian cancer 
patients due to its poor prognosis (Riihimaki et al., 2012). However, according to Figure 13, 
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some fatal first primary cancers like pancreatic cancer can also exacerbate the survival when they 
were SPC. 
CUP is recognized as a metastatic cancer conveying an unfavorable prognosis, resembling or 
often detrimental than pancreatic cancer (Hemminki et al., 2012a; Riihimaki et al., 2013; 
Riihimaki et al., 2014b), however it did not show such unfavorable outcome in this study 
(Figure 13).  The likely reason for this discrepancy is the death registration practice in Sweden 
for CUP. The cause of death is reported by the death registrar reasoned as the cause that directly 
led to the death (Hemminki et al., 2012b). Another deviance is that the 5-year survival of 
leukemia is 62.7% as first primary but it was the second fatal SPC in ovarian cancer patients. 
(Jemal et al., 2017). Most of the cases (10/11) were diagnosed with acute leukemia, which may 
be the plausible explanation for the high mortality.    
4.3 Strength and limitation 
Some notable strength should be mentioned. As this study is based on registered resources with 
practically complete nationwide coverage of medically diagnosed cancers, it has all the 
advantages of registry data.  Firstly, large sample size enables enough power of detection. 
Furthermore, population-based study is more generalizable compared to hospital based-study. 
Additionally, the estimates of familial risks are accurate given that the family relationship is 
documented without recalling bias. 
In the analyses for familial clustering, a novel approach, bi-directional statistical analyses was 
applied to explore association of breast and ovarian cancers with other cancer. In addition, dose-
response relationship between cancer risk and number of affected first-degree relatives is another 
way to prove the existing familial association. This study is the first one performed to explore the 
familial associations among different histological types in breast and ovarian cancer patients. 
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Regarding studies on SPCs, one of the concerns is to accurately differentiate SPC from 
metastases following the first cancer. It was reported that 98% of the second neoplasms in the 
Swedish Cancer Registry were correctly classified and no recorded SPC was found to be a 
metastasis (Frödin et al., 1997). The additional challenge is to identify the true cause that killed 
patients who had multiple cancer diagnosis. An agreement of 77% was reported between the 
cause of death from death certificates and the expected cause of death according to case 
summaries in a Swedish study (Johansson et al., 2009). 
As for the limitation of the study, in the familial risk stratified by histological type, available 
information on histological type were only for cancer diagnosis since the introduction of 
SNOMED coding system in the cancer registry in 1993. The estimation for familial risk of 
cancer may be affected as the follow-up time is too short for intergenerational studies. In 
addition, with better understanding of ovarian cancer new histological classification for ovarian 
cancer has been proposed. However the histology in the cancer database is not updated yet. 
Breast and ovarian cancers are both hormone related cancers, but data on reproductive factors 
like age at menopause and exposure to exogenous hormones, are not available in the cancer 
registry. For the analysis for risk of second cancer, no clinical information such as tumor stage 
and treatment data are another shortage. No individual lifestyle data such as smoking and 
physical activity may confound the relationship between family history and cancer risk but 
socioeconomic factors were adjusted in the regression models, which can reducing the 
confounding to some extent (Hemminki et al., 2003b). What should be noted with caution is that 
due to lack of individual genetic condition the familial aggregation of cancers was explained by 
conjecture.  
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4.4 Conclusions 
1) The familial risks of breast and ovarian cancers with the concordant cancer family history are 
high for early-onset patients and multiple affected relatives; for breast cancer, risk are 
prominently high with mother and father both affected. Familial risk varies among histological 
types. Notably, causes for familial clustering of ovarian cancer seems not to define a specific 
histological type and this can allude to an underlying mechanistic link shared between various   
histological types of ovarian cancer.  
2) Common risk factors are shared by breast cancer and a group of discordant cancers with 
possible involvement of gene-environment interactions related to hormonal and immunological 
pathways. Genetic counselors should alert the family members of breast cancer patients about 
high familial risk shared between breast cancer with some cancers, such as cancers in kidney and 
bladder in females and myeloma. A refurbished genetic approach, which was successful in 
discovery of BRCA1/2 in breast and ovarian cancer families, may be useful for genetic research 
in families with clustering of breast and other related cancers.  
3) A group of other cancers were found to share susceptibility with ovarian cancer and the 
associations with cancers in colorectum, breast, endometrium and liver and CUP showed 
significance in the two-way comparison. Histology-specific familial associations were presented 
in some cancers, such as the only significant association for endometrial cancer with 
endometrioid types and the pairs of breast cancer and endometrioid, serous and mucinous types 
with similar RRs. The association with rare cancers (in nose, male and female genitals) was 
interesting but calls further confirmation with mechanistic studies. 
4) A group of 17% of breast cancer patients developed SPCs during the follow-up period, and 
68.8% of them had first-degree relatives diagnosed with cancer. For breast cancer patients with 
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family history, 18.3% of SPCs other than breast cancer were estimated as the consequence of 
family history. Cancers that have common genetic, reproductive or behavioral risk factors shared 
with breast cancer were found with high familial risks. For the patients with diagnosis of SPC, 
the majority of deaths were due to SPC. Our findings indicate that cancer family history can 
provide evidence on potential risk of SPCs and it is helpful for the counseling about risk factors 
and disease surveillance in breast cancer patients.    
5) SPC occurred in nearly 10% of all ovarian cancer patients and 67.6% of them had positive 
family history of cancer. Family history of cancer in first-degree relatives contributed to the 
elevated risk of concordant SPC regardless of including or excluding individuals from possible 
high-risk families. Breast and colorectal cancers were observed with high familial risks, which 
are acknowledged to develop in HBOC and HNPPC syndromes respectively. Therefore, the 
results together indicate the necessity for physicians to obtain cancer family history upon the 
diagnosis of ovarian cancer which is helpful for disease management and can benefit patients and 
their families.  
The present results can be used in several ways. In clinical practice, these results can increase the 
awareness of clinicians to take family history during cancer diagnosis and make use of it in 
disease management. An important message to clinicians and patients is that family history may 
indicate the possible familial clustering with genetic background, for which different cancers 
may aggregate in different family members or in one individual presenting as multiple primary 
cancers.
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5 NOVELTY 
 This study was based on Swedish Family-Cancer Database, the largest of its kind in the 
world, which provided accurate family relationship and enabled most available power of 
detection. 
 For the familial clustering with concordant cancer, diverse aspects of familial risk was 
explored, from different family relationships, number of affected family members, age at 
diagnosis to histological types. 
 For the familial clustering with discordant cancers, the two-way comparison and trend test 
for dose-response relationship were performed to assess effects of family history on risk of 
cancer. 
 In the analysis for familial clustering of breast cancer with other cancers, some cancers with 
high familial risk were observed when only considering cancer diagnosis in female or male 
first-degree relatives. 
 For the analysis for familial clustering of ovarian cancer with other cancers, stratification of 
histology was considered and some remarkable associations were noted. 
 The impact of family history on the risk of second primary cancer was explored by including 
or excluding individuals from possible high-risk families and the familial risk of second 
primary cancer was still significant after excluding these families 
 Cause of death was assessed in breast and ovarian cancer patients with or without second 
primary cancer and second primary cancer was the leading cause of death for both cancer 
patients with diagnosis of second primary cancer. 
 Different significant levels were implemented throughout the study, which can help with 
identification of the true association from the chance finding. 
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6 SUMMARY 
Female cancers account for 44% among all cancer diagnoses in women globally, among which 
breast cancer is the most frequently diagnosed and ovarian cancer is a relatively fatal disease. 
Familial clustering of these two cancers with the same (concordant) cancer is well recognized, 
but the data on the aggregation with other (discordant) cancers is limited. How cancer family 
history impacts on risk of this cancer as second primary cancer (SPC) in breast and ovarian 
cancers and the related cause of death are also interesting questions for the fact that the cancer 
survival increases in recent years. Hence, this study is to analyze the familial clustering of breast 
and ovarian cancer with the concordant and discordant cancers as well as familial risk of SPC 
and related cause of death in breast and ovarian cancer patients. 
Based on the Swedish Family-Cancer Database, familial risks of breast and ovarian cancers in 
families with first-degree relatives (parents or siblings) affected by the concordant and discordant 
cancers and the risks of other cancers in families with first-degree relatives affected by breast 
and ovarian cancers were estimated. The familial risks were also stratified by sex and histology. 
In the analysis for the impact of family history on SPC risk, the relative risk for SPC in breast 
and ovarian cancer patients in families with first-degree relatives diagnosed with the same cancer 
was compared with that of patients without family history. Based on the diagnosis of SPC cause 
of death in those patients was analyzed. ICD-7 was used to identify cancers and SNOMED was 
to histology. Poisson regression model was performed for risk estimation and calculation of their 
corresponding CIs for 95%, 99% and 99.9%.  
The high familial risks of breast and ovarian cancers with the concordant cancer family history 
are shown for women with younger age diagnosis and those with multiple affected relatives and 
familial risk varies among histological types. Breast cancer shares susceptibility with a group of 
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other cancers for which gene-environment interactions with hormonal and immunological 
pathways could be involved and ovarian and prostate cancers showed most significant 
associations. Some novel associations of breast cancer were found with female kidney and 
bladder cancers and with myeloma.  Ovarian cancer was also observed associated with a group 
of discordant cancers and among them colorectal, breast, endometrial and liver cancers and CUP 
showed significance in the two-way analysis. The novel associations with cancer of nose and that 
of male and female genitals were noted. 
For breast cancer patients in families with individuals diagnosed with cancer, 18.3% of non-
breast SPCs were due to family history. Prominent familial risks were found in cancers that share 
genetic, reproductive or behavioral factors with breast cancer. For ovarian cancer patients, high 
familial risks were found for breast and colorectal cancers, which are known to manifest in 
ovarian cancer-related syndromes. However, family history of a particular cancer contributed to 
the elevated risk of SPC in ovarian cancer patients at the same site regardless of inclusion or 
exclusion of possible high-risk families. SPC was the main cause of death in the breast and 
ovarian cancer patients with SPCs. 
Our study suggested that family history may indicate the possible familial clustering with genetic 
background, for which different cancers may aggregate in different family members or in one 
individual presenting as multiple primary cancers, which provide useful information on genetic 
counseling and disease management in breast and ovarian cancer patients. 
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Zusammenfassung 
44% der weltweit bei Frauen diagnostizierten Tumorerkrankungen betreffen die weiblichen 
Geschlechtsorgane, wobei Brustkrebs am häufigsten diagnostiziert wird und Ovarialkrebs im 
Vergleich eine tödliche Erkrankung darstellt. In beiden Fällen ist das familiäre Clustering 
innerhalb des jeweiligen Krebs bereits bekannt (konkordant), aber die Datengrundlage bezüglich 
des gehäuften Auftretens mit anderen Krebserkrankungen (diskordant) ist bisher noch 
beschränkt. Interessant erscheinen außerdem die Frage nach dem Einfluss der familiären 
Krebsvorgeschichte auf das Risiko, einen zweiten Primärtumor (second primery cancer, SPC) 
der selben Krebsart zu entwickeln, sowie die Frage nach der jeweiligen Todesursache im Falle 
des Brust- und des Ovarialkrebs. Dies ist besonders in Anbetracht der in den letzten Jahren 
steigenden Überlebensraten dieser Erkrankungen von großer Bedeutung. Daher nimmt sich diese 
Studie zum einen die Analyse des familiären Clusterings von Brust- und Ovarialkrebs mit 
konkordanten und diskordanten Krebsarten zum Ziel. Weiterhin sollen das Risiko der 
Entwicklung eines SPCs sowie die einhergehenden Todesursachen von Brust- und 
Ovarialkrebspatienten untersucht werden. 
Basierend auf den Informationen schwedischer Datenbanken zu familiären Krebserkrankungen, 
wurde das familiäre Risiko des Brust- und Ovarialkrebs in Familien geschätzt, deren Mitglieder 
ersten Grades (Eltern oder Geschwister) konkordante und diskordante Krebsrerkrankungen 
zeigten. Zudem wurde das familiäre Risiko anderer Krebsarten in Familien geschätzt, welche im 
ersten Verwandtschaftsgrad Brust- und Ovarialkrebs aufwiesen. Einige der familiären Risiken 
wurden außerdem nach Geschlecht und Histologie stratifiziert. 
In den Analysen des Einflusses der Familiengeschichte auf die Entwicklung eines SPCs wurde 
das relative Risiko eines SPCs bei Brust- und Ovarialkrebspatienten in Familien, deren 
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Mitglieder ersten Verwandtschaftsgrades am selben Krebs erkrankten, mit dem relativen Risiko 
bei Patienten ohne familiäre Krebsvorgeschichte verglichen. Basierend auf SPC-Diagnose, 
wurde die Todesursache dieser Patienten analysiert. 
ICD-7 wurde für die Identifizierung des Krebs genutzt und SNOMED für die Histologie. Die 
Poisson-Regression wurde für die Risikoschätzung und die Berechnung der entsprechenden 
Konfidenzintervalle (CI) von 95%, 99% und 99,9%. 
Das hohe familiäre Risiko von Brust- und Ovarialkrebs bei familiärer Vorgeschichte des 
konkordanten Krebs wurde für Frauen mit einer Diagnose im frühen Alter sowie bei Patientinnen 
mit mehreren betroffenen Verwandten beobachtet. Das familiäre Risiko variiert zudem zwischen 
den verschiedenen histologischen Typen. Brustkrebs hat die genetisch bedingte Anfälligkeit mit 
einer Gruppe anderer Krebserkrankungen gemeinsam, wobei Gen-Umwelt-Interaktionen, 
hormonellen und immunologischen Pathways folgend, eine Rolle spielen könnten. Hierbei 
zeigten sich Ovarial- und Prostatakrebs am stärksten miteinander assoziiert. 
Einige neue Assoziationen von Brustkrebs mit weiblichem Nieren- und Blasenkrebs sowie dem 
Myelom wurden weiterhin gefunden. Außerdem konnte beobachtet werden, dass Ovarialkrebs 
mit einer Gruppe diskordanter Krebserkrankungen assoziiert ist, von welchen kolorektale 
Tumore, Brustkrebs, das Endometrium- und Leberkarzinom sowie CUP Signifikanz in der Zwei-
Weg-Analyse zeigten. Die neue Assoziation mit Nasenkrebs und Krebserkrankungen der 
männlichen und weiblichen Genitalien wurde beobachtet. 
In Familien mit diagnostiziertem Krebs wurden 18,3% der Nicht-Brustkrebs-SPCs bei 
Brustkrebspatienten der familiären Krebsvorgeschichte zugeschrieben. Auffällige familiäre 
Risiken wurden für Krebsarten gefunden, die genetische, reproduktive oder verhaltensbezogene 
Faktoren mit Brustkrebs gemeinsam hatten. Bei Ovarialkrebspatienten wurden hohe familiäre 
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Risikofaktoren für Brustkrebs und das kolorektale Karzinom gefunden. Diese treten 
bekannterweise im Rahmen Ovarialkrebs-assoziierter Syndrome auf. Die familiäre Vorgeschichte 
bestimmter Krebsarten trug zu einem erhöhten Risiko, dass Ovarialkrebspatienten einen SPC 
entwickeln, sowohl bei Inklusion, als auch bei Exklusion der potenziellen Hochrisiko-Familien 
bei. Bei Brust- und Ovarialkrebspatienten mit bekannten SPCs war dieser die hauptsächliche 
Todesursache. 
Unsere Studie deutet darauf hin, dass die familiäre Vorgeschichte auf ein mögliches familiäres 
Clustering mit genetischem Hintergrund hinweist, welches verschiedene Krebsarten in 
unterschiedlichen Familienmitgliedern oder multiple Primärtumoren in einem Individuum 
zusammenfasst. Dies bietet nützliche Informationen für die genetische Beratung und 
Krankheitsbewältigung bei Brust- und Ovarialkrebspatienten. 
 
 
 
 
 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 84 
7 REFERENCES 
 
Alifrangis, C. and Seck, M. J. (2017). Malignant Ovarian Germ Cell Tumours: An 
Overview of Management and Controversies. In: Ovarian Cancers: Advances 
through International Research Cooperation (GINECO, ENGOT, GCIG), eds. Pujade-
Lauraine, E., Ray-Coquard, I. and Lécuru, F., Springer International Publishing, Cham, 
pp. 247-259. 
 
Allan, J. M. (2008). Genetic susceptibility to radiogenic cancer in humans. Health 
physics 95, 677-686. 
 
Amundadottir, L. T., Thorvaldsson, S., Gudbjartsson, D. F., Sulem, P., Kristjansson, K., 
Arnason, S., Gulcher, J. R., Bjornsson, J., Kong, A., Thorsteinsdottir, U. and Stefansson, 
K. (2004). Cancer as a complex phenotype: Pattern of cancer distribution 
within and beyond the nuclear family. Plos Medicine 1, 229-236, doi: 
https://doi.org/10.1371/journal.pmed.0010065. 
 
Bahcall, O. G. (2013). iCOGS collection provides a collaborative model. Nature genetics 
45, 343. 
 
Baker, J. A., Beehler, G. P., Sawant, A. C., Jayaprakash, V., McCann, S. E. and Moysich, K. B. 
(2006). Consumption of coffee, but not black tea, is associated with 
decreased risk of premenopausal breast cancer. The Journal of nutrition 136, 
166-171. 
 
Barlow, L., Westergren, K., Holmberg, L. and Talbäck, M. (2009). The completeness of the 
Swedish Cancer Register–a sample survey for year 1998. Acta oncologica 48, 
27-33. 
 
Barrow, E., Hill, J. and Evans, D. G. (2013). Cancer risk in Lynch syndrome. Familial 
cancer 12, 229-240. 
 
Bermejo, J. L., Eng, C. and Hemminki, K. (2005). Cancer characteristics in Swedish 
families fulfilling criteria for hereditary nonpolyposis colorectal cancer. 
Gastroenterology 129, 1889-1899. 
 
Bermejo, J. L., Rawal, R. and Hemminki, K. (2004). Familial association of specific 
histologic types of ovarian malignancy with other malignancies. Cancer 100, 
1507-1514. 
 
Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., Guimbaud, R., 
Buecher, B., Bignon, Y. J., Caron, O., Colas, C., Nogues, C., Lejeune-Dumoulin, S., 
Olivier-Faivre, L., Polycarpe-Osaer, F., Nguyen, T. D., Desseigne, F., Saurin, J. C., 
Berthet, P., Leroux, D., Duffour, J., Manouvrier, S., Frebourg, T., Sobol, H., Lasset, C. 
and Bonaiti-Pellie, C. (2011). Cancer risks associated with germline mutations in 
MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305, doi: 
10.1001/jama.2011.743. 
 
Brandt, A., Bermejo, J. L., Sundquist, J. and Hemminki, K. (2008). Age of onset in familial 
cancer. Annals of oncology 19, 2084-2088. 
 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 85 
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. and Jemal, A. (2018). Global 
Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality 
Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 
 
BreastCancerLinkageConsortium (1999). Cancer risks in BRCA2 mutation carriers. J Natl 
Cancer Inst 91, 1310-1316. 
 
Brooke, H. L., Talback, M., Hornblad, J., Johansson, L. A., Ludvigsson, J. F., Druid, H., 
Feychting, M. and Ljung, R. (2017). The Swedish cause of death register. Eur J 
Epidemiol 32, 765-773, doi: 10.1007/s10654-017-0316-1. 
 
Brown, M. B. (1975). 400: A method for combining non-independent, one-sided tests 
of significance. Biometrics, 987-992. 
 
Buiatti, E., Crocetti, E., Acciai, S., Gafa, L., Falcini, F., Milandri, C. and La Rosa, M. (1997). 
Incidence of second primary cancers in three Italian population-based 
cancer registries. European Journal of Cancer 33, 1829-1834. 
 
Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., 
Cristiano, B. E., Pearson, R. B. and Phillips, W. A. (2004). Mutation of the PIK3CA 
gene in ovarian and breast cancer. Cancer research 64, 7678-7681. 
 
Campbell, P. T., Newton, C. C., Kitahara, C. M., Patel, A. V., Hartge, P., Koshiol, J., McGlynn, K. 
A., Adami, H.-O., Berrington de González, A., Beane Freeman, L. E., Bernstein, L., 
Buring, J. E., Freedman, N. D., Gao, Y.-T., Giles, G. G., Gunter, M. J., Jenab, M., Liao, L. 
M., Milne, R. L., Robien, K., Sandler, D. P., Schairer, C., Sesso, H. D., Shu, X.-O., 
Weiderpass, E., Wolk, A., Xiang, Y.-B., Zeleniuch-Jacquotte, A., Zheng, W. and Gapstur, 
S. M. (2017). Body Size Indicators and Risk of Gallbladder Cancer: Pooled 
Analysis of Individual-Level Data from 19 Prospective Cohort Studies. Cancer 
Epidemiology Biomarkers &amp; Prevention 26, 597-606, doi: 10.1158/1055-9965.epi-
16-0796. 
 
Cancer, C. G. o. H. F. i. B. (2001). Familial breast cancer: collaborative reanalysis of 
individual data from 52 epidemiological studies including 58 209 women 
with breast cancer and 101 986 women without the disease. The Lancet 358, 
1389-1399. 
 
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R. and Gaudino, G. (2013). BAP1 and 
cancer. Nat Rev Cancer 13, 153-159. 
 
Castellsagué, E., Liu, J., Volenik, A., Giroux, S., Gagné, R., Maranda, B., Roussel-Jobin, A., 
Latreille, J., Laframboise, R., Palma, L., Kasprzak, L., Marcus, V. A., Breguet, M., Nolet, 
S., El-Haffaf, Z., Australie, K., Gologan, A., Aleynikova, O., Oros-Klein, K., Greenwood, 
C., Mes-Masson, A. M., Provencher, D., Tischkowitz, M., Chong, G., Rousseau, F. and 
Foulkes, W. D. (2015). Characterization of a novel founder MSH6 mutation 
causing Lynch syndrome in the French Canadian population. Clinical Genetics 
87, 536-542, doi: 10.1111/cge.12526. 
 
Catasús, L., Bussaglia, E., Rodrı́guez, I., Gallardo, A., Pons, C., Irving, J. A. and Prat, J. (2004). 
Molecular genetic alterations in endometrioid carcinomas of the ovary: 
similar frequency of beta-catenin abnormalities but lower rate of 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 86 
microsatellite instability and PTEN alterations than in uterine endometrioid 
carcinomas. Human pathology 35, 1360-1368. 
 
Chang, E. T., Milne, R. L., Phillips, K.-A., Figueiredo, J. C., Sangaramoorthy, M., Keegan, T. H., 
Andrulis, I. L., Hopper, J. L., Goodwin, P. J. and O’Malley, F. P. (2009). Family history 
of breast cancer and all-cause mortality after breast cancer diagnosis in the 
Breast Cancer Family Registry. Breast cancer research and treatment 117, 167-176. 
 
Chiang, A. J., Chang, C., Huang, C.-H., Huang, W.-C., Kan, Y.-Y. and Chen, J. (2018). Risk 
factors in progression from endometriosis to ovarian cancer: a cohort study 
based on medical insurance data. Journal of gynecologic oncology 29. 
 
Cobain, E. F., Milliron, K. J. and Merajver, S. D. (2016). Updates on breast cancer 
genetics: Clinical implications of detecting syndromes of inherited 
increased susceptibility to breast cancer. Semin Oncol 43, 528-535, doi: 
10.1053/j.seminoncol.2016.10.001. 
 
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008). Ovarian cancer 
and oral contraceptives: collaborative reanalysis of data from 45 
epidemiological studies including 23257 women with ovarian cancer and 
87303 controls. The Lancet 371, 303-314, doi: 10.1016/S0140-6736(08)60167-1. 
 
CollaborativeGrouponEpidemiologicalStudiesofOvarianCancer (2012). Ovarian cancer and 
body size: individual participant meta-analysis including 25,157 women with 
ovarian cancer from 47 epidemiological studies. PLoS Med 9, e1001200, doi: 
10.1371/journal.pmed.1001200. 
 
Corso, G., Figueiredo, J., La Vecchia, C., Veronesi, P., Pravettoni, G., Macis, D., Karam, R., 
Gullo, R. L., Provenzano, E. and Toesca, A. (2018). Hereditary lobular breast 
cancer with an emphasis on E-cadherin genetic defect. Journal of medical 
genetics, jmedgenet-2018-105337. 
 
Couto, E. and Hemminki, K. (2007). Estimates of heritable and environmental 
components of familial breast cancer using family history information. 
British Journal of Cancer 96, 1740-1742, doi: 10.1038/sj.bjc.6603753. 
 
Coyte, A., Morrison, D. S. and McLoone, P. (2014). Second primary cancer risk-the 
impact of applying different definitions of multiple primaries: results from 
a retrospective population-based cancer registry study. BMC cancer 14, 272. 
 
Craig, E. R., Londono, A. I., Norian, L. A. and Arend, R. C. (2016). Metabolic risk factors 
and mechanisms of disease in epithelial ovarian cancer: A review. Gynecol 
Oncol 143, 674-683, doi: 10.1016/j.ygyno.2016.10.005. 
 
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D. and Plummer, M. 
Global burden of cancers attributable to infections in 2008: a review and 
synthetic analysis. The Lancet Oncology 13, 607-615, doi: 10.1016/S1470-
2045(12)70137-7. 
 
Dong, C. and Hemminki, K. (2001). Risk of multiple primary cancers in nasal cancer 
patients. Epidemiology 12, 367-369. 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 87 
 
Donin, N., Filson, C., Drakaki, A., Tan, H. J., Castillo, A., Kwan, L., Litwin, M. and Chamie, K. 
(2016). Risk of second primary malignancies among cancer survivors in the 
United States, 1992 through 2008. Cancer 122, 3075-3086, doi: 
10.1002/cncr.30164. 
 
Durmaz, A. A., Karaca, E., Demkow, U., Toruner, G., Schoumans, J. and Cogulu, O. (2015). 
Evolution of genetic techniques: past, present, and beyond. BioMed research 
international 2015. 
 
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.-W. W., Comber, 
H., Forman, D. and Bray, F. (2013). Cancer incidence and mortality patterns in 
Europe: estimates for 40 countries in 2012. European journal of cancer 49, 1374-
1403. 
 
Frank, C., Fallah, M., Ji, J., Sundquist, J. and Hemminki, K. (2014). The population impact 
of familial cancer, a major cause of cancer. Int J Cancer 134, 1899-1906, doi: 
10.1002/ijc.28510. 
 
Frank, C., Fallah, M., Sundquist, J., Hemminki, A. and Hemminki, K. (2015). Population 
Landscape of Familial Cancer. Sci Rep 5, 12891, doi: 10.1038/srep12891. 
 
Frank, C., Sundquist, J., Hemminki, A. and Hemminki, K. (2017a). Familial Associations 
Between Prostate Cancer and Other Cancers. Eur Urol 71, 162-165, doi: 
10.1016/j.eururo.2016.07.031. 
 
Frank, C., Sundquist, J., Hemminki, A. and Hemminki, K. (2017b). Risk of other cancers in 
families with melanoma: novel familial links. Scientific reports 7, 42601. 
 
Frank, C., Sundquist, J., Yu, H., Hemminki, A. and Hemminki, K. (2017c). Concordant and 
discordant familial cancer: Familial risks, proportions and population 
impact. International journal of cancer 140, 1510-1516. 
 
Frödin, J.-E., Ericsson, J. and Barlow, L. (1997). Multiple primary malignant tumors in a 
national cancer registry. Reliability of reporting. Acta Oncol 36, 465-469. 
 
Gates, M. A., Rosner, B. A., Hecht, J. L. and Tworoger, S. S. (2010). Risk factors for 
epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171, 45-53, doi: 
10.1093/aje/kwp314. 
 
Geary, J., Sasieni, P., Houlston, R., Izatt, L., Eeles, R., Payne, S. J., Fisher, S. and Hodgson, S. V. 
(2008). Gene-related cancer spectrum in families with hereditary non-
polyposis colorectal cancer (HNPCC). Familial cancer 7, 163-172. 
 
Glance, A. (2009). Ovarian cancer: an overview. Am Fam Physician 80, 609-616. 
 
Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A. and Skolnick, M. H. (1994). Systematic 
population-based assessment of cancer risk in first-degree relatives of 
cancer probands. J Natl Cancer Inst 86, 1600-1608. 
 
Greiser, E. M., Greiser, K. H., Ahrens, W., Hagen, R., Lazszig, R., Maier, H., Schick, B. and 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 88 
Zenner, H. P. (2012). Risk factors for nasal malignancies in German men: the 
South-German Nasal cancer study. BMC Cancer 12, 506, doi: 10.1186/1471-2407-
12-506. 
 
Hemminki, K., Aaltonen, L. and Li, X. (2003a). Subsequent primary malignancies after 
endometrial carcinoma and ovarian carcinoma. Cancer 97, 2432-2439. 
 
Hemminki, K., Bevier, M., Hemminki, A. and Sundquist, J. (2012a). Survival in cancer of 
unknown primary site: population-based analysis by site and histology. Ann 
Oncol 23, 1854-1863. 
 
Hemminki, K., Bevier, M., Sundquist, J. and Hemminki, A. (2012b). Cancer of unknown 
primary (CUP): does cause of death and family history implicate hidden 
phenotypically changed primaries? Ann Oncol 23, 2720-2724, doi: mds063 [pii] 
10.1093/annonc/mds063. 
 
Hemminki, K., Bevier, M., Sundquist, J. and Hemminki, A. (2013). Site-specific cancer 
deaths in cancer of unknown primary diagnosed with lymph node 
metastasis may reveal hidden primaries. Int J Cancer 132, 944-950, doi: 
10.1002/ijc.27678. 
 
Hemminki, K., Forsti, A. and Chen, B. (2010a). Breast and prostate cancer: familial 
associations. Nat Rev Cancer 10, 523, doi: nrc2795-c1 [pii] 
10.1038/nrc2795-c1. 
 
Hemminki, K. and Granström, C. (2003). Familial invasive and borderline ovarian 
tumors by proband status, age and histology. International journal of cancer 105, 
701-705. 
 
Hemminki, K., Ji, J., Brandt, A., Mousavi, S. M. and Sundquist, J. (2010b). The Swedish 
Family‐Cancer Database 2009: prospects for histology‐specific and 
immigrant studies. International journal of cancer 126, 2259-2267. 
 
Hemminki, K., Ji, J., Sundquist, J. and Shu, X. (2011a). Familial risks in cancer of 
unknown primary: tracking the primary sites. J Clin Oncol 29, 435-440. 
 
Hemminki, K. and Li, X. (2004). Familial risks of cancer as a guide to gene 
identification and mode of inheritance. Int J Cancer 110, 291-294. 
 
Hemminki, K., Sundquist, J. and Brandt, A. (2011b). Incidence and mortality in epithelial 
ovarian cancer by family history of any cancer. Cancer 117, 3972-3980. 
 
Hemminki, K., Sundquist, J. and Brandt, A. (2012c). Do discordant cancers share familial 
susceptibility? European Journal of Cancer 48, 1200-1207, doi: 
10.1016/j.ejca.2011.09.017. 
 
Hemminki, K., Sundquist, K., Sundquist, J., Hemminki, A. and Ji, J. (2016). Location of 
metastases in cancer of unknown primary are not random and signal 
familial clustering. Sci Rep 6, 22891, doi: 10.1038/srep22891. 
 
Hemminki, K., Zhang, H. and Czene, K. (2003b). Socioeconomic factors in cancer in 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 89 
Sweden. Int J Cancer 105, 692-700. 
 
Hemminki, X. L., Kamila Plna, Charlotta Granström, Pauli Vaittinen, Kari (2001). The Nation-
wide Swedish Family-Cancer Database&Updated Structure and Familial 
Rates. Acta Oncologica 40, 772-777. 
 
Henderson, J. T., Webber, E. M. and Sawaya, G. F. (2018). U.S. Preventive Services Task 
Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: 
Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive 
Services Task Force, Agency for Healthcare Research and Quality (US), Rockville (MD). 
 
Hussain, S., Sundquist, J. and Hemminki, K. (2008). Offspring and sibling risks in 
invasive and in situ squamous cell skin carcinoma: an updated study from 
Sweden on the effects of histology, age and sun exposure. Arch Dermatol in 
press. 
 
Ingham, S. L., Warwick, J., Buchan, I., Sahin, S., O'Hara, C., Moran, A., Howell, A. and Evans, 
D. G. (2013). Ovarian cancer among 8,005 women from a breast cancer family 
history clinic: no increased risk of invasive ovarian cancer in families 
testing negative for BRCA1 and BRCA2. J Med Genet 50, 368-372, doi: 
10.1136/jmedgenet-2013-101607. 
 
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, B., Mariotto, A., Lake, A. 
J., Wilson, R., Sherman, R. L., Anderson, R. N., Henley, S. J., Kohler, B. A., Penberthy, 
L., Feuer, E. J. and Weir, H. K. (2017). Annual Report to the Nation on the Status 
of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst 109, doi: 
10.1093/jnci/djx030. 
 
Jervis, S., Song, H., Lee, A., Dicks, E., Tyrer, J., Harrington, P., Easton, D. F., Jacobs, I. J., 
Pharoah, P. P. and Antoniou, A. C. (2013). Ovarian cancer familial relative risks 
by tumour subtypes and by known ovarian cancer genetic susceptibility 
variants. Journal of medical genetics, jmedgenet-2013-102015. 
 
Ji, J., Sundquist, K., Sundquist, J. and Hemminki, K. (2012). Comparability of cancer 
identification among Death Registry, Cancer Registry and Hospital 
Discharge Registry. Int J Cancer 131, 2085-2093, doi: 10.1002/ijc.27462. 
 
Johansson, L. A., Björkenstam, C. and Westerling, R. (2009). Unexplained differences 
between hospital and mortality data indicated mistakes in death 
certification: an investigation of 1,094 deaths in Sweden during 1995. Journal 
of clinical epidemiology 62, 1202-1209. 
 
Karahalios, E., English, D., Thursfield, V., Simpson, J., Farrugia, H. and Giles, G. (2009). 
Second primary cancers in Victoria. Melbourne: Cancer Council Victoria 113. 
 
Kharazmi, E., Fallah, M., Sundquist, K. and Hemminki, K. (2012). Familial risk of early and 
late onset cancer: nationwide prospective cohort study. Bmj 345, e8076. 
 
Kurian, A. W., Balise, R. R., McGuire, V. and Whittemore, A. S. (2005). Histologic types of 
epithelial ovarian cancer: have they different risk factors? Gynecologic 
oncology 96, 520-530. 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 90 
 
Kurman, R. J. and Shih, I.-M. (2010). The Origin and pathogenesis of epithelial ovarian 
cancer-a proposed unifying theory. The American journal of surgical pathology 34, 
433. 
 
Lagerstedt-Robinson, K., Rohlin, A., Aravidis, C., Melin, B., Nordling, M., Stenmark-Askmalm, 
M., Lindblom, A. and Nilbert, M. (2016). Mismatch repair gene mutation 
spectrum in the Swedish Lynch syndrome population. Oncol Rep 36, 2823-
2835, doi: 10.3892/or.2016.5060. 
 
Lakhani, S. R. (2012). WHO Classification of Tumours of the Breast, International 
Agency for Research on Cancer. 
 
Lakhani, S. R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., McGuffog, L., 
Steele, D., Devilee, P., Klijn, J. G. M., Meijers-Heijboer, H., Radice, P., Pilotti, S., 
Nevanlinna, H., Butzow, R., Sobol, H., Jacquemier, J., Lyonet, D. S., Neuhausen, S. L., 
Weber, B., Wagner, T., Winqvist, R., Bignon, Y.-J., Monti, F., Schmitt, F., Lenoir, G., 
Seitz, S., Hamman, U., Pharoah, P., Lane, G., Ponder, B., Bishop, D. T. and Easton, D. F. 
(2004). Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clinical 
Cancer Research 10, 2473-2481, doi: 10.1158/1078-0432.ccr-1029-3. 
 
Levy-Lahad, E. and Friedman, E. (2007). Cancer risks among BRCA1 and BRCA2 
mutation carriers. British Journal of Cancer 96, 11-15, doi: 10.1038/sj.bjc.6603535. 
 
Li, C. I., Weiss, N. S., Stanford, J. L. and Daling, J. R. (2000). Hormone replacement 
therapy in relation to risk of lobular and ductal breast carcinoma in middle‐
aged women. Cancer: Interdisciplinary International Journal of the American Cancer 
Society 88, 2570-2577. 
 
Li, J., Wen, W. X., Eklund, M., Kvist, A., Eriksson, M., Christensen, H. N., Torstensson, A., 
Bajalica‐Lagercrantz, S., Dunning, A. M. and Decker, B. (2018). Prevalence of BRCA1 
and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. 
International journal of cancer. 
 
Liede, A., Karlan, B. Y. and Narod, S. A. (2004). Cancer risks for male carriers of 
germline mutations in BRCA1 or BRCA2: a review of the literature. Journal of 
Clinical Oncology 22, 735-742. 
 
Loman, N., Johannsson, O., Kristoffersson, U., Olsson, H. and Borg, A. (2001). Family history 
of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a 
population-based series of early-onset breast cancer. J Natl Cancer Inst 93, 
1215-1223. 
 
Lorenzo Bermejo, J. and Hemminki, K. (2005a). Familial risk of cancer shortly after 
diagnosis of the first familial tumor. J Natl Cancer Inst 97, 1575-1579. 
 
Lorenzo Bermejo, J. and Hemminki, K. (2005b). A population-based assessment of the 
clustering of breast cancer in families eligible for testing of BRCA1 and 
BRCA2 mutations. Annals of oncology 16, 322-329. 
 
Makki, J. (2015). Diversity of breast carcinoma: histological subtypes and clinical 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 91 
relevance. Clinical Medicine Insights: Pathology 8, CPath. S31563. 
 
Malander, S., Rambech, E., Kristoffersson, U., Halvarsson, B., Ridderheim, M., Borg, A. and 
Nilbert, M. (2006). The contribution of the hereditary nonpolyposis colorectal 
cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101, 
238-243, doi: 10.1016/j.ygyno.2005.10.029. 
 
Margolin, S., Werelius, B., Fornander, T. and Lindblom, A. (2004). BRCA1 mutations in a 
population-based study of breast cancer in Stockholm County. Genet Test 8, 
127-132, doi: 10.1089/gte.2004.8.127. 
 
Meijers-Heijboer, H., van Den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, 
R., Hollestelle, A., Houben, M., Crepin, E., van Veghel-Plandsoen, M., Elstrodt, F., van 
Duijn, C., Bartels, C., Meijers, C., Schutte, M., McGuffog, L., Thompson, D., Easton, D. 
F., Sodha, N., Seal, S., Barfoot, R., Mangion, J., Chang-Claude, J., Eccles, D., Eeles, R., 
Evans, D. G., Houlston, R., Murday, V., Narod, S., Peretz, T., Peto, J., Phelan, C., Zhang, 
H. X., Szabo, C., Devilee, P., Goldgar, D., Futreal, P. A., Nathanson, K. L., Weber, B. L., 
Rahman, N. and Stratton, M. R. (2002). Low-penetrance susceptibility to breast 
cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 
mutations. Nat Genet 31, 55-59. 
 
Melvin, J. C., Wulaningsih, W., Hana, Z., Purushotham, A. D., Pinder, S. E., Fentiman, I., Gillett, 
C., Mera, A., Holmberg, L. and Van Hemelrijck, M. (2016). Family history of breast 
cancer and its association with disease severity and mortality. Cancer 
medicine 5, 942-949. 
 
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Foulkes, W. D., Warner, E., 
Olopade, O., Eisen, A. and Weber, B. (2005). The risk of ovarian cancer after 
breast cancer in BRCA1 and BRCA2 carriers. Gynecologic oncology 96, 222-226. 
 
Modugno, F., Ness, R. B. and Cottreau, C. M. (2002). Cigarette smoking and the risk of 
mucinous and nonmucinous epithelial ovarian cancer. Epidemiology, 467-471. 
 
Molina-Montes, E., Requena, M., Sánchez-Cantalejo, E., Fernández, M. F., Arroyo-Morales, M., 
Espín, J., Arrebola, J. P. and Sánchez, M.-J. (2015). Risk of second cancers cancer 
after a first primary breast cancer: a systematic review and meta-analysis. 
Gynecologic oncology 136, 158-171. 
 
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F. and Evans, D. 
G. R. (2012). Risk of cancer other than breast or ovarian in individuals with 
BRCA1 and BRCA2 mutations. Familial Cancer 11, 235-242, doi: 10.1007/s10689-
011-9506-2. 
 
Mucci, L. A., Hjelmborg, J. B., Harris, J. R. and et al. (2016). Familial risk and heritability 
of cancer among twins in nordic countries. JAMA 315, 68-76, doi: 
10.1001/jama.2015.17703. 
 
Murff, H. J., Greevy, R. A. and Syngal, S. (2007). The Comprehensiveness of Family 
Cancer History Assessments in Primary Care. Public Health Genomics 10, 174-
180, doi: 10.1159/000101759. 
 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 92 
Murff, H. J., Spigel, D. R. and Syngal, S. (2004). Does this patient have a family history of 
cancer? An evidence-based analysis of the accuracy of family cancer history. 
Jama 292, 1480-1489, doi: 10.1001/jama.292.12.1480. 
 
Naghavi, M., Abajobir, A. A., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abera, S. F., Aboyans, V., 
Adetokunboh, O., Afshin, A. and Agrawal, A. (2017). Global, regional, and national 
age-sex specific mortality for 264 causes of death, 1980–2016: a systematic 
analysis for the Global Burden of Disease Study 2016. The Lancet 390, 1151-
1210. 
 
Naslund-Koch, C., Nordestgaard, B. G. and Bojesen, S. E. (2016). Increased Risk for Other 
Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes 
Estimated From the Copenhagen General Population Study. J Clin Oncol 34, 
1208-1216, doi: 10.1200/jco.2015.63.3594. 
 
NationalBoardofHealthandWelfare (2017). Statistics on Cancer  Incidence 2016  
 Official Satatistics of Sweden 
http://www.socialstyrelsen.se/statistics/statisticaldatabase/cancer. 
 
Negri, E., Pelucchi, C., Franceschi, S., Montella, M., Conti, E., Dal Maso, L., Parazzini, F., 
Tavani, A., Carbone, A. and La Vecchia, C. (2003). Family history of cancer and risk 
of ovarian cancer. Eur J Cancer 39, 505-510. 
 
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., 
Casadei, S., Yi, Q. and Burger, R. A. (2016). Inherited mutations in women with 
ovarian carcinoma. JAMA oncology 2, 482-490. 
 
Nyante, S. J., Dallal, C. M., Gierach, G. L., Park, Y., Hollenbeck, A. R. and Brinton, L. A. (2013). 
Risk factors for specific histopathological types of postmenopausal breast 
cancer in the NIH-AARP Diet and Health Study. American journal of 
epidemiology 178, 359-371. 
 
Obata, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix-Trench, G., Thomas, E. J. and 
Campbell, I. G. (1998). Frequent PTEN/MMAC mutations in endometrioid but 
not serous or mucinous epithelial ovarian tumors. Cancer research 58, 2095-
2097. 
 
Olsen, C. M., Nagle, C. M., Whiteman, D. C., Ness, R., Pearce, C. L., Pike, M. C., Rossing, M. A., 
Terry, K. L., Wu, A. H. and Risch, H. A. (2013). Obesity and risk of ovarian cancer 
subtypes: evidence from the Ovarian Cancer Association Consortium. 
Endocrine-related cancer 20, 251-262. 
 
Pal, T., Akbari, M., Sun, P., Lee, J., Fulp, J., Thompson, Z., Coppola, D., Nicosia, S., Sellers, T. 
and McLaughlin, J. (2012). Frequency of mutations in mismatch repair genes in 
a population-based study of women with ovarian cancer. British journal of 
cancer 107, 1783. 
 
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., 
Hoffman, M., Martino, M. A. and Wakeley, K. (2005). BRCA1 and BRCA2 mutations 
account for a large proportion of ovarian carcinoma cases. Cancer 104, 2807-
2816. 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 93 
 
Palomaki, G. E. (2015). Is it time for BRCA1/2 mutation screening in the general adult 
population?: impact of population characteristics. Genet Med 17, 24-26, doi: 
10.1038/gim.2014.167. 
 
Pandey, M. and Shukla, V. K. (2003). Lifestyle, parity, menstrual and reproductive 
factors and risk of gallbladder cancer. Eur J Cancer Prev 12, 269-272, doi: 
10.1097/01.cej.0000082604.47188.5d. 
 
Pavlidis, N. and Pentheroudakis, G. (2012). Cancer of unknown primary site. Lancet 379, 
1428-1435, doi: S0140-6736(11)61178-1 [pii] 
10.1016/S0140-6736(11)61178-1. 
 
Peto, J. (2002). Breast cancer susceptibility—a new look at an old model. Cancer Cell 1, 
411-412. 
 
Pharoah, P. D., Antoniou, A., Bobrow, M., Zimmern, R. L., Easton, D. F. and Ponder, B. A. 
(2002). Polygenic susceptibility to breast cancer and implications for 
prevention. Nature genetics 31, 33. 
 
Pukkala, E., Engholm, G., Hojsgaard Schmidt, L. K., Storm, H., Khan, S., Lambe, M., Pettersson, 
D., Olafsdottir, E., Tryggvadottir, L., Hakanen, T., Malila, N., Virtanen, A., Johannesen, 
T. B., Laronningen, S. and Ursin, G. (2017). Nordic Cancer Registries - an 
overview of their procedures and data comparability. Acta Oncol, 1-16, doi: 
10.1080/0284186x.2017.1407039. 
 
Rahman, N. (2014). Realizing the promise of cancer predisposition genes. Nature 505, 
302-308, doi: 10.1038/nature12981. 
 
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., 
Gentry-Maharaj, A., Hayward, J. and Philpott, S. (2015). Germline mutations in the 
BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. JNCI: 
Journal of the National Cancer Institute 107. 
 
Reid, B. M., Permuth, J. B. and Sellers, T. A. (2017). Epidemiology of ovarian cancer: a 
review. Cancer biology & medicine 14, 9. 
 
Rhiem, K., Engel, C., Graeser, M., Zachariae, S., Kast, K., Kiechle, M., Ditsch, N., Janni, W., 
Mundhenke, C. and Golatta, M. (2012). The risk of contralateral breast cancer in 
patients from BRCA1/2 negative high risk families as compared to patients 
from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast 
Cancer Research 14, R156. 
 
Riihimaki, M., Hemminki, A., Fallah, M., Thomsen, H., Sundquist, K., Sundquist, J. and 
Hemminki, K. (2014a). Metastatic sites and survival in lung cancer. Lung Cancer 
86, 78-84, doi: 10.1016/j.lungcan.2014.07.020. 
 
Riihimaki, M., Hemminki, A., Sundquist, J. and Hemminki, K. (2016). Patterns of 
metastasis in colon and rectal cancer. Sci Rep 6, 29765, doi: 10.1038/srep29765. 
 
Riihimaki, M., Hemminki, A., Sundquist, K. and Hemminki, K. (2013). Time trends in 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 94 
survival from cancer of unknown primary: small steps forward. Eur J Cancer 
49, 2403-2410, doi: 10.1016/j.ejca.2013.02.022. 
 
Riihimaki, M., Hemminki, A., Sundquist, K. and Hemminki, K. (2014b). Causes of death in 
patients with extranodal cancer of unknown primary: searching for the 
primary site. BMC Cancer 14, 439, doi: 10.1186/1471-2407-14-439. 
 
Riihimaki, M., Thomsen, H., Brandt, A., Sundquist, J. and Hemminki, K. (2012). Death causes 
in breast cancer patients. Ann Oncol 23, 604-610, doi: mdr160 [pii] 
10.1093/annonc/mdr160. 
 
Riihimäki, M., Thomsen, H., Brandt, A., Sundquist, J. and Hemminki, K. (2011). What do 
prostate cancer patients die of? The oncologist, theoncologist. 2010-0338. 
 
Riman, T., Dickman, P. W., Nilsson, S., Correia, N., Nordlinder, H., Magnusson, C. M. and 
Persson, I. R. (2002). Risk factors for invasive epithelial ovarian cancer: 
results from a Swedish case-control study. American journal of epidemiology 156, 
363-373. 
 
Risbridger, G. P., Davis, I. D., Birrell, S. N. and Tilley, W. D. (2010). Breast and prostate 
cancer: more similar than different. Nat Rev Cancer 10, 205-212, doi: nrc2795 [pii] 
10.1038/nrc2795. 
 
Rosso, S., De Angelis, R., Ciccolallo, L., Carrani, E., Soerjomataram, I., Grande, E., Zigon, G., 
Brenner, H. and Group, E. W. (2009). Multiple tumours in survival estimates. 
European Journal of Cancer 45, 1080-1094. 
 
Samuel, N., Villani, A., Fernandez, C. V. and Malkin, D. (2014). Management of familial 
cancer: sequencing, surveillance and society. Nature Reviews Clinical Oncology 
11, 723. 
 
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T. and Noguchi, M. 
(2000). Loss of heterozygosity on 10q23. 3 and mutation of the tumor 
suppressor gene PTEN in benign endometrial cyst of the ovary: possible 
sequence progression from benign endometrial cyst to endometrioid 
carcinoma and clear cell carcinoma of the ovary. Cancer research 60, 7052-7056. 
 
Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P., Krol, A. D., van der Maazen, 
R. W., Roesink, J., Raemaekers, J. M., de Boer, J. P., Zijlstra, J. M., van Imhoff, G. W., 
Petersen, E. J., Poortmans, P. M., Beijert, M., Lybeert, M. L., Mulder, I., Visser, O., 
Louwman, M. W., Krul, I. M., Lugtenburg, P. J. and van Leeuwen, F. E. (2015). Second 
Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N 
Engl J Med 373, 2499-2511, doi: 10.1056/NEJMoa1505949. 
 
Schmidtke, J., Pabst, B. and Nippert, I. (2005). DNA-based genetic testing is rising 
steeply in a national health care system with open access to services: a 
survey of genetic test use in Germany, 1996–2002. Genetic testing 9, 80-84. 
 
Siegel, R. L., Miller, K. D. and Jemal, A. (2017). Cancer statistics, 2017. CA: a cancer journal 
for clinicians 67, 7-30. 
 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 95 
Siegel, R. L., Miller, K. D. and Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer 
Journal for Clinicians 68, 7-30, doi: doi:10.3322/caac.21442. 
 
Skol, A. D., Sasaki, M. M. and Onel, K. (2016). The genetics of breast cancer risk in the 
post-genome era: thoughts on study design to move past BRCA and towards 
clinical relevance. Breast Cancer Res 18, 99, doi: 10.1186/s13058-016-0759-4. 
 
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M. and Brawley, O. W. (2011). 
Cancer screening in the United States, 2011. CA: A Cancer Journal for Clinicians 
61, 8-30. 
 
Soegaard, M., Jensen, A., Høgdall, E., Christensen, L., Høgdall, C., Blaakær, J. and Kjaer, S. K. 
(2007). Different Risk Factor Profiles for Mucinous and Nonmucinous 
Ovarian Cancer: Results from the Danish MALOVA Study. Cancer 
Epidemiology Biomarkers &amp;amp; Prevention 16, 1160. 
 
Song, H., Dicks, S. J. R., Tyrer, J. P., Intermaggio, M. P., Hayward, J., Edlund, C. K., Conti, D., 
Harrington, P., Fraser, L. and Philpott, S. (2015). Contribution of germline 
mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in 
the population. Journal of Clinical Oncology 33, 2901. 
 
Sopik, V., Phelan, C., Cybulski, C. and Narod, S. A. (2015). BRCA1 and BRCA2 mutations 
and the risk for colorectal cancer. Clin Genet 87, 411-418, doi: 10.1111/cge.12497. 
 
Stewart, L. M., Spilsbury, K., Jordan, S., Stewart, C., Holman, C. A. J., Powell, A., Reekie, J. and 
Cohen, P. (2018). Risk of high-grade serous ovarian cancer associated with 
pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiology 55, 
110-116. 
 
Stratton, M. R. (1997). Pathology of familial breast cancer: differences between breast 
cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. The 
Lancet 349, 1505-1510. 
 
Sud, A., Thomsen, H., Sundquist, K., Houlston, R. S. and Hemminki, K. (2017). Risk of second 
cancer in Hodgkin lymphoma survivors and the influence of family history. J 
Clin Oncol 35, 1584-1590. 
 
Teerlink, C. C., Albright, F. S., Lins, L. and Cannon-Albright, L. A. (2012). A comprehensive 
survey of cancer risks in extended families. Genetics in Medicine 14, 107-114. 
 
Travis, L. B., Demark Wahnefried, W., Allan, J. M., Wood, M. E. and Ng, A. K. (2013). 
Aetiology, genetics and prevention of secondary neoplasms in adult cancer 
survivors. Nat Rev Clin Oncol 10, 289-301, doi: 10.1038/nrclinonc.2013.41. 
 
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A. R., Winer, E. 
P. and Garber, J. E. (2016). Frequency of Germline Mutations in 25 Cancer 
Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J 
Clin Oncol 34, 1460-1468, doi: 10.1200/jco.2015.65.0747. 
 
Vogt, A., Schmid, S., Heinimann, K., Frick, H., Herrmann, C., Cerny, T. and Omlin, A. (2017). 
Multiple primary tumours: challenges and approaches, a review. ESMO Open 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 96 
2, e000172, doi: 10.1136/esmoopen-2017-000172. 
 
Watson, P., Bützow, R., Lynch, H. T., Mecklin, J.-P., Järvinen, H. J., Vasen, H. F., Madlensky, 
L., Fidalgo, P., Bernstein, I. and on HNPCC, I. C. G. (2001). The clinical features of 
ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic 
oncology 82, 223-228. 
 
Weigelt, B., Geyer, F. C. and Reis-Filho, J. S. (2010). Histological types of breast cancer: 
how special are they? Molecular oncology 4, 192-208. 
 
Weir, H. K., Johnson, C. J. and Thompson, T. D. (2013). The effect of multiple primary 
rules on population-based cancer survival. Cancer Causes & Control 24, 1231-
1242. 
 
Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Setiawan, V. W., 
Visvanathan, K., Weiderpass, E. and Adami, H.-O. (2016). Ovarian cancer risk 
factors by histologic subtype: an analysis from the ovarian cancer cohort 
consortium. Journal of Clinical Oncology 34, 2888-2898. 
 
Wood, M. E., Kadlubek, P., Pham, T. H., Wollins, D. S., Lu, K. H., Weitzel, J. N., Neuss, M. N. 
and Hughes, K. S. (2014). Quality of cancer family history and referral for 
genetic counseling and testing among oncology practices: a pilot test of 
quality measures as part of the American Society of Clinical Oncology 
Quality Oncology Practice Initiative. Journal of Clinical Oncology 32, 824. 
 
Wood, M. E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P. and Travis, L. B. (2012). Second 
malignant neoplasms: assessment and strategies for risk reduction. J Clin 
Oncol 30, 3734-3745, doi: 10.1200/jco.2012.41.8681. 
 
WorldHealthOrganization (2012). Biological agents. Volume 100 B. A review of human 
carcinogens. IARC monographs on the evaluation of carcinogenic risks to 
humans/World Health Organization, International Agency for Research on Cancer 100, 
1-441. 
 
Yu, H., Frank, C., Sundquist, J., Hemminki, A. and Hemminki, K. (2017). Common cancers 
share familial susceptibility: implications for cancer genetics and 
counselling. Journal of medical genetics 54, 248-253. 
 
Yurgelun, M. B., Hiller, E. and Garber, J. E. (2015). Population-Wide Screening for 
Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? J Clin 
Oncol 33, 3092-3095, doi: 10.1200/JCO.2015.60.8596. 
 
Zaorsky, N. G., Churilla, T., Egleston, B., Fisher, S., Ridge, J., Horwitz, E. and Meyer, J. (2016). 
Causes of death among cancer patients. Annals of oncology 28, 400-407. 
 
Ziogas, A., Gildea, M., Cohen, P., Bringman, D., Taylor, T. H., Seminara, D., Barker, D., Casey, 
G., Haile, R. and Liao, S.-Y. (2000). Cancer risk estimates for family members of 
a population-based family registry for breast and ovarian cancer. Cancer 
Epidemiology and Prevention Biomarkers 9, 103-111. 
 
Zur Hausen, H. (2002). Papillomaviruses and cancer: from basic studies to clinical 
Breast and ovarian cancers in women………………………………………………….. …………..……Reference 
Guoqiao Zheng............................................................................................................................. 97 
application. Nature reviews cancer 2, 342. 
 
Breast and ovarian cancers in women…………………………………………….. ……..……Curriculum Vitae 
Guoqiao Zheng............................................................................................................................. 98 
8 PUBLICATIONS 
 
Publications related to this thesis: 
#Zheng, G., Yu, H., Hemminki, A., Försti, A., Sundquist, K., & Hemminki, K. (2017). Familial 
associations of female breast cancer with other cancers. International journal of cancer, 141(11), 
2253-2259. (Published) 
Zheng, G., Yu, H., Kanerva, A., Försti, A., Sundquist, K., & Hemminki, K. (2018). Familial 
Ovarian Cancer Clusters with Other Cancers. Scientific reports, 8. (Published) 
Zheng, G., Yu, H., Kanerva, A., Försti, A., Sundquist, K., & Hemminki, K. (2018). Familial 
risks of ovarian cancer by age at diagnosis, proband type and histology. PloS one, 13(10), 
e0205000. (Published) 
Zheng, G., Chattopdhyay, S., Försti, A., Sundquist, K., & Hemminki, K. (2018). Familial risks 
of second primary cancers and mortality in ovarian cancer patients. Clinical Epidemiology, 10, 
1457-1466. (Published) 
Zheng, G., Hemminki, A., Försti, A., Sundquist, J., Sundquist, K., & Hemminki, K. Second 
primary cancer after female breast cancer: familial risks and cause of death. Cancer Medicine. 
(Accepted) 
#The corresponding results for risk of breast cancer in this thesis (section 3.1.3) had been adjusted by 
parity, so there is slightly difference between them. 
 
Other publications: 
Zheng, G., Yu, H., Hemminki, A., Försti, A., Sundquist, K., & Hemminki, K. (2017). Familial 
associations of male breast cancer with other cancers. Breast cancer research and treatment, 
166(3), 897-902. (Published) 
Chattopadhyay, S.*, Zheng, G.*, Sud, A.*, Yu, H., Sundquist, K., Sundquist, J., ... & 
Hemminki, K. (2018). Risk of second primary cancer following myeloid neoplasia and risk of 
myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in 
Sweden. The Lancet Haematology, 5(8), e368-e377. (Published, *equal contribution) 
Chattopadhyay, S. , Sud, A. , Zheng, G. , Yu, H. , Sundquist, K. , Sundquist, J. , Försti, A. , 
Houlston, R. , Hemminki, A. & Hemminki, K. (2018). Second primary cancers in non‐Hodgkin 
lymphoma: Bidirectional analyses suggesting role for immune dysfunction. International journal 
of cancer, 143, 2449-2457. https://doi:10.1002/ijc.31801 (Published) 
Chattopadhyay, S., Zheng, G., Hemminki, O., Försti, A., Sundquist, K., & Hemminki, K. 
(2018). Prostate cancer survivors: Risk and mortality in second primary cancers. Cancer 
medicine. 2018;00:1-8. https://doi.org/10.1002/cam4.1764 (Published) 
Zheng, G., Yu, H., Kanerva, A., Försti, A., Sundquist, K., & Hemminki, K. (2018). Borderline 
ovarian tumors share familial risks with themselves and invasive cancers. Cancer Epidemiology 
and Prevention Biomarkers, cebp-0503. (Published) 
 
Breast and ovarian cancers in women…………………………………………….. ……..……Curriculum Vitae 
Guoqiao Zheng............................................................................................................................. 99 
9 CURRICULUM VITAE  
 
Personal Data  
First name  Guoqiao 
 
Family name Zheng 
 
Date of birth 11.Jan.1990 
 
Place of birth Chongqing, China 
 
Nationality Chinese 
 
 
University Education 
2016.10-now Doctor of Philosophy, Human Science, German Cancer Research Center, Germany 
Thesis: Breast and ovarian cancers in women: familial clustering, second primary 
cancers and cause of death 
Supervisor: Kari Hemminki 
 
2013.09-2016.06 Master of Medicine, Occupational and Environmental Health, School of Public 
Health, Fudan University 
Thesis: Telomere length and gene expression of related genes in Vinyl chloride 
monomer exposure workers 
Supervisor: Zhaolin Xia 
 
2008.09-2013.06 Bachelor of Medicine, Preventive Medicine, School of Public Health, Fudan 
University 
Thesis: Ergonomic Assessment on Nursing Tasks in Hemodialysis Center 
Supervisor: Kezhi Jin 
 
 
School Education 
2005.09-2008.07 High school study, Chongqing No.8 school 
 
2002.09-2005.07 Middle school study, Chongqing Rongchang An’fu school 
 
1996.09-2002.07 Primary school study, Chongqing Rongchang An’fu Guqiao primary school 
 
 
 
Breast and ovarian cancers in women…...…Acknowledgements 
Guoqiao Zheng............................................................................................................................. 100 
10 ACKNOWLEGEMENTS 
 
Firstly, my special gratitude goes to Kari, who gave me the opportunity to study in the Division 
of Molecular Genetic Epidemiology. Your research insights, passion and immense knowledge 
always inspire me and your guidance helped me in all the time of my research and my thesis. It is 
such a great pleasure to work with you. 
I would further thank Asta. Although we were not working together, your preciseness on the 
manuscript revision always enlightens me.  
Thanks to Hongyao, Elham, Haiying, Luyao, Erina and Yasmeen, you create such a comfortable 
working environment. My especial thanks go to Hongyao for helping me get starting my study. 
You were always very patient with my questions. 
I’m grateful to Hauke for fixing the problem with Swedish server.  
With a special mention to Marion, many thanks for everything that you’ve done for supporting 
my work and study here. 
I’d express my sincere gratitude to Subhayan. I enjoyed a lot working with you. Your research 
enthusiasm amazed me. I can always get an answer from you regarding every question. Thank 
you for the suggestion and support every time when I was struggling with my work and life. 
Thanks to our lunch group (Subhayan, Hao, Pankaj, Ofure and Ye) for the fun from every lunch 
talk and hotpot get-together. 
Special thanks go to Aayushi and Mando for helping me translate the summary into German. 
Outside our department, I would say thanks to Wenjie and Xiaoya for the encouragement when I 
was down. You are such great friends to me.  
I would show my sincere appreciation to China Scholar Council for providing me stipend to 
study in Germany. 
Last but not the least, my sincere gratitude goes to my family for your endless love that supports 
me here. You always trust and support my decision, so I can pursuit my dream in my way. Many 
thanks to my dear sister; you are always there for me.  
 
Breast and ovarian cancers in women……………………………………………..………………….……Appendix 
Guoqiao Zheng............................................................................................................................. 101 
11 APPENDIX 
 
1. Supplementary Tables 
 
 
 
Supplementary Table 1  ICD-7 or PAD code for the subtype cancer sites in FCD 
Cancer sites ICD-7 code (first 4 digits) PAD code 
Liver  
Liver, primary 1550 - 
Gall bladder 1551 - 
Extrahepatic bile ducts 1552 - 
Ampulla of vater 1553 - 
Eye 
Melanoma  192 176 
Retinoblastoma  192 436 
Endocrine glands 
Adrenal  1950 - 
Parathyroid  1951 - 
Thymus  1952 - 
Pituitary  1953 - 
Insuloma of pancreas 1955 - 
Other  1957 - 
Multiple endocrine glands 1958 - 
Unspecified endocrine glands 1959 - 
Leukemia 
Acute lymphatic 2040 - 
Chronic lymphatic 2041 - 
Acute myeloid  2050 - 
Chronic myeloid 2051 - 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2  Proportion of invasive and in situ female breast cancer when there 
were 0, 1, 2 and ≥3 first-degree relatives diagnosed with breast cancer 
Breast 
cancer 
0FDR 1FDR 2FDRs 3FDRs 
Total 
N % N % N % N % 
Invasive 63794 95.2 11351 94.4 889 93.2 26 92.9 76060 
In situ 3237 4.8 678 5.6 65 6.8 2 7.1 3982 
FDR, first-degree relative 
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Supplementary Table 3 Familial association of female breast cancer with other cancers in female relatives 
Other cancer site Estimation item 
Cases with 1 FDR Cases with 2 FDRs Cases with ≥3 FDRs 
P-trend 
N RR 95%CI N RR 95%CI N RR 95%CI 
Upper aerodigestive tract 
Risk of breast cancer 435 1.04 0.95-1.14 3 4.18 1.35-
1213.14 
- - - 
- 
0.3015 
Risk of other cancer 306 1.13 1.00-1.27 17 1.30 0.81-2.09 2 3.14 0.78-12.56 0.0145 
Pancreas 
Risk of breast cancer 772 1.03 0.96-1.11 6 2.12 0.95-4.72 - - - 
- 
0.2776 
Risk of other cancer 310 1.14 1.01-1.28 14 0.94 0.55-1.59 1 1.23 0.17-8.74 0.0692 
Kidney 
Risk of breast cancer 733 1.01 0.94-1.09 3 1.04 0.34-3.28 - - - 
- 
0.7435 
Risk of other cancer 295 1.00 0.89-1.13 11 0.74 0.41-1.33 3 3.90 1.26-12.08 0.9974 
Bladder 
Risk of breast cancer 700 1.06 0.99-1.14 2 0.71 0.18-2.83 - - - 
- 
0.1341 
Risk of other cancer 335 1.10 0.98-1.23 14 0.87 0.51-1.47 3 3.60 1.16-11.17 0.1224 
Melanoma 
Risk of breast cancer 1016 1.03 0.97-1.09 11 1.17 0.62-2.01 - - - 
- 
0.3575 
Risk of other cancer 1364 1.07 1.01-1.13 77 1.41 1.13-1.76 3 1.18 0.38-3.65 0.0010 
Skin, squamous cell 
Risk of breast cancer 984 0.91 0.86-0.98 6 0.91 0.41-2.02 - - - 
- 
0.0062 
Risk of other cancer 499 1.16 1.06-1.28 24 1.10 0.74-1.64 3 2.78 0.90-8.64 0.0013 
Eye 
Risk of breast cancer 96 1.18 0.97-1.44 - - - 
- 
- - - 
- 
0.1148 
Risk of other cancer 86 1.38 1.10-1.72 4 1.45 0.54-3.87 - - - 
- 
0.0065 
Thyroid gland 
Risk of breast cancer 360 1.08 0.97-1.20 2 1.23 0.31-4.92 - - - 
- 
0.1396 
Risk of other cancer 347 1.05 0.94-1.17 26 1.89 1.28-2.78 1 1.52 0.21-10.81 0.0398 
Myeloma 
Risk of breast cancer 367 0.97 0.87-1.07 3 2.43 0.78-7.53 - - - 
- 
0.6505 
Risk of other cancer 162 1.10 0.94-1.29 5 0.64 0.27-1.54 2 4.87 1.22-19.49 0.3341 
Leukemia 
Risk of breast cancer 722 0.99 0.92-1.07 4 1.08 0.40-2.87 - - - 
- 
0.8991 
Risk of other cancer 487 1.08 0.99-1.19 28 1.43 0.98-2.07 1 1.03 0.14-7.32 0.0274 
Unknown primary 
Risk of breast cancer 1098 1.04 0.98-1.11 4 1.42 0.51-3.77 - - - 
- 
0.1388 
Risk of other cancer 471 1.14 1.04-1.26 32 1.44 1.02-2.05 3 2.47 0.80-7.67 0.0006 
All cancers
a
 
Risk of breast cancer 26313 1.26 1.24-1.28 3632 1.61 1.56-1.67 453 2.01 1.81-2.21 <0.0001 
Risk of other cancer 24453 1.28 1.27-1.30 1599 1.67 1.59-1.76 69 1.47 1.16-1.86 <0.0001 
All cancers
b
 
Risk of breast cancer 18750 1.04 1.03-1.06 1377 1.05 1.00-1.11 118 1.22 1.02-1.47 <0.0001 
Risk of other cancer 13152 1.04 1.02-1.06 726 1.14 1.06-1.23 43 1.36 1.01-1.84 <0.0001 
FDR: first-degree relatives; 
Bolding, italic and underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 1.00 respectively;  
a: all cancers include breast cancers and all other cancers;b: all cancers include all other cancers except breast cancer. 
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Supplementary Table 4 Familial association of female breast cancer with cancers in male relatives 
Other cancer site Estimation item 
Cases with 1 FDR Cases with 2 FDRs Cases with ≥3 FDRs 
P-trend 
N RR 95%CI N RR 95%CI N RR 95%CI 
Stomach 
Risk of breast cancer 1539 1.07 1.02-1.12 8 1.10 0.55-2.20 2 24.03 6.01-96.08 0.0065 
Risk of other cancer 342 1.11 0.99-1.24 29 1.72 1.19-2.48 2 1.82 0.45-7.27 0.0034 
Small intestine 
Risk of breast cancer 164 1.19 1.02-1.39  - - 
- 
- - - 
- 
0.0292 
Risk of other cancer 91 0.92 0.74-1.14 9 1.75 0.91-3.37 1 3.21 0.45-22.83 0.8400 
Anus 
Risk of breast cancer 34 0.92 0.66-1.29  - - 
- 
- - - 
- 
0.6169 
Risk of other cancer 21 0.60 0.39-0.94 1 0.53 0.07 3.76  - 
- 
0.0128 
Liver 
Risk of breast cancer 743 1.08 1.00-1.16 3 1.70 0.55-5.26 - - 
- 
0.0361 
Risk of other cancer 291 1.02 0.90-1.15 17 1.10 0.68-1.77 3 2.98 0.96-9.26 0.4406 
Pancreas 
Risk of breast cancer 858 1.06 0.99-1.14 1 0.40 0.06-2.90 - - - 
- 
0.0989 
Risk of other cancer 354 1.12 1.01-1.25 21 1.20 0.78-1.85 2 1.70 0.43 6.82 0.0230 
Lung 
Risk of breast cancer 2939 1.09 1.05-1.13 42 1.24 0.91-1.68 - - - 
- 
<0.0001 
Risk of other cancer 1146 1.02 0.96-1.09 73 1.15 0.91-1.45 4 0.97 0.36-2.58 0.2705 
Bladder 
Risk of breast cancer 2178 1.05 1.01-1.10 19 0.97 0.62-1.51 2 1.91 0.48-7.62 0.0227 
Risk of other cancer 969 1.01 0.94-1.08 65 1.24 0.97-1.58 3 0.92 0.30-2.87 0.3608 
Melanoma 
Risk of breast cancer 1000 1.05 0.99-1.12 12 1.26 0.71-2.22 - - - 
- 
0.0676 
Risk of other cancer 1251 1.06 1.00-1.12 51 0.91 0.69-1.19 3 0.96 0.31-2.98 0.1597 
Skin, squamous cell 
Risk of breast cancer 1449 1.04 0.99-1.09 15 1.88 1.14-3.12 - - - 
- 
0.0792 
Risk of other cancer 642 1.06 0.98-1.15 31 0.90 0.64-1.29 - - - 
- 
0.3341 
Endocrine gland 
Risk of breast cancer 359 1.17 1.05-1.29  - - 
- 
- - - 
- 
0.0045 
Risk of other cancer 352 1.13 1.01-1.26 17 1.08 0.67-1.75 - - 
- 
0.0353 
Connective tissue 
Risk of breast cancer 206 1.02 0.89-1.17 - - - 
- 
- - - 
- 
0.7809 
Risk of other cancer 192 1.20 1.03-1.39 11 1.47 0.81-2.66 - - - 
- 
0.0094 
Non-Hodgkin lymphoma 
Risk of breast cancer 1015 1.04 0.97-1.11 5 1.03 0.43-2.47 - - - 
- 
0.2290 
Risk of other cancer 810 1.09 1.01-1.17 36 0.97 0.70-1.35 3 1.35 0.44-4.20 0.0414 
Leukemia 
Risk of breast cancer 989 1.08 1.02-1.15 7 1.19 0.57-2.50 - - - 
- 
0.0114 
Risk of other cancer 688 1.08 1.00-1.17 34 1.16 0.83-1.63 1 0.58 0.08-4.15 0.0387 
All cancers
a
 
Risk of breast cancer 26039 1.08 1.07-1.10 2972 1.18 1.14-1.22 379 1.34 1.21-1.48 <0.0001 
Risk of other cancer 19550 1.07 1.06-1.09 1021 1.08 1.01-1.14 63 1.09 0.85-1.40 <0.0001 
All cancers
b
 
Risk of breast cancer 25994 1.08 1.06-1.10 2958 1.18 1.13-1.22 376 1.33 1.20-1.47 <0.0001 
Risk of other cancer 19509 1.07 1.06-1.09 1018 1.07 1.01-1.14 63 1.09 0.85-1.40 <0.0001 
FDR: first-degree relatives;  Bolding, italic and underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 1.00 respectively;  
a: all cancers include breast cancers and all other cancers; b: all cancers include all other cancers except breast cancer
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Supplementary Table 5 Familial associations of ovarian cancer with liver cancers 
Subtypes 
Risk of ovarian cancer Risk of liver cancers 
N RR 95% CI N RR 95% CI 
Liver, primary 92 1.05 0.85-1.29 74 1.07 0.85-1.35 
Gall bladder 95 1.27 1.03-1.55 30 1.05 0.73-1.51 
Extrahepatic bile ducts 33 1.37 0.97-1.93 23 1.47 0.97-2.22 
Ampulla of vater 14 1.40 0.83-2.37 9 1.27 0.66-2.46 
Bolding, italic and underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 1.00 
respectively;  
 
 
 
 
 
 
 
 
 
 
Supplementary Table 6 Familial associations of histology-specific ovarian cancers with gall 
bladder cancer  
Subtypes Histology 
Risk of ovarian cancer Risk of  gall bladder cancer 
N RR 95% CI N RR 95% CI 
Gall bladder 
Undifferentiated  3 2.35 0.75-7.36 2 6.95 1.74-27.83 
Clear cell 3 0.92 0.29-2.85 0 - - 
Endometrioid  7 1.09 0.52-2.29 2 1.62 0.40-6.49 
Serous 35 1.24 0.89-1.73 9 1.78 0.93-3.44 
Mucinous 12 2.75 1.56-4.88 4 4.66 1.75-12.42 
Non-epithelial 3 1.94 0.62-6.07 0 - - 
Bolding, italic and underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 1.00 
respectively;  
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Supplementary Table 7 Cause of death according to follow-up time since first cancer diagnosis 
in breast cancer patients with or without second primary cancer (2001-2015) 
Breast 
cancer 
Cause of death 
<1 year 
(% in 
column) 
1-4 years 
(% in 
column) 
5-10 years 
(% in 
column) 
>10 years 
(% in 
column) 
All 
(% in column) 
With SPC 
Breast cancer a 8 (7.1) 55 (9.4) 70 (8.8) 25 (10.7) 158 (9.2) 
Breast cancer b 47 (41.6) 194 (33.2) 198 (25.0) 46 (19.7) 485 (28.1) 
SPC 32 (28.3) 203 (34.8) 345 (43.5) 83 (35.6) 663 (38.5) 
HPC 3 (2.6) 25 (4.3) 34 (4.3) 17 (7.3) 79 (4.6) 
Other cancers 9 (8.0) 36 (6.2) 61 (7.7) 26 (11.2) 132 (7.7) 
Other causes 14 (12.4) 71 (12.2) 85 (10.7) 36 (15.4) 206 (12.0) 
All  
(N, % in row) 
113 (6.6) 584 (33.9) 793 (46.0) 233 (13.5) 1723 (100.0) 
Without 
SPC 
Breast cancer 538 (74.0)  2010 (81.1)  1591 (72.6)  268 (62.6)  4407 (75.7) 
Other cancers  36 (5.0)  74 (3.0)  91 (4.2)  15 (3.5)  216 (3.7) 
Other causes  153 (21.0)  393 (15.9)  510 (23.3)  145 (33.9) 1201 (20.6) 
All 
(N, % in row) 
 727 (12.5)  2477 (42.5)  2192 (37.6)  428(7.4)  5824 (100.0) 
 
a, breast cancer patients diagnosed with non-breast second primary cancer and dying of breast cancer; b, 
breast cancer patients diagnosed with second breast cancer and dying of breast; SPC, second primary 
cancer; HPC, higher order (3
rd
, 4
th
 or 5
th
) primary cancer 
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Supplementary Table 8  Causes of death in breast cancer patients diagnosed with second primary cancer 
Second cancer 
Total number of  deaths and % of 
all patient with SPC 
Cause of death 
Breast cancer SPC HPC Other cancers Other causes 
N % N % N % N % N % N % 
 Upper aerodigestive tract 46 32.2 11 23.9 17 40.0 5 10.9 7 15.2 6 13.0 
Esophagus 33 75.0 1 3.0 28 84.8 1 3.0 3 9.1 0 0.0 
 Stomach  88 87.1 13 14.8 64 72.7 0 0.0 7 8.0 4 4.5 
 Small intestine 15 32.6 3 20.0 9 60.0 0 0.0 2 13.3 1 6.7 
 Colorectum 307 38.6 35 11.4 203 66.1 9 2.9 24 7.8 36 11.7 
Liver   117 80.1 7 6.0 89 76.1 1 0.8 10 8.5 10 8.5 
Pancreas 162 87.6 2 1.2 144 88.9 1 0.6 5 3.1 10 6.2 
 Lung  610 72.6 51 8.4 496 81.3 7 1.1 15 2.4 41 6.7 
 Breast  1990 23.0 - - 1478 74.3 159 8.0 70 3.5 283 14.2 
Cervix 47 48.4 10 21.3 24 51.1 3 6.4 5 10.6 5 10.6 
Endometrium  168 25.3 48 28.6 36 21.4 12 7.1 41 24.4 31 18.4 
Ovary 237 59.4 23 9.7 166 70.0 12 5.1 25 10.5 11 4.6 
 Other female genitals 22 41.5 1 4.5 6 27.3 5 22.7 6 27.3 4 18.2 
 Kidney  74 39.6 14 18.9 47 63.5 3 4.0 2 2.7 8 10.8 
 Bladder   68 33.5 17 25.0 29 42.6 6 8.8 3 4.4 13 19.1 
  Melanoma 78 17.4 28 35.9 24 30.8 8 10.2 6 7.7 12 15.4 
 Skin, squamous cell  57 13.6 22 38.6 6 10.5 7 12.3 4 7.0 18 31.6 
Eye 10 40.0 0 0.0 1 10.0 1 10.0 7 70.0 1 10.0 
 Nervous system 91 43.3 22 24.2 44 48.4 2 2.2 12 13.2 11 12.1 
 Thyroid gland 21 23.1 7 33.3 9 42.8 2 9.5 0 0.0 3 3.3 
 Endocrine gland  37 20.6 13 35.1 5 13.5 5 13.5 5 13.5 9 24.3 
Bone 7 70.0 5 71.4 0 0.0 0 0.0 2 28.6 0 0.0 
 Connective tissue 32 48.5 7 21.9 11 34.4 2 6.2 7 21.9 5 15.6 
  Non-Hodgkin lymphoma 89 38.0 14 15.7 53 59.5 1 1.1 6 6.7 15 15.6 
Hodgkin lymphoma 5 33.3 0 0.0 1 20.0 1 20.0 1 20.0 2 40.0 
Meyloma 39 48.1 2 5.1 30 76.9 1 2.6 2 5.1 4 10.2 
 Leukemia  105 46.2 10 9.5 67 63.8 7 6.7 12 11.4 9 8.6 
Cancer of unknown primary 213 81.0 70 32.9 25 11.7 1 0.5 107 50.2 10 4.7 
All 
a
 2838 45.0 446 15.7 1656 58.4 103 3.6 347 12.2 286 10.1 
a:second breast cancer was excluded from all cancers; SPC, second primary cancer; HPC, higher (3
rd
, 4
th
 or 5
th
) primary cancer.
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Supplementary Table 9 Relative risk of second primary cancers according to family history of 
concordant cancer in ovarian cancer patients after removing high risk families 
Cancer site 
Patients with ovarian cancer 
P-trend Negative family history  Positive family history  
N RR 95%CI N RR 95%CI 
Upper aerodigestive tract 12 1.12 0.64-1.97 0 - - - 
Stomach 16 2.25 1.37-3.68 1 3.46 0.49-24.62 0.54 
Small intestine 10 3.29 1.76-6.14 0 - - - 
Colorectum 114 1.94 1.61-2.33 24 3.80 2.54-5.67 <0.001 
Colon 86 2.04 1.65-2.52 14 4.80 2.94-8.11 <0.001 
Rectum 37 1.82 1.32-2.51 1 1.42 0.20-10.11 0.33 
Liver 21 1.84 1.20-2.82 1 3.17 0.45-22.5 0.32 
Pancreas 36 2.40 1.73-3.33 3 8.58 2.77-26.62 0.52 
Lung 74 1.47 1.17-1.85 12 3.43 1.95-6.04 <0.001 
Breast 204 1.04 0.90-1.19 49 2.24 1.69-2.96 <0.001 
Other female genitals 11 2.11 1.16-3.82 0 - - - 
Kidney 21 1.64 1.07-2.53 1 2.59 0.36-18.38 0.32 
Bladder 40 2.64 1.93-3.60 3 5.46 1.76-16.94 0.53 
Melanoma 37 1.05 0.76-1.45 2 1.84 0.46-7.37 0.97 
Skin, squamous cell 20 0.76 0.49-1.17 3 3.30 1.06-10.23 0.06 
Nervous system 16 0.70 0.43-1.14 1 1.57 0.22-11.14 0.29 
Thyroid gland 10 1.60 0.86-2.98 0 - - - 
Endocrine glands 22 1.38 0.91-2.10 0 - - - 
Connective tissue 11 3.18 1.75-5.76 0 - - - 
Non-Hodgkin 
lymphoma 
17 0.88 0.55-1.42 1 1.49 0.21-10.58 0.32 
Leukemia 29 1.70 1.18-2.45 0 - - - 
Cancer of unknown primary 51 2.59 1.97-3.42 3 4.08 1.32-12.66 0.56 
All cancers 
a
 360 1.52 1.37-1.68 734 1.77 1.64-1.90 <0.001 
All cancers 
b
 334 1.41 1.26-1.57 689 1.67 1.55-1.81 <0.001 
a, all cancers including second ovarian cancer, b, all cancers excluding second ovarian cancer. 
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Supplementary Table 10 Causes of death in ovarian cancer patients diagnosed with second 
primary cancer 
Second cancer 
Total number of  
deaths and % of all 
patient with SPC 
Cause of death 
Ovarian 
cancer 
SPC Other cancers Other causes 
N % N % N % N % N % 
 Upper aerodigestive tract 2 16.7 1 50 1 50 0 0 0 0 
 Stomach  15 88.2 3 20.0 9 60.0 3 20.0 0 0 
 Small intestine 9 90.0 4 44.4 1 11.1 3 33.3 1 11.1 
 Colorectum 75 52.4 12 16.0 39 52.0 18 24.0 6 8.0 
Liver   18 78.3 3 16.7 13 72.2 2 11.1 0 0 
Pancreas 34 87.2 0 0 31 91.2 1 2.9 2 5.9 
 Lung  66 76.7 8 12.1 48 72.7 6 9.1 4 6.1 
 Breast  88 33.7 33 37.5 34 38.6 10 11.4 11 12.5 
 Other female genitals 5 45.5 1 20.0 1 20.0 3 60.0 0 0.0 
 Kidney  7 31.8 3 42.9 4 57.1 0 0 0 0.0 
 Bladder   20 44.4 2 10.0 12 60.0 4 20.0 2 10.0 
  Melanoma 11 27.5 5 45.4 3 27.3 3 27.3 0 0.0 
 Skin, squamous cell 7 30.4 4 57.1 0 0.0 1 14.3 2 28.6 
 Nervous system 12 66.7 0 0.0 6 50.0 4 33.3 2 16.7 
 Thyroid gland 2 20.0 0 0.0 2 100.0 0 0 0 0.0 
 Endocrine gland  4 18.2 1 25.0 0 0.0 0 0 3 75.0 
 Connective tissue 7 63.6 1 14.3 1 14.3 4 57.1 1 14.3 
  Non-Hodgkin lymphoma 8 44.4 0 0 1 12.5 6 75.0 1 12.5 
 Leukemia  15 51.7 2 13.3 11 73.3 2 13.3 0 0.0 
Cancer of unknown primary  47 82.5 23 48.9 5 10.6 16 34.0 3 6.4 
All 544 49.0 159 29.2 229 42.1 102 18.8 54 9.9 
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2. Supplementary Figures 
 
 
Supplementary Figure 1 Risk of histology with grey background was significant within concordant 
histology of ovarian cancer. Risk of the two histologies between full lines was significant in the two-way 
comparison. Risk of the two histologies between imaginary line was significant in one way and the 
histology the arrow points to is from offspring. 
 
 
 
